

United States General Accounting Office

Report to the Chairman, Subcommittee on Oversight and Investigations, Committee on Commerce, House of Representatives

October 1995

MEDICAL DEVICES

FDA Review Time



GAO	United States General Accounting Office Washington, D.C. 20548								
	Program Evaluation and Methodology Division								
	B-261822								
	October 30, 1995								
	The Honorable Joe Barton								
	Chairman, Subcommittee on Oversight								
	and Investigations								
	Committee on Commerce								
	House of Representatives								
	Dear Mr. Chairman:								
	As you know, the Food and Drug Administration (FDA) regulates the manufacture and marketing of medical devices in this country. Some criticism has been expressed that FDA's review of medical devices is excessively lengthy and can impose inordinate delays upon the introduction of new devices into the market. At your request, we examined FDA's review time and how it has changed from fiscal year 1989 to May 18, 1995. We analyzed data provided by FDA on applications to market new devices or to begin clinical research on unapproved devices. We briefed your staff on the findings of our preliminary analysis in June 1995, and we have since requested and received comments on these findings from FDA.								
Background									
Types of FDA Reviews	Medical devices can range in complexity from a simple tongue depressor to a sophisticated CT (computed tomography) x-ray system. Most of the devices reach the market through FDA's premarket notification (or $510(k)$) review process. ¹ Under its $510(k)$ authority, FDA may determine that a device is substantially equivalent to a device already on the market and therefore not likely to pose a significant increase in risk to public safety. When evaluating $510(k)$ applications, FDA makes a determination regarding whether the new device is as safe and effective as a legally marketed predicate device. Performance data (bench, animal, or clinical) are required in most $510(k)$ applications. ²								

 $^{^1\!}Premarket$ notification is commonly called 510(k) in reference to section 510(k) of the Federal Food, Drug, and Cosmetic Act.

 $^{^{2}510(}k)$ applications must contain a description of the device, description of the predicate device with which it is substantially equivalent, proposed labeling, intended use, and directions for use.

	An alternative mode of entry into the market is through the premarket approval (PMA) process. PMA review is more stringent and typically longer than 510(k) review. For PMAS, FDA determines the safety and effectiveness of the device based on information provided by the applicant. Nonclinical data are included as appropriate. ³ However the answers to the fundamental questions of safety and effectiveness are determined from data derived from clinical trials. ⁴
	FDA also regulates research conducted to determine the safety and effectiveness of unapproved devices. FDA approval is required only for "significant risk" devices. ⁵ Applicants submit applications for such devices to obtain an investigational device exemption (IDE) from regulatory requirements and approval to conduct clinical research. For an IDE, unlike PMAs and 510(k)s, it is the proposed clinical study that is being assessed—not just the device.
Modification of Cleared or Approved Applications for Devices	Modifications of medical devices, including any expansion of their labeled uses, are also subject to FDA regulation. Applications to modify a device that entered the market through a PMA are generally linked to the original PMA application and are called PMA supplements. In contrast, modifications to a 510(k) device are submitted as new 510(k) applications. References may be made to previous 510(k) applications.
Measuring the Length of FDA Reviews	FDA uses several measures of duration to report the amount of time spent reviewing applications. In this letter, we use only three of those measures. The first is simply the time that elapses between FDA's receipt of an application and its final decision on it (total elapsed time). The second measure is the time that FDA has the application under its review process (FDA time). This includes both the time the application is under active review and the time it is in the FDA review queue. The amount of time FDA's
	 ³Nonclinical data may include microbiological, toxicological, immunological, biocompatibility, shelf life, animal, engineering (stress, wear, fatigue) data. ⁴For PMAs, information on the device and its components, the manufacturing process, labeling that includes its intended use and directions for use as well as clinical and nonclinical studies are included in the submission. ⁵A "significant risk" device is one that is intended as an implant, used in supporting or sustaining human life, of substantial importance in diagnosing, curing, mitigating or treating disease, or otherwise prevents impairment of human health, and presents a potential for serious risks to the health, safety, or welfare of a subject (21 C.F.R. 812.3(m)). For a nonsignificant risk device only Institutional Review Board approval is required.

review process has been suspended, waiting for additional information from the applicant, is our third measure (non-FDA time).

Our measures of review time are not intended to be used to assess the agency's compliance with time limits for review established under the Federal Food, Drug, and Cosmetic Act (the act).⁶ The time limits for PMA, 510(k), and IDE applications are 180, 90, and 30 days, respectively. FDA regulations allow for both the suspension and resetting of the FDA review clock under certain circumstances.⁷

How review time is calculated differs for 510(k)s and PMAs. If a PMA application is incomplete, depending on the extent of the deficiencies, FDA may place the application on hold and request further information. When the application is placed on hold, the FDA review clock is stopped until the agency receives the additional information. With minor deficiencies, the FDA review clock resumes running upon receipt of the information. With major deficiencies, FDA resets the FDA clock to zero upon receipt of the information. In this situation, all previously accrued FDA time is disregarded. (The resetting of the FDA clock can also be triggered by the applicant's submission of unsolicited supplementary information.) The amount of time that accrues while the agency is waiting for the additional information constitutes non-FDA time. For 510(k)s, the FDA clock is reset upon receipt of a response to either major or minor deficiencies.

For this report, we define FDA time as the total amount of time that the application is under FDA's review process. That is, our measure of FDA time does not include the time that elapses during any suspension, but does include time that elapsed before the resetting of the FDA clock. The total amount of time that accrues while the agency is waiting for additional information constitutes non-FDA time. (The sum of FDA and non-FDA time is our first measure of duration—total elapsed time.)

Classes and Tiers of Medical Devices

The act establishes three classes of medical devices, each with an increasing level of regulation to ensure safety and effectiveness. The least regulated, class I devices, are subject to compliance with general controls. Approximately 40 percent of the different types of medical devices fall into

 6 FDA, as indicated by its own reports, has sometimes failed to meet these time limits. For example, in 1994, only 45 percent of its 510(k) reviews were completed within 90 days.

⁷See 21 C.F.R. 814.37 and 814.40 for PMAs and 21 C.F.R. 807.87(k) for 510(k)s. The review of IDE applications is not subject to the resetting of the FDA review clock; investigations for which IDE applications are submitted may begin within 30 days of application receipt if FDA fails to act (see 21 C.F.R. 812.30).

class I. At the other extreme is premarket approval for class III devices, which constitute about 12 percent of the different types of medical devices. Of the remainder, a little over 40 percent are class II devices, and about 3 percent are as yet unclassified.⁸

In May 1994, FDA implemented a three-tier system to manage its review workload. Classified medical devices are assigned to one of three tiers according to an assessment of the risk posed by the device and its complexity. Tier 3 devices are considered the riskiest and require intensive review of the science (including clinical data) and labeling. Review of the least risky devices, tier 1, entails a "focused labeling review" of the intended use. In addition to the three tiers is a group of class I devices that pose little or no risk and were exempted from the premarket notification (510(k)) requirements of the act.⁹

Under the class and tier systems, approximately 20 percent of the different types of medical devices are exempted from premarket notification.¹⁰ A little over half of all the different types of medical devices are classified as tier 2 devices. Tiers 1 and 3 constitute 14 and 12 percent of the different types of medical devices, respectively.¹¹

Results in Brief

Review times and trends for medical device applications varied widely over the period beginning October 1, 1988, through May 18, 1995. For 510(k) applications submitted in a given fiscal year, the review time remained stable over the 3 years from 1989 to 1991, then rose sharply in 1992 and 1993 before dropping in 1994. For 1994, the median was 152 days. The mean time to a decision was higher, at 166 days, and this mean will

⁹These exempted devices remain subject to other requirements of the act. (See footnote 8.)

⁸General controls for class I devices include registering device manufacturing facilities, providing FDA with regularly updated lists of marketed devices, complying with good manufacturing practices (as established by FDA), and maintaining records and filing reports of device-related injuries and malfunctions. The Safe Medical Devices Act of 1990 revised the requirements for class II devices, subjecting them to both general and special controls. Special controls include performance standards, postmarket surveillance, patient registries, and other controls as deemed necessary. Class III devices require clinical data to demonstrate safety and effectiveness.

¹⁰Our 20-percent figure was determined by obtaining a frequency distribution by tiers of the information FDA provided.

¹¹Medical devices have both a class and a tier designation associated with them. Although tiers were not implemented until 1994, for this report, we have applied the tier classification retrospectively to our data to examine review time.

continue to grow as the remaining open cases (13 percent) are completed. $^{\rm 12}$

The review time trend for original PMAs was less clear, in part because a large proportion of the applications have yet to be completed. Open cases ranged from 4 percent of 1989 to 81 percent of 1994 applications. More than 40 percent of the 1992 and 1993 applications were still open. The median for 1994 was undetermined as less than 50 percent of the applications were completed. For 1993, the median review time was 804 days.

The review time for PMA supplements, however, fluctuated slightly in the first 3 years, before peaking in 1992 and declining thereafter. The median for 1994 was 193 days as opposed to a mean of 162 days. Again, the mean will increase when the remaining open cases (21 percent) are closed.


Not all the time that elapsed between an application's submission and its final determination was spent under FDA's review process. In many instances, FDA had to wait for additional information. This non-FDA time comprised about one-fifth of total elapsed review time for 510(k)s. It constituted about one-fourth of total elapsed review time for original PMAs and one-third for PMA supplements.

Principal Findings

Premarket Notifications (510(k)s)

From 1989 through 1991, the median time between the submission of a 510(k) application and FDA's decision (total elapsed time) was relatively stable at about 80 to 90 days. The next 2 years showed a sharp increase that peaked at 230 days in 1993. Although the median review time showed a decline in 1994 (152 days), it remained higher than that of the initial 3 years. (See figure 1.)

¹²We report our findings here in terms of two measures: median review time (that is, how long the case representing the midpoint in review time took to complete review), and mean review time (the average time to complete review). The median includes all cases (so long as at least one-half of cases submitted in a given year were completed). By necessity, the mean includes only those cases that have been completed. Both measures are reported by year of submission, not year of decision. For greater detail on the two measures and the implications of their use, see pp. 12-14.




^aThe median includes open cases.

Similarly, the mean also indicated a peak in review time in 1993 and a subsequent decline. The mean review time increased from 124 days in 1989 to 269 days in 1993. In 1994, the mean dropped to 166 days; however, this mean will increase as the 13 percent of the applications that remained open are closed. (See table II.1.)

Of all the applications submitted to FDA to market new devices during the period under review, a little over 90 percent were for 510(k)s. Between 1989 and 1994, the number of 510(k) applications remained relatively stable, ranging from a high of 7,023 in 1989 to a low of 5,774 in 1991. In 1994, 6,446 applications were submitted.

Of the 40,950 510(k) applications submitted during the period under review, approximately 73 percent were determined to be substantially equivalent. (That is, the device is equivalent to a predicate device already on the market and thus is cleared for marketing.) Only 2 percent were found to be nonequivalent, and 6 percent remained open. Other decisions—including applications for which a 510(k) was not required and those that were withdrawn by the applicant—account for the rest. (See appendix I for details on other FDA decision categories.) For applications determined to be substantially equivalent, non-FDA time—the amount of time FDA placed the application on hold while waiting for additional information—comprised almost 20 percent of the total elapsed time. (See table II.7.) Figure 2 displays FDA and non-FDA time to determine equivalency for 510(k) applications.



^aOpen cases are not included. The means shown will increase when open cases are completed.

The trends in review time differed for original PMAs and PMA supplements. There was no clear trend in review times for original PMA applications using either medians or means since a large proportion of the applications had yet to be completed. The median time between the submission of an application and FDA's decision (total elapsed time) fluctuated from a low of 414 days in 1989 to a high of 984 days in 1992. Less than 50 percent of the applications submitted in 1994 were completed; thus, the median review time was undetermined. (See figure 3.)

Figure 2: Mean Time to Determine Equivalency for 510(k)s by FDA and Non-FDA Time^a

Premarket Approvals

(PMAs)




Figure 3: Median Review Time for Original PMAs by Fiscal Year^a

^aThe median includes open cases. Data for 1994 are omitted because less than 50 percent of the applications submitted had been completed.

Except for 1989, the means were lower than the medians because of the large number of open cases. The percent of applications that remained open increased from 4 percent in 1989 to 81 percent in 1994. The means, then, represent the time to a decision for applications that were less time-consuming. When the open cases are completed, lengthy review times will cause an increase in the means. (See table III.1.)

For PMA supplements, the median time ranged from 126 days to 173 days in the first 3 years, then jumped to 288 days in 1992. In 1993 and 1994, the median declined to 242 and 193 days, respectively. (See figure 4.)




Figure 4: Median Review Time for PMA Supplements by Fiscal Year^a

^aThe median includes open cases.

This trend was reflected in the mean review time that peaked at 336 days in 1992. Although the mean dropped to 162 days in 1994, this is expected to increase because 21 percent of the applications had not been completed at the time of our study. (See table III.7.)


Applications for original PMAs made up less than 1 percent of all applications submitted to FDA to market new devices in the period we reviewed. PMA supplements comprised about 8 percent of the applications.

The number of applications submitted for PMA review declined each year. In 1989, applications for original PMAs numbered 84. By 1994, they were down to 43. Similarly, PMA supplements decreased from 804 in 1989 to 372 in 1994. (See tables III.1 and III.7.)

Of the 401 applications submitted for original PMAS, 33 percent were approved, 26 were withdrawn, and nearly a third remained open. The remainder (about 9 percent) fell into a miscellaneous category. (See appendix I.) A much higher percentage of the 3,640 PMA supplements (78 percent) were approved in this same period, and fewer PMA supplements were withdrawn (12 percent). About 9 percent of the


applications remained open, and 2 percent fell into the miscellaneous category.

For PMA reviews that resulted in approval, non-FDA time constituted approximately one-fourth of the total elapsed time for original PMAs and about one-third for PMA supplements. The mean FDA time for original PMAs ranged from 155 days in 1994 to 591 days in 1992. Non-FDA times for those years were 34 days in 1994 and 165 days in 1992. For PMA supplements, FDA review times were lower, ranging from a low of 105 days (1990) to a high of 202 days (1992). Non-FDA time for those years were 59 days (1990) and 98 days (1992), respectively. (See table III.13.) Figures 5 and 6 display the proportion of FDA and non-FDA time for the subset of PMAs that were approved.



^aData for 1994 are omitted because less than 50 percent of the applications submitted had been completed. Open cases are not included. The mean times shown will increase when open cases are closed.

Figure 5: Mean Time to an Approval for Original PMAs by FDA and Non-FDA Time^a



Investigational Device Exemptions (IDEs)	For IDES, the mean review time between submission and FDA action was 30 days, and it has not changed substantially over time. Unlike 510(k)s and PMAS, IDES are "deemed approved" if FDA does not act within 30 days. Of the 1,478 original IDE submissions from fiscal year 1989 to 1995, 33 percent were initially approved (488) and 62 percent were denied or withdrawn (909). The number of IDE submissions each year ranged from a high of 264 in 1990 to a low of 171 in 1994. (See table IV.1.)
Objectives, Scope, and Methodology	Our objective was to address the following general question: How has the time that 510(k), PMA, and IDE applications spend under FDA review changed between fiscal year 1989 and the present? To answer that question, we also looked at a subset of applications that were approved, distinguishing the portion of time spent in FDA's review process (FDA time) from that spent waiting for additional information (non-FDA time). For applications that were approved, we present the average number of

amendments that were subsequently added to the initial application as well as the average number of times FDA requested additional information from the applicant. (Both of these activities affect FDA's review time.)


We used both the median and mean to characterize review time. We use the median for two reasons. First, a large proportion of the applications have yet to be completed. Since the median is the midpoint when all review times are arranged in consecutive order, its value can be determined even when some applications requiring lengthy review remain open. In contrast, the mean can only be determined from completed applications. (In this case, applications that have been completed by May 18, 1995.) In addition, the mean will increase as applications with lengthy reviews are completed.

To illustrate, for applications submitted in 1993, the mean time to a decision was 269 days for 510(k) applications that have been closed. However, 3 percent of the applications have yet to be decided. If these lengthy reviews were arbitrarily closed at May 18, 1995 (the cutoff date for our data collection), the mean would increase to 285 days. In contrast, the median review time (230 days) would remain the same regardless of when these open applications were completed.

The second reason for using the median is that the distributions of review time for 510(k), original PMA, and PMA supplement applications are not symmetric, that is, having about the same number of applications requiring short reviews as lengthy reviews. The median is less sensitive to extreme values than the mean. As a result, the review time of a single application requiring an extremely lengthy review would have considerably more effect on the mean than the median. Figure 7 shows the distribution for 510(k)s submitted in 1993, the most recent year in which at least 95 percent of all 510(k) applications had been completed. The distribution is skewed with a mean review time of 269 days and a median review time of 222 days for all completed applications.¹³

¹³See appendix III for the distribution of review time for original PMAs and PMA supplements.

Figure 7: Time to a Decision for 510(k)s Submitted in Fiscal Year 1993^a



^aThe number of cases in this frequency distribution is 6,101. (The one application with over 1,500 days was dropped from this figure.) As of May 18, 1995, 3 percent of applications submitted had not been completed and were not included. When these applications are closed, the mean will increase.

To provide additional information, we report on the mean review times as well as the median. The discrepancy between the two measures gives some indication of the distribution of review time. When the mean is larger than the median, as in the case of the 510(k)s above, it indicates that a group of applications required lengthy reviews.¹⁴ Another reason we report

¹⁴For original PMAs, the mean is smaller than the median. The smaller mean results from the large number of open cases. Applications requiring lengthy reviews have yet to be completed. As these reviews are completed, the mean will increase.

the means is that, until recently, FDA reported review time in terms of means.

In appendix I, we provide the categories we used to designate the different FDA decisions and how our categories correspond to those used by FDA. Detailed responses to our study objective are found in tabular form in appendixes II, III, and IV for 510(k)s, PMAs, and IDEs, respectively.

We report our findings according to the fiscal year in which the applications were submitted to FDA. By contrast, FDA commonly reports review time according to the fiscal year in which the review was completed.¹⁵ Although both approaches measure review time, their resultant statistics can vary substantially. For example, several complex applications involving lengthy 2-year reviews submitted in 1989 would increase the average review time for fiscal year 1989 in our statistics and for fiscal year 1991 in FDA's statistics. Consequently, the trend for review time based on date-of-submission cohorts can differ from the trend based on date-of-decision cohorts. (See appendix V for a comparison of mean review time based on the two methods.)

The two methods provide different information and are useful for different purposes. Using the date-of-decision cohort is useful when examining productivity and the management of resources. This method takes into consideration the actual number of applications reviewed in a given year including all backlogs from previous years. Alternatively, using the date-of-submission cohort is useful when examining the impact of a change in FDA review policy, which quite often only affects those applications submitted after its implementation.¹⁶ To minimize the effect of different policies on review time within a cohort, we used the date-of-submission method.

We conducted our work in accordance with generally accepted government auditing standards between May and June 1995.

Agency Comments

Officials from FDA reviewed a draft of this report and provided written comments, which are reproduced in appendix VI. Their technical

¹⁶FDA has indicated that it plans to include statistics on review time based on the year of submission in its reports.

 $^{^{15}\}text{Using}$ date-of-decision cohorts obviates the problem of open cases. Both means and medians can be easily determined.

comments, which have been incorporated into the text where appropriate, have not been reprinted in the appendix.

FDA believed that the report misrepresented the current state of the program as the draft did not acknowledge recent changes in the review process. FDA officials suggested a number of explanations for the apparent trends in the data we reported (see appendix VI). Although recent initiatives to improve the review process provide a context in which to explain the data, they were outside the scope of our work. We were not able to verify the effect these changes have actually had on review time. To the extent that these changes did affect review time, they are reflected in the review times as presented and are likely to be reflected in future review times.

The agency also believed that the draft did not reflect the recent improvements in review time. We provided additional measures of review time in order to present the review times for the more recent years. We have also included more information on the difference between the date-of-submission and date-of-decision cohorts, and we have expanded our methodological discussion in response to points FDA made on the clarity of our presentation. (Additional responses to the agency comments are included in appendix VI.)

As agreed with your office, unless you publicly announce its contents earlier, we plan no further distribution of this report until 30 days after its date of issue. We will then send copies to other interested congressional committees, the Secretary of the Department of Health and Human Services, and the Commissioner of Food and Drugs. Copies will also be made available to others upon request. If you or your staff have any questions about this report, please call me at (202) 512-3092. The major contributors to this report are listed in appendix VII.

Sincerely yours,

g he

Kwai-Cheung Chan Director of Program Evaluation in Physical Systems Areas

Contents

Letter	1
Appendix I FDA Decision Codes and GAO's Categories	22
Appendix II Premarket Notification (510(k)) Tables II.1 - II.12	24
Appendix III Premarket Approval Tables III.1 - III.18	39
Appendix IV Investigational Device Exemption Tables IV.1 - IV.6	65
Appendix V Comparision in Table V of Alternative Methods for Determining Average Days to Decision by Fiscal Year	73

Appendix VI Comments From the Food and Drug Administration		74
Appendix VII Major Contributors to This Report		87
Table	Table I.1: Correspondence Between GAO Categories and FDA Decision Codes	22
Figures	Figure 1: Median Review Time for 510(k)s by Fiscal Year Figure 2: Mean Time to Determine Equivalency for 510(k)s by FDA and Non-FDA Time	6 7
	Figure 3: Median Review Time for Original PMAs by Fiscal Year Figure 4: Median Review Time for PMA Supplements by Fiscal Year	8 9
	Figure 5: Mean Time to an Approval for Original PMAs by FDA and Non-FDA Time	10
	Figure 6: Mean Time to an Approval for PMA Supplements by FDA and Non-FDA Time	11
	Figure 7: Time to a Decision for 510(k)s Submitted in Fiscal Year 1993	13
	Figure III.1: Average Days to Decision on Premarket Approvals by Milestone by Year, October 1, 1988 - May 18, 1995	42
	Figure III.2: Time to a Decision for Original PMAs Submitted in Fiscal Year 1989	44
	Figure III.3: Time to a Decision for PMA Supplements Submitted in Fiscal Year 1991	45
	Figure VI.1: Total Elapsed Time for 510(k) Reviews, 1989-95: Mean, Median for Closed Cases, and Median for All Cases ^a	84

Contents

Abbreviations

Computed tomography
Division of Clinical Laboratory Devices
Division of Cardiovascular, Respiratory and Neurological
Devices
Division of General and Restorative Devices
Division of Ophthalmic Devices
Division of Reproductive, Abdominal, Ear, Nose and Throat,
and Radiological Devices
Food and Drug Administration
Investigational device exemption
Premarket approval

Appendix I FDA Decision Codes and GAO's Categories

FDA uses different categories to specify the type of decision for 510(k)s, PMAS, and IDES. For our analysis, we collapsed the multiple decision codes into several categories. The correspondence between our categories and FDA's are in table I.1.

Table I.1: Correspondence BetweenGAO Categories and FDA DecisionCodes

Type of application	GAO category	FDA decision code
Premarket notification	Equivalent	Equivalent
	Nonequivalent	Nonequivalent
	Other	Additional information requested; applicant cannot respond within 30 days
		Forwarded to drugs/biologics
		Deleted/duplicate
		Deleted
		Drug (CDER) review required
		Exempted by regulation
		General purpose article
		Closeout letter issued
		Not actively regulated
		Not a device
		Not a finished product
		Not a required submission
		Preamendment exempt
		Refuse to accept
		Reconditioner/remanufacturer
		Transitional device
		Withdrawn by applicant
Premarket approval	Approved	Approved
	Denied	Denied
	Withdrawn	Withdrawn
	Other	Abandoned
		Converted
		Reclassified
		Other

(continued)

Type of application	GAO category	FDA decision code
Investigational device exemption	Approved	Approved
		Approved with conditions
		Deemed approved and request information
	Denied	Disapproved
		Refuse to accept
	Withdrawn	Deemed approved/immediate withdraw
		Immediate withdrawal by FDA
		Withdrawn by sponsor
	Other	Acknowledge incoming
		Study exempt from part 812
		Inadequate incoming
		Incomplete
		Product jurisdiction pending
		Product jurisdiction transferred
		No response necessary
		Nonsignificant risk device study
		Other
		Request for progress report
		Investigation terminated/ inadequate/no final report
		Telephone response
		Voluntary termination requested

Premarket Notification (510(k)) Tables II.1 -II.12

Tables	Page
Table II.1: Average Days to Decision on 510(k)s and Number of Open Cases by Fiscal Year	27
Table II.2: Summary of Average Days to Decision on 510(k)s and Number of Open Cases	28
Table II.3: Average Days to Decision and Number of Open Cases for 510(k)s by Class of Medical Device	29
Table II.4: Average Days to Decision and Number of Open Cases for 510(k)s by Tier of Medical Device	30
Table II.5: Average Days to Decision and Number of Open Cases for 510(k)s by Medical Specialty of Device	31
Table II.6: Average Days to Decision and Number of Open Cases for 510(k)s by Reviewing Division	32
Table II.7: Average Days to Equivalency for 510(k)s by Fiscal Year	33
Table II.8: Average Days to Equivalency for 510(k)s by Class, Tier, Medical Specialty, and Division	34
Table II.9: Average Days to Equivalency for 510(k)s by Class of Medical Device	35
Table II.10: Average Time to Equivalency for 510(k)s by Tier of Medical Device	36
Table II.11: Average Time to Equivalency for 510(k)s by Medical Specialty of Device	37
Table II.12: Average Time to Equivalency for 510(k)s by Reviewing Division	38

Review Time for Premarket Notification	The following tables present the data for premarket notifications, or 510(k)s, for fiscal years 1989 through May 18, 1995. The first set of tables (tables II.1 through II.6) presents the time to a decision—from the date the application is submitted to the date a decision is rendered.
	We first present a summary table on the time to a decision by fiscal year (table II.1). The grand total for the number of applications includes open cases—that is, applications for which there had not been any decision made as of May 18, 1995. As the distribution for time to a decision is not symmetric (see figure 1 in the letter), we present the means and percentiles to characterize the distribution. (The means and percentiles do not include open cases.)
	The second table is a summary of the time to a decision by class, tier, medical specialty of the device, and reviewing division (table II.2). The next four tables (II.3 through II.6) provide the details for these summary tables. The totals in these tables include only applications for which a decision has been rendered.
	The class, tier, and medical specialty of some of the devices have yet to be determined and are designated with N/A. Medical specialties <u>other</u> than general hospital or general and plastic surgery include anesthesiology; cardiovascular; clinical chemistry; dental; ear, nose, and throat; gastroenterology/urology; hematology; immunology; microbiology; neurology; obstetrics/gynecology; ophthalmic; orthopedic; pathology; physical medicine; radiology; and clinical toxicology.
	The five reviewing divisions in FDA's Center for Devices and Radiological Health are Division of Clinical Laboratory Devices (DCLD); Division of Cardiovascular, Respiratory and Neurological Devices (DCRND); Division of General and Restorative Devices (DGRD); Division of Ophthalmic Devices (DOD); and Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices (DRAER).
	The second set of tables (tables II.7 through II.12) presents the mean time to determine equivalency. We provide the means for total FDA time, non-FDA time, and total elapsed time. FDA time is the total amount of time the application was under FDA review including queue time—the time to equivalency without resetting the FDA review clock. The total elapsed time, the duration between the submission of the application and FDA's decision, equals the sum of the FDA and non-FDA time.

Appendix II Premarket Notification (510(k)) Tables II.1 -II.12

We deleted cases that had missing values or apparent data entry errors for the values relevant to calculating FDA and non-FDA time. Therefore, the total number of applications determined to be equivalent in this group of tables differs from that in the first set. Again, we have two summary tables, followed by four tables providing time to determine equivalency by class, tier, medical specialty, and reviewing division (tables II.7 through II.12).

Table i				ision on 510 lay 18, 1995)	• •	nd Numb	er of O	pen C	ases	by Fiscal	Year		
Fiscal	Equi	valent	Non	equivalent	0	ther	Pe	ercent	ile		O	ben	Grand
year	N	Days	Ν	Days	Ν	Days	5	50	95	Mean	N	Days	total
1989	5258	98	108	167	1655	205	19	86	336	124	2	2188	7023
1990	4633	100	142	162	1060	207	15	83	347	121	0	0	5835
1991	4513	124	140	225	1110	263	18	90	466	153	11	1458	5774
1992	4888	204	203	260	1388	387	32	164	685	245	54	1086	6533
1993	4654	233	108	296	1340	391	52	222	651	269	204	749	6306
1994	4342	141	86	182	1207	254	26	126	427	166	811	363	6446
1995	1429	70	16	73	260	49	14	58	153	67	1328	122	3033
Total	29717	146	803	217	8020	278	21	111	518	175	2410	285	40950

	Equivalent				Nonequivalent Other						Perc	entile		Open	Grand	
Class	Ν	Percent	Days	N	Percent	t Days	N	Percent	t Days	5	50	95	Mean		Percent	total
ł	7819	96.0	112	9	0.1	181	315	3.9	93	18	81	324	111	2	0	8145
1	20196	99.6	153	36	0.2	170	35	0.2	413	23	102	440	154	4	0	20271
111	1113	97.5	215	24	2.1	245	3	0.3	306	37	156	638	216	1	1	1141
N/A	589	5.2	207	734	6.4	218	7667	67.3	285	20	245	664	275	2403	21.1	11393
Tier																
1	5604	98.1	120	7	0.1	231	101	1.8	114	17	86	349	120	2	0	5714
2	21510	99.6	149	36	0.2	159	49	0.2	278	23	98	434	149	4	0	21599
3	1448	97.4	210	26	1.7	249	11	0.7	218	38	155	579	211	1	1	1486
Exempt	882	82.0	115	1	0.1	54	192	17.9	92	18	79	324	111	0	0	1075
N/A	273	2.5	189	733	6.6	218	7667	69.2	285	20	249	667	276	2403	21.7	11076
Medical specialty																
General hospital	3294	99.0	152	3	0.1	553	31	0.9	166	22	109	430	152	0	0	3328
General/plastic surgery	3899	98.1	134	6	0.2	225	70	1.8	105	19	90	372	134	0	0	3 9 75
Other	22513	98.6	147	62	0.3	178	254	1.1	130	22	94	434	147	7	0	22836
N/A	11	0.1	203	732	6.8	219	7665	70.9	285	20	255	669	279	2403	22.2	10811
Division																
DCLD	5437	80.0	108	71	1.0	205	916	13.5	217	21	81	405	125	376	5.5	6800
DCRND	4892	70.1	167	182	2.6	213	1380	19.8	328	30	156	520	203	527	7.5	6981
DGRD	12419	69.8	150	406	2.3	209	4007	22.5	270	20	117	523	180	962	5.4	17794
DOD	1300	70.8	115	8	0.4	291	462	25.2	207	21	88	435	140	65	3.5	1835
DRAER	5667	75.5	161	128	1.7	238	1240	16.5	323	23	117	599	191	471	6.3	7506
N/A	2	5.9	233	8	23.5	300	15	44.1	389	7	288	1361	269	9	3.3	34
Total	29717	72.2	146	803	2.0	217	8020	19.6	278	21	111	518	175	2410	5.9	40950

Fiscal		Equiv	/alent	None	quivalent	Ot	her	Т	otal	Open
year	Class	-	Days		Days		Days	N	Days	N
1989	I	2003	87	1	54	28	63	2032	87	0
	IF	2956	103	5	196	5	245	2966	103	0
	Ш	239	127	6	145	0	0	245	127	0
	N/A	60	104	96	168	1622	207	1778	201	2
	Total	5258	98	108	167	1655	205	7021	124	2
1990	I	1087	79	2	50	4	80	1093	79	0
	11	3236	103	6	245	3	147	3245	103	0
	111	241	155	11	294	2	287	254	162	0
	N/A	69	124	123	148	1051	208	1243	197	0
	Total	4633	100	142	162	1060	207	5835	121	0
1991	F	928	84	2	158	10	49	940	84	0
	H	3299	128	4	196	6	832	3309	129	0
	111	199	220	3	393	0	0	202	222	0
	N/A	87	172	131	223	1094	262	1312	252	11
	Total	4513	124	140	225	1110	263	5763	153	11
1992	I	1106	157	2	231	66	120	1174	155	0
	11	3496	211	12	117	10	363	3518	211	0
	111	183	292	0	0	0	0	183	292	0
	N/A	103	296	189	269	1312	401	1604	378	54
	Total	4888	204	203	260	1388	387	6479	245	54
1993	I	1112	186	0	0	76	138	1188	183	0
	11	3253	241	2	129	8	423	3263	241	0
	111	147	360	2	164	1	344	150	357	0
	N/A	142	302	104	302	1255	406	1501	389	204
	Total	4654	233	108	296	1340	391	6102	269	204
1994	I	1225	110	2	349	45	106	1272	110	1
	11	2952	150	6	189	3	264	2961	150	1
		77	238	2	141	0	0	79		1
	N/A	88	176	76	178	1159	260	1323	250	808
	Total	4342	141	86	182	1207	254	5635	166	811
1995	I	358	67	0	0	86	40	444		1
	11	1004		1	90	0	0	1005		3
	111		111	0		0		27		0
	N/A	40	82	15	72	174		229		1324
	Total	1429	70	16	73	260	49	1705	67	1328

3 239 122 7 147 0 0 246 123 0 Exempt 195 66 1 54 8 44 204 65 0 N/A 43 92 95 168 1621 207 1759 202 2 Total 5258 98 108 167 1655 205 7021 124 2 1990 1 715 79 1 66 2 38 718 79 0 2 3528 101 7 215 1 266 3536 101 0 Exempt 106 84 0 0 2 123 108 85 0 N/A 38 93 123 148 1051 206 207 5835 121 0 1991 1 614 110 2 304 6 288 622 132	Fiscal year	Tier	Equiva N	alent Days		ļuivalent Days	Oth N	ner Days	Tota N	al Days	Open N
2 3162 102 5 196 9 166 3176 102 0 3 239 122 7 147 0 0 246 123 0 N/A 43 92 95 168 1621 207 1759 202 2 Total 5258 98 108 167 1655 205 7021 124 2 100 1 715 79 1 66 2 38 718 79 0 2 3528 101 7 215 1 266 3536 101 0 3 246 163 11 294 4 187 261 169 0 N/A 38 93 123 148 1051 120 108 0 1212 198 0 162 1060 207 5835 121 0 0 333 160 122 122 100 1353 121 0 1414 123 15763	1989	1	1619	90	0	0	17	72	1636	90	0
3 239 122 7 147 0 0 246 123 0 N/A 43 92 95 168 1621 207 1759 202 2 Total 5258 98 108 167 1655 205 7021 124 2 1990 1 715 79 1 66 2 38 718 79 0 2 3528 101 7 215 1 266 3536 101 0 Exempt 106 84 0 0 2 123 108 85 0 N/A 38 93 123 148 1051 208 622 122 198 1 614 110 2 304 6 288 622 123 100 2 3513 121 44 123 5 768 522 204 0											
Exempt 195 66 1 54 8 44 204 65 0 N/A 43 92 95 168 1621 207 1759 202 22 1990 1 715 79 1 66 2 38 718 79 0 2 3528 101 7 215 1 266 3536 101 0 3 246 163 11 294 4 187 261 169 0 Exempt 106 84 0 0 2 123 108 85 0 N/A 38 93 123 148 1051 208 1212 198 0 1 614 110 2 304 6 288 622 113 0 2 3513 121 4 123 5 768 153 11 Total											
N/A 43 92 95 168 1621 207 1759 202 2 1990 1 715 79 1 66 2 38 718 79 0 2 3528 101 7 215 1 266 3536 101 0 3 246 163 11 294 4 187 261 169 0 Exempt 106 84 0 0 2 123 108 85 0 N/A 38 93 123 148 1051 206 1212 198 0 70tal 4633 100 142 162 1060 207 5835 121 0 2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 255 111 0 3											
Total 5258 98 108 167 1655 205 7021 124 2 1990 1 715 79 1 66 2 38 718 79 0 2 3528 101 7 215 1 266 3536 101 0 3 246 163 11 294 4 187 261 169 0 Exempt 106 84 0 0 2 123 108 85 0 N/A 38 93 123 148 1051 208 1212 198 0 1 614 110 2 304 6 288 622 113 0 2 3513 121 4 123 5708 3521 121 0 2 3513 114 122 1094 262 1258 253 111 105 95<											
2 3528 101 7 215 1 266 3536 101 0 3 246 163 11 294 4 187 261 169 0 Exempt 106 84 0 0 2 123 108 85 0 N/A 38 93 123 148 1051 208 1212 198 0 Total 4633 100 142 162 1060 207 5835 121 0 2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 252 204 0 N/A 33 174 131 223 1094 262 1258 253 11 1992 1 733 190 1 98 10 110 744 189 0 2											
2 3528 101 7 215 1 266 3536 101 0 3 246 163 11 294 4 187 261 169 0 N/A 38 93 123 148 1051 208 1212 198 0 Total 4633 100 142 162 1060 207 5835 121 0 1991 1 614 110 2 304 6 288 622 113 0 2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 252 204 0 N/A 33 174 131 223 1094 262 1258 253 111 192 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 177 0 385 3770 <td>1990</td> <td>1</td> <td>715</td> <td>79</td> <td>1</td> <td>66</td> <td>2</td> <td>38</td> <td>718</td> <td>79</td> <td>0</td>	1990	1	715	79	1	66	2	38	718	79	0
3 246 163 11 294 4 187 261 169 0 Exempt 106 84 0 0 2 123 108 85 0 Total 4633 100 142 162 1060 207 5835 121 0 1991 1 614 110 2 304 6 288 622 113 0 2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 252 204 0 Exempt 105 95 0 0 4 40 109 93 0 N/A 33 174 131 223 1094 262 1258 253 111 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770		2	3528	101	7						
Exempt 106 84 0 0 2 123 108 85 0 N/A 38 93 123 148 1051 208 1212 198 0 Total 4633 100 142 162 1060 207 5835 121 0 1991 1 614 110 2 304 6 288 622 113 0 2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 252 204 0 N/A 33 174 131 223 1094 262 1258 253 11 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 <											
N/A 38 93 123 148 1051 208 1212 198 0 1991 1 614 110 2 304 6 288 622 113 0 2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 252 204 0 Exempt 105 95 0 0 4 40 109 93 0 N/A 33 174 131 223 1094 262 1258 253 111 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 3 234 279 1 363 1 748 236 282 0 3											
Total 4633 100 142 162 1060 207 5835 121 0 1991 1 614 110 2 304 6 288 622 113 0 2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 252 204 0 Exempt 105 95 0 0 4 40 109 93 0 N/A 33 174 131 223 1094 262 1258 253 111 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 56 118 188 149 0 N/A 41 339 189 2											
2 3513 121 4 123 5 708 3522 122 0 3 248 202 3 393 1 60 252 204 0 N/A 33 174 131 223 1094 262 1258 253 111 Total 4513 124 140 225 1110 263 5763 153 11 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 3 234 279 1 363 1 748 236 282 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 193 1 793 200 0 0 26 195 819											
3 248 202 3 393 1 60 252 204 0 Exempt 105 95 0 0 4 40 109 93 0 N/A 33 174 131 223 1094 262 1258 253 11 Total 4513 124 140 225 1110 263 5763 153 11 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 </td <td>1991</td> <td>1</td> <td>614</td> <td>110</td> <td>2</td> <td>304</td> <td>6</td> <td>288</td> <td>622</td> <td>113</td> <td>0</td>	19 91	1	614	110	2	304	6	288	622	113	0
Exempt 105 95 0 0 4 40 109 93 0 N/A 33 174 131 223 1094 262 1258 253 111 Total 4513 124 140 225 1110 263 5763 153 11 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 3 234 279 1 363 1 748 236 282 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 26 195 819 199 </td <td></td> <td>2</td> <td>3513</td> <td>121</td> <td>4</td> <td>123</td> <td>5</td> <td>708</td> <td>3522</td> <td>122</td> <td>0</td>		2	3513	121	4	123	5	708	3522	122	0
N/A 33 174 131 223 1094 262 1258 253 111 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 3 234 279 1 363 1 748 236 282 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 42 126 197 177 0 2 3404 235 2 129 12 250 3418 235		3	248	202	3	393	1	60	252	204	0
N/A 33 174 131 223 1094 262 1258 253 111 Total 4513 124 140 225 1110 263 5763 153 11 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 3 234 279 1 363 1 748 236 282 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 2 1314 235 0		Exempt	105	95	0	0	4	40			0
Total 4513 124 140 225 1110 263 5763 153 11 1992 1 733 190 1 98 10 110 744 189 0 2 3748 202 12 117 10 385 3770 202 0 3 234 279 1 363 1 748 236 282 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 26 195 819 199 0 2 3404 235 2 129 12 250 3418 235 <td></td> <td>•</td> <td></td> <td>174</td> <td>131</td> <td></td> <td>1094</td> <td></td> <td></td> <td></td> <td></td>		•		174	131		1094				
2 3748 202 12 117 10 385 3770 202 0 3 234 279 1 363 1 748 236 282 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 26 195 819 199 0 2 3404 235 2 129 12 250 3418 235 0 3 245 329 2 190 5 168 252 325 0 Exempt 155 191 0 0 42 126 197 177 0											
3 234 279 1 363 1 748 236 282 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 26 195 819 199 0 2 3404 235 2 129 12 250 3418 235 0 3 245 329 2 190 5 168 252 325 0 3 245 329 2 190 5 168 252 325 0 Kempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344<	1992		733	190			10	110	744	189	0
3 234 279 1 363 1 748 236 282 0 Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 26 195 819 199 0 2 3404 235 2 129 12 250 3418 235 0 3 245 329 2 190 5 168 252 325 0 3 245 329 2 190 5 168 252 325 0 Kempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344<		2	3748	202	12	117	10	385	3770	202	0
Exempt 132 162 0 0 56 118 188 149 0 N/A 41 339 189 269 1311 400 1541 370 54 Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 26 195 819 199 0 2 3404 235 2 129 12 250 3418 235 0 3 245 329 2 190 5 168 252 325 0 Exempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344 204 Total 4654 233 108 296 1340 391 6102 269			234	279			1	748	236		0
N/A 41 339 189 269 1311 400 1541 370 54 1993 1 793 200 0 0 26 195 819 199 245 54 1993 1 793 200 0 0 26 195 819 199 0 2 3404 235 2 129 12 250 3418 235 0 3 245 329 2 190 5 168 252 325 0 Exempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344 204 Total 4654 233 108 296 1340 391 6102 269 204 1994 1 848 104 3 282 8 138		Exempt	132	162	0	0	56	118			0
Total 4888 204 203 260 1388 387 6479 245 54 1993 1 793 200 0 0 26 195 819 199 0 2 3404 235 2 129 12 250 3418 235 0 3 245 329 2 190 5 168 252 325 0 Exempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344 204 Total 4654 233 108 296 1340 391 6102 269 204 1994 1 848 104 3 282 8 138 859 105 1 2 3115 150 5 197 6 211 3126 150 <td></td> <td>N/A</td> <td>41</td> <td></td> <td>189</td> <td>269</td> <td>1311</td> <td>400</td> <td>1541</td> <td></td> <td>54</td>		N/A	41		189	269	1311	400	1541		54
2 3404 235 2 129 12 250 3418 235 0 3 245 329 2 190 5 168 252 325 0 Exempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344 204 Total 4654 233 108 296 1340 391 6102 269 204 1994 1 848 104 3 282 8 138 859 105 1 2 3115 150 5 197 6 211 3126 150 1 3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0		Total			203	260	1388	387	6479	245	54
3 245 329 2 190 5 168 252 325 0 Exempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344 204 Total 4654 233 108 296 1340 391 6102 269 204 1994 1 848 104 3 282 8 138 859 105 1 2 3115 150 5 197 6 211 3126 150 1 3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 </td <td>1993</td> <td></td> <td>793</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0</td>	1993		793								0
Exempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344 204 Total 4654 233 108 296 1340 391 6102 269 204 1994 1 848 104 3 282 8 138 859 105 1 2 3115 150 5 197 6 211 3126 150 1 3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811		2	3404	235	2	129	12	250	3418	235	0
Exempt 155 191 0 0 42 126 197 177 0 N/A 57 286 104 302 1255 406 1416 344 204 Total 4654 233 108 296 1340 391 6102 269 204 1994 1 848 104 3 282 8 138 859 105 1 2 3115 150 5 197 6 211 3126 150 1 3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811		3	245	329		190	5	168	252	325	0
Total 4654 233 108 296 1340 391 6102 269 204 1994 1 848 104 3 282 8 138 859 105 1 2 3115 150 5 197 6 211 3126 150 1 3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811 1995 1 282 60 0 0 32 37 314 57 1 2 1040 72 1 90 6 35 1050 72 <t< td=""><td></td><td>Exempt</td><td>155</td><td>191</td><td>0</td><td>0</td><td>42</td><td>126</td><td>197</td><td></td><td>0</td></t<>		Exempt	155	191	0	0	42	126	197		0
1 848 104 3 282 8 138 859 105 1 2 3115 150 5 197 6 211 3126 150 1 3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811 1995 1 282 60 0 0 32 37 314 57 1 2 1040 72 1 90 6 35 1050 72 3 3 49 92 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 0		N/A	57	286	104	302	1255	406	1416		204
2 3115 150 5 197 6 211 3126 150 1 3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811		Total	4654	233	108	296	1340	391	6102	269	204
3 187 182 2 141 0 0 189 180 1 Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811 1995 1 282 60 0 0 32 37 314 57 1 2 1040 72 1 90 6 35 1050 72 3 3 49 92 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324	1994										
Exempt 158 103 0 0 34 94 192 102 0 N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811 1995 1 282 60 0 0 32 37 314 57 1 2 1040 72 1 90 6 35 1050 72 3 3 49 92 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324											
N/A 34 177 76 178 1159 260 1269 154 808 Total 4342 141 86 182 1207 254 5635 166 811 1995 1 282 60 0 0 32 37 314 57 1 2 1040 72 1 90 6 35 1050 72 3 3 49 92 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324											
Total 4342 141 86 182 1207 254 5635 166 811 1995 1 282 60 0 0 32 37 314 57 1 2 1040 72 1 90 6 35 1050 72 3 3 49 92 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324											
1995 1 282 60 0 0 32 37 314 57 1 2 1040 72 1 90 6 35 1050 72 3 3 49 92 0 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324		N/A		177	76	178					808
2 1040 72 1 90 6 35 1050 72 3 3 49 92 0 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324		Total	4342	141	86	182	1207	254	5635	166	811
3 49 92 0 0 0 49 92 0 Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324	1995				-						
Exempt 31 69 0 0 46 41 77 52 0 N/A 27 82 15 72 176 54 218 8 1324											
N/A 27 82 15 72 176 54 218 8 1324											
Total 1429 70 16 73 260 49 1705 67 1328				82			176	54		8	1324
		Total	1429	70	16	73	260	49	1705	67	1328

		Eguiv	alent	None	quivalent	0	ther	Tot	tal	Oper
year	Medical specialty	•	Days		Days	-	Days		Days	N
1989	General hospital	1219	105	95	168	1	78	1220	105	0
	General/plastic surgery	496	71	0	0	13	40	509	70	0
	Other	3539	99	13	159	20	124	3572	99	Ó
	N/A	4	106	95	168	1621	207	1720	204	2
	Total	5258	98	108	167	1655	205	7021	124	2
1990	General hospital	410	97	2	665	0	0	412	99	0
	General/plastic surgery	453	83	2	496	5	141	460	86	Ō
	Other	3767	103	15	165	4	158	3786	103	ŏ
	N/A	3	110	123	148	1051	208	1177	201	Ő
	Total	4633	100	142	162	1060	208 207	5835	121	0
1991	General hospital	400	136	0	0	1	76	401	136	0
	General/plastic surgery	570	111	Ő	õ	6	58	576	110	Ő
	Other	3541	124	9	253	9	562	3559	126	ŏ
	N/A	2	490	131	223	1094	262	1227	256	11
	Total	4513	124	140	225	1110	263	5763	153	11
1992	General hospital	369	277	0	0	8	319	377	278	0
	General/plastic surgery	662	200	3	77	7	162	672	199	Ō
	Other	3857	197	11	149	62	139	3930	196	ŏ
	N/A	0	0	189	269	1311	400	1500	371	54
	Total	4888	204	203	260	1388	387	6479	245	54
1993	General hospital	389	284	0	0	12	137	401	280	0
	General/plastic surgery	752	221	1	126	21	165	774	219	0
	Other	3512	230	4	175	52	175	3568	229	0
	N/A	1	302	103	303	1255	406	1359	346	204
	Total	4654	233	108	296	1340	391	6102	269	204
1994	General hospital	398	146	1	329	2	259	401	147	0
	General/plastic surgery	692	103	0	0	5	130	697	104	0
	Other	3251	148	9	198	41	107	3301	148	3
	N/A	1	203	76	178	1159	260	1236	154	808
	Total	4342	141	86	182	1207	254	5635	166	811
1995	General hospital	109	78	0	0	7	39	116	76	0
	General/plastic surgery	274	62	0	0	13	40	287	61	0
	Other	1046	72	1	90	66	40	1113	70	4
	N/A	0	0	15	72	174	54	189	7	1324
	Total	1429	70	16	73	260	49	1705	67	1328

1989 DCLD 101 76 8 130 168 142 1187 85 10 DGRD 2494 97 59 187 1102 214 3655 133 0 DGRD 2494 97 59 187 1102 214 3655 133 0 DCALD 106 85 0 0 36 120 142 94 0 DRAER 793 108 23 147 170 182 986 121 2 NA 1 511 0 0 5175 6 231 0 DGRD 968 129 32 145 189 274 1035 6 0 0 31 115 204 86 0 0 31 15 20 0 135 0 0 31 135 10 12 255 110 2 26 290 12	Fiscal		Equiv			uivalent	Ot		То		Ope
DCRND 853 119 18 140 174 247 1045 141 0 DCRD 2494 97 59 187 1102 214 3655 133 0 DCD 106 85 0 0 36 120 142 94 0 DRAER 733 108 23 147 170 182 986 121 2 N/A 1 511 0 0 5 175 6 231 0 DCRD 903 122 10 227 122 151 1005 82 0 DCRD 1649 96 81 162 255 177 2255 117 0 DCD 173 81 0 0 31 115 2245 121 124 0 DCRD 173 81 12 181 130 202 978 101 2	year	Division	N	Days	N	Days	N	Days	N	Days	N
DGRD 2494 97 59 187 1102 214 3655 133 0 DRAER 793 108 23 147 170 182 996 121 2 Total 558 98 108 167 1655 702 124 2 1990 DCLD 903 72 10 227 122 151 1035 82 0 DCRND 906 129 32 145 189 274 1129 154 0 DCRND 906 112 2255 1210 135 0 0 1110 2245 141 0 DCR 1649 96 81 162 207 5835 121 0 DCR 1643 160 142 162 1000 207 5835 121 0 DCLD 836 85 12 181 130 202 978 101 <td>1989</td> <td></td>	1989										
DOD 106 85 0 0 36 120 142 946 121 2 NA 1 511 0 0 5 175 6 231 0 Total 5258 98 108 167 1655 205 7021 122 2 1990 DCLD 903 72 10 227 122 151 1035 82 0 DGRD 1649 96 81 162 525 179 2255 117 0 DCR 173 81 0 0 31 115 204 86 0 DCR 7533 100 142 162 1060 207 5835 121 0 1991 DCRND 881 159 12 181 30 202 978 101 2 DCRD 1761 121 64 172 526 225 2351					18		174		1045	141	
DRAER 793 108 23 147 170 182 986 121 2 Total 5258 99 108 167 1655 705 701 122 2 1990 DCLD 903 72 10 227 122 151 1035 82 0 DCRND 906 129 32 145 189 274 1129 154 0 DCR 1649 96 81 162 525 170 235 0 DCA 173 81 0 0 31 115 204 86 0 DCA 836 85 12 181 130 202 978 101 2 DCR 881 159 26 299 233 336 1130 166 31 DCR 121 64 122 526 231 146 22 225 1131 1											
N/A 1 511 0 0 5 175 6 231 0 1990 DCLD 903 72 10 227 122 151 1035 82 0 DCRD 906 129 32 145 199 2255 170 0 225 170 0 0 31 115 2265 170 0 0 0 31 115 204 86 0 DCRD 1000 111 18 128 192 255 1210 135 0 0 1 572 1 1010 2 841 0 DCRD 881 159 26 259 223 336 1130 196 3 0 0 32 145 124 0 13 145 12 162 110 124 0 0 0 13 165 11 110 124 0 0											
Total 5258 98 108 167 1655 205 7021 124 2 1990 DCLD 903 72 10 227 122 151 1035 82 0 DCRND 908 129 32 145 189 274 1129 154 0 DCRD 1649 96 81 162 525 179 2255 117 0 DCR 0 111 18 122 265 1210 135 0 DRA 0 0 1672 1 1010 2 841 0 DCRD 881 159 26 259 223 336 1130 196 3 DCRD 127 102 3 342 40 178 170 124 0 DCRD 127 102 3 342 175 173 1 N/A 1 3											
1990 DCLD 903 72 10 227 122 151 1035 82 DCRND 908 129 32 145 189 274 1129 154 0 DCRD 1649 96 81 162 525 179 2255 117 0 DCD 173 81 0 0 31 115 204 86 0 DRAER 1000 111 18 128 192 265 1210 135 0 Total 4633 100 142 162 1060 207 5835 121 0 1991 DCLD 836 85 12 181 130 202 978 101 2 DCRD 1761 121 64 172 262 235 136 9 187 3 Total 4513 124 140 225 1100 263 2763											
DCRND 908 129 32 145 189 274 1129 154 0 DGRD 1649 96 81 162 525 179 2255 117 0 DCD 173 81 0 0 31 115 224 86 0 DRAER 1000 111 18 128 192 265 1210 135 0 VA 0 0 142 162 1060 207 5835 121 0 1991 DCLD 836 85 12 181 130 202 978 101 2 DCRND 881 159 26 259 223 336 1130 146 3 DCRD 1761 121 64 172 526 225 2351 146 2 146 3 147 3 147 13 141 142 2 167 3<	4000		002	70	10	227	100	151	1025	0 2	0
DGRD 1649 96 81 162 525 179 2255 117 0 DOD 173 81 0 0 31 1115 204 86 0 DRAER 1000 11 18 128 192 285 1210 135 0 Total 4633 100 142 162 1060 207 5835 121 0 1991 DCLD 836 85 12 181 130 202 978 101 2 DCRD 881 159 26 225 2351 146 2 D D 143 140 225 1110 263 5763 153 111 NA 1 3 7 308 1 86 9 187 33 110 268 100 DRAER 967 133 111 142 2 1110 263 5763 153 <td< td=""><td>1990</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	1990										
DOD 173 81 0 0 31 115 204 86 0 NA 0 0 1 672 1 1010 2 841 0 Total 4633 100 142 162 1060 207 5835 121 0 1991 DCLD 836 85 12 181 130 202 978 101 2 DCRD 881 159 26 259 223 336 1130 196 3 DGRD 1761 121 64 172 526 225 2351 146 2 DCD 127 102 3 342 40 178 170 124 0 0 176 142 2 173 1 175 110 263 5763 153 11 1992 DCLD 969 119 25 223 144 387 109 268 <td></td>											
DRAER 1000 111 18 128 192 265 1210 135 0 Total 4633 100 142 162 1060 207 5833 121 0 1991 DCLD 836 85 12 181 130 202 978 101 2 DCND 881 159 26 259 223 336 1130 196 3 DGRD 1761 121 64 172 526 225 2351 146 2 DOD 127 102 3 342 400 178 173 1 N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 111 1992 DCLD 969 119 25 223 145 278 1139 961											
N/A 0 0 1 672 1 1010 2 841 0 1991 DCLD 836 85 12 181 130 202 978 101 2 DGRD 881 159 26 259 223 336 1130 196 3 DGRD 1761 121 64 172 526 225 2351 146 2 DOD 127 102 3 342 40 178 170 124 0 DRAER 907 134 28 298 190 342 1125 173 1 N/A 1 3 7 308 1 86 9 137 3 3 101 263 5763 153 111 1992 DCLD 969 119 25 223 145 278 1109 261 10 D 262 18 10											
Total 4633 100 142 162 1060 207 5835 121 0 1991 DCLD 836 85 12 181 130 202 978 101 2 DCRND 881 159 26 259 223 336 1130 196 3 DGRD 1761 121 64 172 526 225 2351 146 2 DOD 127 102 3 342 40 178 170 124 0 DRAER 907 134 28 298 190 342 1125 173 1 N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 111 1992 DCLD 961 182 201 70 289 291 94											
1991 DCLD 836 85 12 181 130 202 978 101 2 DGRD 1761 121 64 172 526 225 2351 146 2 DOD 127 102 3 342 40 178 170 124 0 DRAER 907 134 28 288 190 342 1125 173 1 N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 11 1992 DCLD 669 119 25 223 145 278 1139 142 2 DCRND 812 237 53 250 244 387 109 265 16 10 0 0 0 0 0 34 126 279 19											
DCRND 881 159 26 259 223 336 1130 196 3 DGRD 1761 121 64 172 526 225 2351 146 2 DOD 127 102 3 342 40 178 170 124 0 DRAER 907 134 28 298 190 342 1125 173 1 N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 111 1992 DCLD 969 119 25 223 145 278 1109 268 10 0 0 0 260 138 312 272 264 389 239 194 0 DCRD 167 154 2 201 70 289 239 1	400 -										
DGRD 1761 121 64 172 526 225 2351 146 2 DOD 127 102 3 342 40 178 170 124 0 DRAER 907 134 28 298 190 342 1125 173 1 N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 111 1992 DCLD 969 119 25 223 145 278 1139 142 2 2 DCRND 812 237 53 250 244 387 109 268 10 DGRD 167 154 2 201 70 289 239 194 0 DCA 168 204 203 260 1388 387 6479 <t< td=""><td>1991</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	1991										
DOD 127 102 3 342 40 178 170 124 0 DRAER 907 134 28 298 190 342 1125 173 1 N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 11 1992 DCLD 969 119 25 223 145 278 1139 142 2 2 0 0 268 10 0											
DRAER 907 134 28 298 190 342 1125 173 1 N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 11 1992 DCLD 969 119 25 223 145 278 1139 142 2 DCRND 812 237 53 250 244 387 1109 268 10 DGRD 167 154 2 201 70 289 239 194 0 DCAER 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 8 92 8 57 5 Total 4888 204 203 260 1388 387 6479 245 54											
N/A 1 3 7 308 1 86 9 187 3 Total 4513 124 140 225 1110 263 5763 153 111 1992 DCLD 969 119 25 223 145 278 1139 142 2 DCRND 812 237 53 250 244 387 1109 268 10 DGRD 1953 220 94 272 677 391 2724 262 18 DOD 167 154 2 201 70 289 239 194 0 DRAER 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 8 92 8 57 5 Total 4888 204 203 260 1388 387 6479 245 54											
Total 4513 124 140 225 1110 263 5763 153 111 1992 DCLD 969 119 25 223 145 278 1139 142 2 DCRND 812 237 53 250 244 387 1109 268 10 DGRD 1953 220 94 272 677 391 2724 262 18 DCD 167 154 2 201 70 289 239 194 0 DRARE 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 0 8 57 54 1993 DCLD 788 165 6 239 167 319 961 188 21 DGRD 2077 260 45 315 583 412 2705 283 96											
DCRND 812 237 53 250 244 387 1109 268 10 DGRD 1953 220 94 272 677 391 2724 262 18 DOD 167 154 2 201 70 289 239 194 0 DRAER 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 8 92 8 57 5 Total 4888 204 203 260 1388 387 6479 245 54 1993 DCLD 788 165 6 239 167 319 961 188 21 DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 <											
DCRND 812 237 53 250 244 387 1109 268 10 DGRD 1953 220 94 272 677 391 2724 262 18 DOD 167 154 2 201 70 289 239 194 0 DRAER 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 8 92 8 57 5 Total 4888 204 203 260 1388 387 6479 245 54 1993 DCLD 788 165 6 239 167 319 961 188 21 DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 <	1002		060	110	25	222	145	279	1120	142	2
DGRD 1953 220 94 272 677 391 2724 262 18 DOD 167 154 2 201 70 289 239 194 0 DRAER 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 0 8 92 8 57 5 Total 4888 204 203 260 1388 387 6479 245 54 1993 DCLD 788 165 6 239 167 319 961 188 21 DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 384 311 251 <td< td=""><td>1352</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	1352										
DOD 167 154 2 201 70 289 239 194 0 DRAER 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 0 8 92 8 57 5 Total 4888 204 203 260 1388 387 6479 245 54 1993 DCLD 788 165 6 239 167 319 961 188 21 DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 348 1311 251 3 DRAER 866 249 20 355 230 384 1136 269 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>											
DRAER 987 236 29 274 244 480 1260 279 19 N/A 0 0 0 0 8 92 8 57 5 Total 4888 204 203 260 1388 387 6479 245 54 1993 DCLD 788 165 6 239 167 319 961 188 21 DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 348 311 251 3 DRAER 866 249 20 355 230 384 1136 268 42 N/A 0 0 0 0 0 0 149 231 881											
N/A 0 0 0 0 0 8 92 8 57 5 1993 DCLD 788 165 6 239 167 319 961 188 21 DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 348 311 251 3 DRAER 866 249 20 355 230 384 1136 268 42 N/A 0 0 0 0 0 0 1 1 Total 4654 233 108 296 1340 391 6102 269 204 1994 DCLD 724 160 8 220 149 231 881 146											
Total 4888 204 203 260 1388 387 6479 245 54 1993 DCLD 788 165 6 239 167 319 961 188 21 DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 348 311 251 3 DRAER 886 249 20 355 230 384 1136 268 422 N/A 0 0 0 0 0 0 0 1 Total 4654 233 108 296 1340 391 6102 269 204 1994 DCLD 724 160 8 220 149 231 881 146											
DCRND 687 219 35 242 267 412 989 261 411 DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 384 311 251 3 DRAER 886 249 20 355 230 384 1136 268 42 N/A 0 0 0 0 0 0 0 149 231 881 146 158 DCLD 724 160 8 220 149 231 881 146 158 DCRND 590 176 18 179 260 294 868 174 185 DGRD 1863 128 52 181 481 256 2396 138 269 DOD 377 92 0 0 131 198			4888	204	203	260	1388				
DCRND 687 219 35 242 267 412 989 261 41 DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 348 311 251 3 DRAER 886 249 20 355 230 384 1136 268 42 N/A 0 0 0 0 0 0 0 0 1 Total 4654 233 108 296 1340 391 6102 269 204 1994 DCLD 724 160 8 220 149 231 881 146 158 DGRD 1963 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117	1993	DCLD	788	165	6	239	167	319	961	188	21
DGRD 2077 260 45 315 583 412 2705 283 96 DOD 216 211 2 404 93 348 311 251 3 DRAER 886 249 20 355 230 384 1136 268 42 N/A 0 0 0 0 0 0 0 1 Total 4654 233 108 296 1340 391 6102 269 204 1994 DCLD 724 160 8 220 149 231 881 146 158 DCRND 590 176 18 179 260 294 868 174 185 DGRD 1863 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117 11											
DOD 216 211 2 404 93 348 311 251 3 DRAER 886 249 20 355 230 384 1136 268 42 N/A 0 0 0 0 0 0 0 0 1 Total 4654 233 108 296 1340 391 6102 269 204 1994 DCLD 724 160 8 220 149 231 881 146 158 DCRND 590 176 18 179 260 294 868 174 185 DGRD 1863 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117 11 DRAER 788 151 8 158 186 251 982 145 1											
N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 1 Total 4654 233 108 296 1340 391 6102 269 204 1994 DCLD 724 160 8 220 149 231 881 146 158 DGRD 590 176 18 179 260 294 868 174 185 DGRD 1863 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117 11 DRAER 788 151 8 158 186 251 982 145 168 N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							93				
Total 4654 233 108 296 1340 391 6102 269 204 1994 DCLD 724 160 8 220 149 231 881 146 158 DCRND 590 176 18 179 260 294 868 174 185 DGRD 1863 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117 11 DRAER 788 151 8 158 186 251 982 145 168 N/A 0 <		DRAER	886	249	20	355	230		1136	268	42
1994 DCLD 724 160 8 220 149 231 881 146 158 DCRND 590 176 18 179 260 294 868 174 185 DGRD 1863 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117 11 DRAER 788 151 8 158 186 251 982 145 168 N/A 0 </td <td></td>											
DCRND 590 176 18 179 260 294 868 174 185 DGRD 1863 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117 11 DRAER 788 151 8 158 186 251 982 145 168 N/A 0		Total	4654	233	108	296	1340	391	6102	269	204
DGRD 1863 128 52 181 481 256 2396 138 289 DOD 377 92 0 0 131 198 508 117 11 DRAER 788 151 8 158 186 251 982 145 168 N/A 0	1994				8						
DOD 377 92 0 0 131 198 508 117 11 DRAER 788 151 8 158 186 251 982 145 166 N/A 0											
DRAER 788 151 8 158 186 251 982 145 168 N/A 0											
N/A 0											
Total 4342 141 86 182 1207 254 5635 166 811 1995 DCLD 206 79 2 133 35 56 243 43 193 DCRND 161 70 0 0 23 74 184 27 288 DGRD 622 70 11 56 113 45 746 38 557 DOD 134 57 1 90 61 37 196 40 51 DRAER 306 71 2 96 28 62 336 41 239 N/A 0 0 0 0 0 0 0 0 0											
1995 DCLD 206 79 2 133 35 56 243 43 193 DCRND 161 70 0 0 23 74 184 27 288 DGRD 622 70 11 56 113 45 746 38 557 DOD 134 57 1 90 61 37 196 40 51 DRAER 306 71 2 96 28 62 336 41 239 N/A 0 0 0 0 0 0 0 0 0			-	-	-	-	-	-	-	-	-
DCRND 161 70 0 0 23 74 184 27 288 DGRD 622 70 11 56 113 45 746 38 557 DOD 134 57 1 90 61 37 196 40 51 DRAER 306 71 2 96 28 62 336 41 239 N/A 0 0 0 0 0 0 0 0											
DGRD 622 70 11 56 113 45 746 38 557 DOD 134 57 1 90 61 37 196 40 51 DRAER 306 71 2 96 28 62 336 41 239 N/A 0 0 0 0 0 0 0 0	1995										
DOD 134 57 1 90 61 37 196 40 51 DRAER 306 71 2 96 28 62 336 41 239 N/A 0 0 0 0 0 0 0 0											
DRAER 306 71 2 96 28 62 336 41 239 N/A 0 0 0 0 0 0 0 0 0 0											
N/A 0 0 0 0 0 0 0 0 0											
		Total	1429	70		73	260		1705	69	1328

Fiscal		Total FDA	Non-FDA	Time		entiles e laps	
year	N	time	time	lapse	5	50	95
1989	5149	80	21	101	18	77	252
1990	4518	81	20	102	16	78	274
1991	4275	94	25	119	19	86	322
1992	4368	152	34	185	33	132	505
1993	3123	173	28	201	49	161	486
1994	2650	100	23	122	24	92	318
1995	834	60	7	66	14	57	148
Total	24917	108	25	133	21	90	378

Table II.7: Average Days to Equivalency for 510(k)s by Fiscal Year (October 1, 1988 - May 18, 1995)

Table II.8: Average Day Tier, Medica May 18, 1995	l Specia		or 510(k)s by sion (Octobe	
Class	N	Total FDA time	Non-FDA time	Time Iapse
I	6839	85	19	104
11	16726	115	25	140
111	917	144	46	189
N/A	435	144	33	177
Tier				
1	5001	90	22	111
2	17774	111	25	136
3	1134	150	40	191
Exempt	797	94	12	106
N/A	211	117	34	151
Medical specialty				
General hospital	2773	108	31	139
General/plastic surgery	3093	109	17	125
Other	19044	108	25	133
N/A	7	66	12	77
Division				
DCLD	4415	78	18	96
DCRND	4222	122	36	158
DGRD	10307	113	24	137
DOD	1134	92	13	105
DRAER	4837	117	24	141
N/A	2	203	54	257
Total	24917	108	25	133

GAO/PEMD-96-2 FDA Medical Device Review Time

Fiscal year Class	N	Total FDA time	Non-FDA time	Time lapse
1989	1966	66	23	88
I	2894	88	19	106
111	230	104	31	135
N/A	59	84	16	101
Total	5149	80	21	101
1 990	1073	64	16	80
11	3153	84	21	105
111	227	115	36	151
N/A	65	94	24	117
Total	4518	81	20	102
1991	898	68	15	84
II	3115	97	27	123
111	18 1	153	47	201
N/A	81	115	44	159
Total	4275	94	25	119
1992	1017	126	23	150
II	3109	156	35	191
11	156	186	68	254
N/A	86	226	49	275
Total	4368	152	34	185
1993	800	145	18	162
11	2170	179	31	210
111	80	237	62	299
N/A	73	215	30	245
Total	3123	173	28	201
1994	870	78	16	94
11	1699	109	25	134
111	31	155	71	226
N/A	50	114	32	146
Total	2650	100	23	122
1995 I	215	51	10	61
	586	62	5	67
	12	100	13	113
<u>N/A</u>	21	69	6	75
Total	834	60	7	66

Fiscal year	Tier	N	Total FDA time	Non-FDA time	Time Iapse
•					•
1989	1	1589	67	25	91
	2	3096	86	19	105
	3	230	109	27	137
	Exempt	194	57	9	66
	N/A	40	7 1	17	87
	Total	5149	80	21	101
1990	1	705	67	17	84
	2	3447	82	20	102
	3	227	118	41	159
	Exempt	105	75	8	84
	N/A	34	73	18	89
	Total	4518	81	20	102
1991	1	584	82	24	106
	2	3335	93	25	117
	3	223	138	42	181
	Exempt	102	83	12	94
	N/A	31	112	42	154
	Total	4275	94	25	119
1992	1	679	149	28	177
	2	3329	150	34	184
	3	207	200	53	253
	Exempt	122	126	17	143
	N/A	31	176	62	238
	Total	4368	152	34	185
	TULAT	4300	152	34	105
1993	1	586	151	18	169
	2	2242	174	31	205
	3	139	238	45	283
	Exempt	121	166	13	179
	N/A	35	195	41	236
	Total	3123	173	28	201
4004	4	650	74	20	01
1994	1	658	71	20	91 122
	2	1752	110	23	133
	3	85	131	41	172
	Exempt	131	81	14	95
	N/A	24	106	53	159
	Total	2650	100	23	122
1995	1	200	52	4	56
	2	573	61	7	69
	3	23	85	10	94
	Exempt	22	55	5	60
	N/A	16	64	5	70
	Total	834	60	7	66

Table II.10: Average Days to Equivalency for 510(k)s by Tier of Medical Device (October 1, 1988 - May 18, 1995)

Fiscal year	Medical specialty	N	Total FDA time	Non-FDA time	Time Iapse
1989	General hospital	1198	79	30	109
	General/plastic surgery	489	55	19	74
	Other	3459	84	18	102
	N/A	3	38	0	38
	Total	5149	80	21	101
1990	General hospital	402	79	25	104
	General/plastic surgery	441	75	14	88
	Other	3672	82	21	103
	N/A	3	90	20	110
	Total	4518	81	20	102
1991	General hospital	379	90	37	127
	General/plastic surgery	534	89	16	106
	Other	3361	95	25	120
	N/A	1	75	22	97
	Total	4275	94	25	119
1992	General hospital	324	211	40	251
	General/plastic surgery	583	165	25	189
	Other	3461	144	35	179
	N/A	0	0	0	0
	Total	4368	152	34	185
1993	General hospital	213	217	26	243
	General/plastic surgery	495	184	17	201
	Other	2415	166	31	197
	N/A	0	0	0	0
	Total	3123	173	28	201
1994	General hospital	206	102	34	136
	General/plastic surgery	403	82	11	93
	Other	2041	103	24	127
	N/A	0	0	0	0
	Total	2650	100	23	122
1995	General hospital	51	72	5	77
	General/plastic surgery	148	55	3	58
	Other	635	60	8	67
	N/A	0	0	0	0
	Total	834	60	7	66
Total		24917	108	25	133

Table II.11: Average Days to Equivalency for 510(k)sby Medical Specialty of
Device (October 1, 1988 - May 18, 1995)

			er 1, 1988 - M		by Reviewing
Fiscal year	Division	N	Total FDA time	Non-FDA time	Time Iapse
1989	DCLD	994	68	11	79
	DCRND	818	103	24	127
	DGRD	2451	75	24	100
	DOD	105	72	10	82
	DRAER	780	87	20	107
	N/A	1	403	108	511
	Total	5149	80	21	101
1990	DCLD	888	60	16	76
	DCRND	866	100	27	127
	DGRD	1611	79	19	98
	DOD	170	67	13	80
	DRAER	983	90	23	113
	N/A	0	0	0	0
	Total	4518	81	20	102
1991	DCLD	799	64	20	84
	DCRND	825	118	35	153
	DGRD	1663	90	24	114
	DOD	120	91	11	102
	DRAER	867	104	27	131
	N/A	1	3	0	3
	Total	4275	94	25	119
1992	DCLD	884	88	23	111
	DCRND	730	168	61	228
	DGRD	1741	172	32	204
	DOD	160	136	13	148
	DRAER	853	165	30	195
	N/A	0	0	0	0
	Total	4368	152	34	185
1993	DCLD	508	115	19	134
	DCRND	499	149	47	196
	DGRD	1352	205	26	231
	DOD	156	161	19	180
	DRAER	608	171	29	200
	N/A	0	0	0	0
	Total	3123	173	28	201
1994	DCLD	269	118	28	146
	DCRND	382	113	34	146
	DGRD	1141	94	21	115
	DOD	318	69	17	86
	DRAER	540	110	21	131
	N/A	0	0	0	0
	Total	2650	100	23	122
1995	DCLD	73	62	9	71
	DCRND	102	58	8	65
	DGRD	348	59	7	66
	DOD	105	53	3	56
	DRAER	206	64	6	70
	N/A	0	0	0	0
	Total	834	60	7	66

Premarket Approval Tables III.1 - III.18

Tables	Page
Table III.1: Average Days to Decision on Original PMAS by Fiscal Year and Number of Open Cases	47
Table III.2: Summary of Average Days to Decision on PMAs and Number of Open Cases	48
Table III.3: Average Days to Decision on Original PMAS by Class of Medical Device and Number of Open Cases	49
Table III.4Average Days to Decision on Original PMAS by Tierof Medical Device and Number of Open Cases	50
Table III.5: Average Days to Decision on Original PMAS by Medical Specialty of Device and Number of Open Cases	51
Table III.6: Average Days to Decision on Original PMAS by Reviewing Division and Number of Open Cases	52
Table III.7: Average Days to Decision on PMA Supplements byFiscal Year and Number of Open Cases	53
Table III.8: Summary of Average Days to Decision on PMA Supplements and Number of Open Cases	54
Table III.9: Average Days to Decision on PMA Supplements byClass of Medical Device and Number of Open Cases	55
Table III.10:Average Days to Decision on PMA Supplements byTier of Medical Device and Number of Open Cases	56
Table III.11:Average Days to Decision on PMA Supplements byMedical Specialty of Device and Number of Open Cases	57
Table III.12:Average Days to Decision on PMA Supplements byReviewing Division and Number of Open Cases	58
Table III.13: Average Days to Approval for PMAS by Fiscal Year	59
Table III.14:Average Days to Approval for PMAS by Class, Tier,Medical Specialty, and Reviewing Division	60

Table III.15: Average Days to Approval for PMAs by Fiscal Yearand Class of Medical Device	61
Table III.16: Average Days to Approval for PMAS by Fiscal Yearand Tier of Medical Device	62
Table III.17:Average Days to Approval for PMAS by Fiscal Yearand Medical Specialty of Device	63
Table III.18:Average Days to Approval for PMAs by Fiscal Yearand Reviewing Division	64

Review Time for Premarket Approval	In reviewing a PMA application, FDA conducts an initial review to determine whether the application contains sufficient information to make a determination on its safety and effectiveness. A filing decision is made—filed, filed with deficiencies specified, or not filed—based on the adequacy of the information submitted. The manufacturer is notified of the status of the application at this time, especially since deficiencies need to be addressed.
	As part of the substantive review, a small proportion of PMA applications are also reviewed by an advisory panel. ¹ These panels include clinical scientists in specific medical specialties and representatives from both industry and consumer groups. The advisory panels review the applications and provide recommendations to the agency to either approve, deny, or conditionally approve them. FDA then makes a final determination on the application.
	To examine in greater detail those cases where the intermediate milestones were applicable, we calculated the average duration between the various dates—submission, filing, panel decision, and final decision. The number of applications differs for each of the milestones as not all have filing or panel dates. (See figure III.1.)

 $^{^1\!}O\!f$ the 401 original PMAs, 87 (22 percent) were reviewed by panels. Of the 3,640 PMA supplements, only 9 (0.2 percent) received panel review.

						Origina	I PMAs	5			
Fiscal year	to fi	nission ling Days	par	ig to iel Days	dec	nel to cision Days	to p	mission banel Days		nission cision Days	Total application
1989	61	117	32	161	30	344	32	309	81	513	84
1990	61	194	33	201	28	615	33	397	67	744	77
1991	48	106	10	208	10	435	10	343	60	580	72
1992	49	203	10	432	8	260	10	587	37	674	66
1993	29	179	1	295	1	216	1	357	21	462	40
1994	31	99	1	301	0	0	1	373	8	222	43
1995	10	46	0	0	0	0	0	0	1	23	19
Total	289	148	87	216	77	444	87	379	275	591	401
						PMA su	ıpplem	ents			
	Subn	nission	Filing to		Panel to		Submission		Submission		
	to f	iling	par	iel	deo	cision	to panel		to decision		Total
Fiscal		Dava	N	Days	Ν	Days	N	Days	Ν	Days	application
Fiscal year	Ν	Days									
	N 15	152	5	113	5	194	5	227	803	219	804
year		-	5 3	113 161	5 3	194 536	5 3	227 403	803 650	219 193	804 660
year 1989	15	- 152									
year 1989 1990	15 6	152 143 128 185	3	161	3	536	3	403	650	193 261 336	660 595 605
year 1989 1990 1991 1992 1993	15 6 6 1	152 143 128	3 0 1 0	161 0	3 0 1 0	536 0	3 0	403 0	650 577 572 351	193 261 336 266	660 595 605 394
year 1989 1990 1991 1992	15 6 6	152 143 128 185 688 0	3 0 1 0 0	161 0 516	3 0 1 0 0	536 0 206	3 0 1 0 0	403 0 581 0 0	650 577 572 351 295	193 261 336 266 162	660 595 605 394 372
year 1989 1990 1991 1992 1993	15 6 6 1	152 143 128 185 688	3 0 1 0	161 0 516 0	3 0 1 0	536 0 206 0	3 0 1 0	403 0 581 0	650 577 572 351	193 261 336 266	660 595 605 394


The following tables present information on review time for PMA applications for fiscal years 1989 through 1995. Original PMA applications are distinguished from PMA supplements. Some observations were deleted from our data because of apparent data entry errors. The first set of tables (tables III.1 through III.6) presents the time to a decision for original PMAS—from the date the application is submitted to the date a decision is rendered. The second set of tables (tables III.7 through III.12) provides similar information, in the same format, for PMA supplements.

We first present a summary table on the time to a decision by fiscal year (tables III.1 and III.7). Again, the grand total for the number of applications includes the number of open cases—that is, applications for which there had not been any decision made as of May 18, 1995. As with 510(k)s, the distributions of time to a decision for original PMAs and PMA supplements are not symmetric. Thus we report means and percentiles to characterize these distributions. (These means and percentiles do not include open cases.)

Figure III.2 presents the distribution for original PMAS submitted in 1989, the most recent year for which at least 95 percent of the applications had been completed. Figure III.3 presents the distribution for PMA supplements submitted in 1991, the most recent year with at least a 95-percent completion date.


Figure III.2: Time to a Decision for Original PMAs Submitted in Fiscal Year 1989^a

Frequency



^aThe number of cases in this frequency distribution is 81. As of May 18, 1995, about 4 percent of the applications submitted had not been completed and were not included.

Figure III.3: Time to a Decision for PMA Supplements Submitted in Fiscal Year 1991^a



^aThe number of cases in this frequency distribution is 577. As of May 18, 1995, 3 percent of the applications submitted had not been completed and were not included.

The second table is a summary of the time to a decision by class, tier, relevant medical specialty of the device, and reviewing division (tables III.2 and III.8). The two summary tables are followed by four tables (tables III.3 through III.6 and III.9 through III.12) presenting the details by class, tier, medical specialty, and reviewing division. The totals in these tables include only applications for which a decision has been rendered.

The class, tier, and medical specialty of some of the devices have yet to be determined and are designated with N/A. Medical specialities <u>other</u> than cardiovascular or ophthalmic include anesthesiology; clinical chemistry; dental; ear, nose, and throat; gastroenterology/urology; general and plastic surgery; general hospital; hematology; immunology; microbiology; neurology; obstetrics/gynecology; orthopedic; pathology; physical medicine; radiology; and clinical toxicology.

The third set of tables provides information on the time to an approval, for both original PMAs and PMA supplements (tables III.13 through III.18). Four different measures of duration are provided—total FDA time, non-FDA time, total elapsed time, and FDA review time. Total FDA time is the amount of time the application is under FDA's review process. Non-FDA time is the time the FDA clock is suspended waiting for additional information from the applicant. The total elapsed time, the duration from the date the application is submitted to the date of FDA's decision, equals the sum of total FDA and non-FDA time. FDA review time is FDA time for the last cycle—excluding any time accrued before the latest resetting of the FDA clock.

Again, we first provide a summary table for time to an approval by fiscal year (table III.13). In this table, we also provide the number of amendments or the number of times additional information was added to the initial submission. Not all amendments were for information requested by FDA as can be seen from the number of requests for information.

Table III.13 is followed by a summary by class, tier, medical specialty, and reviewing division (table III.14). Tables III.15 though III.18 provide the details for these two summary tables.

Fiscal	Appr	oved	Withd	rawn	C	Other		Perce	entile		C)pen	Grand
year	Ň	Days	Ν	Days	NI	Days	5	50	95	Mean	Ν	Days	total
1989	45	412	27	747	9	320	57	409	1373	513	3	2140	84
1990	36	758	22	740	9	698	29	700	1697	744	10	1813	77
1991	21	556	27	528	12	741	51	559	1422	580	12	1427	72
1992	21	756	11	583	5	529	106	734	1127	674	29	1150	66
1993	7	575	12	406	2	402	210	447	792	462	19	705	40
1994	3	189	5	241	0	0	133	234	294	222	35	396	43
1995	0	0	1	23	0	0	23	23	23	23	18	120	19

		Approv	ed		Withdray	vn		Other			Perce	ntile			Open	Grand
	N	Percent	Days	N	Percent	Days	N	Percent	Days	5	50	95	Mean		Percent	total
Class			•						•							
L	3	42.9	636	1	14.3	747	1	14.3	683	277	683	1206	668	2	28.6	7
11	25	52.1	364	10	20.8	735	11	22.9	851	71	465	1343	561	2	4.2	48
111	99	43.8	630	48	21.2	785	14	6.2	686	116	597	1503	681	65	28.8	226
N/A	6	5.0	766	46	38.3	379	11	9.2	168	0	327	841	379	57	47.5	120
Tier																
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
2	62	59.0	454	18	17.1	720	12	11.4	791	60	431	1455	550	13	12.4	105
3	62	35.4	707	43	24.6	774	13	7.4	728	168	653	1603	734	57	32.6	175
Exempt	1	20.0	1206	1	20.0	747	1	20.0	683	683	747	1206	879	2	40.0	5
N/A	8	6.9	589	43	37.1	377	11	9.5	168	0	342	815	368	54	46.6	116
Medical specialty																
Cardiovascular	34	54.0	712	8	12.7	983	5	7.9	444	225	738	1373	729	16	25.4	63
Ophthalmic	55	57.3	456	13	13.5	673	9	9.4	903	60	360	1521	545	19	19.8	96
Other	39	30.2	650	41	31.8	741	12	9.3	775	168	631	1702	707	37	28.7	129
N/A	5	4.4	669	43	38.1	377	11	9.7	168	0	327	837	363	54	47.8	113
Division																
DCLD	15	25.0	515	17	28.3	563	2	3.3	322	133	493	1313	528	26	43.3	60
DCRND	36	40.9	713	19	21.6	680	8	9.1	453	82	636	1239	670	25	28.4	88
DGRD	12	15.0	721	26	32.5	561	9	11.3	671	42	630	1707	623	33	41.3	80
DOD	58	46.0	461	27	21.4	506	16	12.7	515	9	357	1372	482	25	19.8	126
DRAER	12	25.5	763	16	34.0	780	2	4.3	1473	102		1702	819	17	36.2	47
Total	133	33.2	586	105	26.2	602	37	9.2	581	42	513	1455	591	126	31.4	401

Fiscal year	Class		oved Days	Withd N	lrawn Days		ther Days		otai Days	Open N
1989	I	0	0	0	0	0	0	0	0	0
	II	14	269	4	870	3	661	21	440	0
		31	476	11	1016	1	1	43	603	3
	N/A Total	0 45	0 412	12 27	459 747	5 9	179 320	17 81	377 513	0 3
1990	I	1	277	0	0	0	0	1	277	0
	II	4	532	2	818	4	1310	10	900	0
	III	30	787	9	1125	1	956	40	868	10
	N/A	1	1252	11	411	4	21	16	366	0
	Total	36	758	22	740	9	698	67	744	10
1991	I II	0 2	0	0 1	0 926	1 2	683 844	1 5	683 665	1 1
		2 19	357 577	20	926 611	29	044 724	5 48	619	9
	N/A	19	0	20 6	185	9	/24 0	40	185	9 1
	Total	21	556	27	528	12	741	60	580	12
1992	l	1	1206	1	747	0	0	2	977	1
	II	4	589	2	419	1	0	7	456	0
	III	15	765	7	563	2	885	24	716	24
	N/A	1	837	1	888	2	437	4	650	4
	Total	21	756	11	583	5	52 9	37	674	29
1993	I.	1	426	0	0	0	0	1	426	0
	11	0	0	1	468	1	447	2	458	1
		2	545	1	210	1	357	4	414	7
	N/A Total	4 7	627 575	10 12	419 406	0 2	0 402	14 21	479 462	11 19
1994	I	0	0	0	0	0	0	0	0	0
	11	1	147	0	0	0	0	1	147	0
	111	2	211	0	0	0	0	2	211	7
	N/A	0	0	5	241	0	0	5	241	28
	Total	3	189	5	241	0	0	8	222	35
1995	 }	0 0	0	0 0	0 0	0 0	0 0	0	0 0	0 0
		0	0	0	0	0	0	0	0	0 5
	N/A	0	0	1	23	0	0	1	23	13
	Total	0	Ő	1	23	0	Õ	1	23 23	18
Total		133	586	105	602	37	581	275	591	126

Fiscal year	Tier		roved Days		hdrawn Days		ther Days		otal Days	Oper N
1989	1	0	0	0	0	0	0	0	0	0
	2	27	325	5	849	0	0	32	407	0
	3	17	534	11	973	4	496	32	680	3
	Exempt	0	0	Ö	0	ò	0	0	0	Õ
	N/A	1	664	11	474	5	179	17	399	õ
	Total	45	412	27	747	9	320	81	512	3
1990	1	0	0	0	0	0	0	0	0	0
	2	15	586	3	731	4	1310	22	738	1
	3	19	936	8	1196	1	956	28	1011	9
	Exempt	Ō	0	ō	0	Ó	0	0	0	Ō
	N/A	2	353	11	411	4	21	17	313	ŏ
	Total	36	758	22	740	9	698	67	744	10
1991										
	1	0	0	0	0	0	0	0	0	0
	2	9	401	4	930	4	579	17	567	2
	3	12	673	18	526	7	841	37	633	8
	Exempt	0	0	0	0	1	683	1	683	1
	N/A	ŏ	õ	5	213	ò	0	5	213	1
	Total	21	556	27	528	12	741	60	580	12
1992	1	0	0	0	0	0	0	0	0	0
	2	9	712	5	467	2	564	16	617	4
	3	10	742	5	666	1	643	16	712	22
	Exempt	1	1206	1	747	ò	0	2	977	
	N/A	1	837	ò	0	2	437	3	570	2
	Total	21	756	11	583	5	529	37	674	29
1993	1	0	0	0	0	0	0	0	0	0
	2	1	426	1	468	2	402	4	425	1
	3	2	545	1	210	ō	0	3	433	8
	Exempt	ō	0	ò	0	ŏ	ŏ	õ	0	õ
	N/A	4	627	10	419	ŏ	ŏ	14	479	10
	Total	7	575	12	406	2	402	21	462	19
1994	1	0	0	0	0	0	0	0	0	0
	2	1	147	Ő	õ	ŏ	õ	1	147	2
	3	2	211	õ	ŏ	õ	ŏ	2	211	5
	Exempt	ō	0	ŏ	ŏ	ŏ	ŏ	ō	0	ő
	N/A	0	ő	5	241	Ő	0	5	241	28
	Total	3	189	5	241	Ő	õ	8	222	35
1995	1	0	0	0	0	о	0	0	0	0
	2	0	ŏ	ŏ	ŏ	ŏ	ŏ	Ő	ŏ	3
	2	0	ŏ	ŏ	0	0	0	0	ŏ	2
			ŏ	0		0	0	1		2
	Exempt	0			0				23	
	N/A Total	0 0	0 0	1 1	23 23	0 0	0 0	0 1	0 23	13 18
Total										

Table III.4: Average Days to Decision on Original PMAs by Tier of Medical Device

Fiscal /ear	Medical specialty		roved Days		idrawn Days	-	ther Days		otal Days	Ope N
989	Cardiovascular	9	546	2	1374	1	1	12	638	1
	Ophthalmic	25	306	3	538	0	0	28	331	0
	Other	11	543	11	962	3	661	25	742	2
	N/A	0	0	11	474	5	179	16	382	0
	Total	45	412	27	747	9	320	81	513	3
1990	Cardiovascular	7	942	1	993	1	956	9	949	2
	Ophthalmic	11	607	3	880	3	1447	17	803	3
	Other	18	779	7	1161	1	900	26	886	5
	N/A	0	0	11	411	4	21	15	307	C
	Total	36	758	22	740	9	698	67	744	10
1991	Cardiovascular	8	759	4	826	3	421	15	709	C
	Ophthalmic	9	401	3	931	3	618	15	550	3
	Other	4	499	15	473	6	962	25	594	8
	N/A	0	0	5	213	0	0	5	213	1
	Total	21	556	27	528	12	741	60	580	12
992	Cardiovascular	7	757	1	819	0	0	8	765	5
	Ophthalmic	9	777	4	426	1	1127	14	702	7
	Other	4	684	6	648	2	322	12	606	15
	N/A	1	837	0	0	2	437	3	570	2
	Total	21	756	11	583	5	529	37	674	29
993	Cardiovascular	2	545	0	0	0	0	2	545	4
	Ophthalmic	0	0	0	0	2	402	2	402	1
	Other	1	426	2	339	0	0	3	368	4
	N/A	4	627	10	419	0	0	14	479	10
	Total	7	575	12	406	2	402	21	462	19
1994	Cardiovascular	1	225	0	0	0	0	1	225	3
	Ophthalmic	1	147	0	0	0	0	1	147	2
	Other	1	196	0	0	0	0	1	196	2
	N/A	0	0	5	241	0	0	5	241	28
	Total	3	189	5	241	0	0	8	222	38
1995	Cardiovascular	0	0	0	0	0	0	0	0	
	Ophthalmic	0	0	0	0	0	0	0	0	3
	Other	0	0	0	0	0	0	0	0	1
	N/A	0	0	1	23	0	0	1	23	13
	Total	0	0	1	23	0	0	1	23	18
Total		133	586	105	602	37	581	275	591	126

Fiscal year	Division		roved Days		ndrawn Days		ther Days		otal Days	Oper N
1989	DCLD	3	411	2	1087	0	0	5	682	1
	DCRND	10	583	9	722	1	1	20	617	1
	DGRD	3	551	3	858	4	691	10	699	1
	DOD	25	306	4	450	4	29	33	290	Ó
	DRAER	4	541	9	790	Ó	0	13	714	Ō
	Total	45	412	27	747	9	320	81	513	3
1990	DCLD	5	495	3	882	0	0	8	640	2
	DCRND	8	892	1	993	2	519	11	833	2
	DGRD	7	797	7	933	1	900	15	867	2
	DOD	11	607	8	522	6	724	25	608	3
	DRAER	5	1084	3	645	Ō	0	8	919	1
	Total	36	758	22	740	9	698	67	744	10
1991	DCLD	3	470	4	363	0	0	7	409	0
	DCRND	8	759	5	696	5	516	18	674	1
	DGRD	1	585	10	371	2	753	13	446	6
	DOD	9	401	5	615	3	618	17	502	3
	DRAER	0	0	3	848	2	1473	5	1098	2
	Total	21	556	27	528	12	741	60	580	12
1992	DCLD	3	727	3	619	2	322	8	585	4
	DCRND	7	757	2	666	0	0	9	737	7
	DGRD	1	837	1	632	2	437	4	586	3
	DOD	9	777	4	426	1	1127	14	702	8
	DRAER	1	556	1	888	Ó	0	2	722	7
	Total	21	756	11	583	5	529	37	674	29
1993	DCLD	1	426	3	356	0	0	4	373	4
	DCRND	2	545	2	308	0	0	4	426	6
	DGRD	0	0	3	288	0	0	3	288	6
	DOD	3	564	4	581	2	402	9	536	1
	DRAER	1	815	0	0	0	0	1	815	2
	Total	7	575	12	406	2	402	21	462	19
1994	DCLD	0	0	2	188	0	0	2	188	10
	DCRND	1	225	0	0	0	0	1	225	7
	DGRD	0	0	1	256	0	0	1	256	9
	DOD	1	147	2	287	0	0	3	240	5
	DRAER	1	0	0	0	0	0	1	196	4
	Total	3	189	5	241	0	0	8	222	35
1995	DCLD	0	0	0	0	0	0	0	0	5
	DCRND	0	0	0	0	0	0	0	0	1
	DGRD	0	0	1	23	0	0	1	23	6
	DOD	0	0	0	0	0	0	0	0	5
	DRAER	0	0	0	0	0	0	0	0	1
	Total	0	0	1	23	0	0	1	23	18
Total		133	586	105	602	37	581	275	591	126

 Table III.6: Average Days to Decision on Original PMAs by Reviewing Division and Number of Open Cases (October 1, 1988 - May 18, 1995)

Fiscal	Appr	oved	Withd	rawn	0	ther		Perce	entile		C	Open	Grand
year	Ň	Days	Ν	Days	Ν	Days	5	50	95	Mean	Ν	Days	total
1989	640	190	137	363	26	167	22	172	576	219	1	2057	804
1990	557	164	70	442	23	142	18	125	597	193	10	1870	660
1991	493	226	72	462	12	479	18	154	1042	261	18	1476	595
1992	474	300	84	478	13	747	24	251	924	336	34	1119	605
1993	311	250	30	403	10	372	22	217	674	266	43	747	394
1994	269	165	22	141	4	75	21	144	378	162	77	394	372
1995	78	80	5	74	1	39	21	75	182	79	126	120	210
otal	2822	211	420	404	89	305	21	167	749	238	309	527	3640

		Approv	/ed		Withdra	wn		Other			Perce	ntile			Open	Grand
Class	N	Percent			Percent		N	Percent	Days	5	50	95	Mean		Percent	total
I	2	25.0	98	2	25.0	740	1	12.5	0	0	114	1329	335	3	37.5	8
11	588	83.3	159	66	9.3	390	22	3.1	479	16	105	699	192	30	4.2	706
11	2223	76.4	224	350	12.0	405	65	2.2	244	23	176	758	249	272	9.3	2910
N/A	9	56.3	276	2	12.5	353	1	6.3	746	22	193	777	328	4	25.0	16
Tier		•														
1	2	33.3	98	2	33.3	740	1	16.7	0	0	114	1329	335	1	16.7	6
2	1317	76.5	229	265	15.4	369	38	2.2	359	21	171	840	255	101	5.9	1721
3	1487	78.7	195	151	8.0	464	49	2.6	261	21	161	647	221	202	10.7	1889
Exempt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
N/A	16	66.7	241	2	8:3	206	1	4.2	746	30	212	777	264	5	20.8	24
Medical																
specialty																
Cardiovascular	985	81.2	183	83	6.8	476	22	1.8	63	20	159	576	203	123	10.1	1213
Ophthalmic	1239	77.3	229	251	15.7	346	36	2.2	354	20	173	767	251	77	4.8	1603
Other	592	72.8	218	86	10.6	503	30	3.7	409	25	165	924	261	105	12.9	813
N/A	6	54.5	371	0	0	0	1	9.1	746	30	468	777	425	4	36.4	11
Division																
DCLD	131	74.9	201	21	12.0	430	3	1.7	176	28	140	829	232	20	11.4	175
DCRND	1025	80.7	186	86	6.8	478	22	1.7	63	20	160	585	205	137	10.8	1270
DGRD	253	72.7	222	36	10.3	520	20	5.7	367	25	174	1015	266	39	11.2	348
DOD	1244	77.3	228	252	15.7	345	36	2.2	354	20	173	767	251	78	4.8	1610
DRAER	169	71.3	226	25	10.5	552	8	3.4	643	19	165	961	283	35	14.8	237
Total	2822	77.5	211	420	11.5	404	89	2.4	305	21	167	749	238	309	8.5	3640

Fiscal year	Class		roved Days		hdrawn Days		ther Days		otal Days	Open N
1989	I	0	0	0	0	0	0	0	0	0
	11	154	170	10	394	8	409	172	194	0
	HI	485	195	127	361	18	60	630	225	1
	N/A	1	569	0	0	0	0	1	569	0
	Total	640	190	137	363	26	167	803	219	1
1990	I	1	114	2	740	1	0	4	398	0
	11	116	127	8	294	8	187	132	141	1
	111	439	174	58	455	14	127	511	205	9
	N/A	1	131	2	353	0	0	3	279	0
	Total	557	164	70	442	23	142	650	193	10
1991	L	1	81	0	0	0	0	1	81	0
	II	112	154	15	391	4	937	131	205	1
		379	247	57	481	7	180	443	276	17
	N/A	1	777	0	0	1	746	2	762	0
	Total	493	226	72	462	12	479	577	261	18
1992	I	0	0	0	0	0	0	0	0	0
	Ħ	85	206	18	482	1	1161	104	263	2
	111	388	320	66	477	12	713	466	352	32
	N/A	1	468	0	0	0	0	1	468	0
	Total	474	300	84	478	13	747	571	336	34
1993	I.	0	0	0	0	0	0	0	0	2
		71	162	10	476	1	877	82	209	3
		240	276	20	366	9	316	269	284	37
	N/A	0	0	0	0	0	0	0	0	1
	Total	311	250	30	403	10	372	351	266	43
1994	I.	0	0	0	0	0	0	0	0	1
	II 	44	133	5	32	0	0	49	122	9
	111	222	172	17	173	4	75	243	171	66
	N/A Total	3 269	138 165	0 22	0 141	0 4	0 75	3 295	138 162	1 77
1995	1	0	0	0	0	0	0	0	0	0
	ŀ	6	57	ŏ	ŏ	ŏ	ŏ	6	57	14
	iii	70	82	5	74	1	39	76	81	110
	N/A	2	64	Ő	í o	Ö	0	2	64	2
	Total	78	80	5	74	1	39	84	79	126
Total		2822	211	420	404	89	305	3331	238	309

Table III.9: Average Days to Decision on PMA Supplements by Class of Medical Device and Number of Open Cases (October 1, 1988 - May 18, 1995)

Fiscal year	Tier		roved Days		hdrawn Days)ther Days		otal Days	Ope N
1989	1	0	0	0	0	0	0	0	0	0
	2	399	214	105	340	12	50	516	235	0
	3	238	149	32	440	14	268	284	188	1
	Ň/A	3	243	ō	Ō	Ó	0	3	243	Ó
	Total	640	190	137	363	26	167	803	219	1
1990	1	1	114	2	740	1	0	4	398	0
	2	283	166	38	337	6	0	327	183	4
	3	268	163	29	570	16	205	313	202	6
	N/A	5	163	1	93	0	0	6	151	0
	Total	557	164	70	442	23	142	650	193	10
1991										
	1	1	81	0	0	0	0	1	81	0
	2	227	263	47	405	8	580	282	296	6
	3	263	194	25	570	3	123	291	225	12
	N/A	2	412	0	0	1	746	3	523	0
	Total	493	226	72	462	12	479	577	261	18
1992	1	0	0	0	0	0	0	0	0	0
	2	196	345	46	487	7	749	249	383	7
	3	276	267	37	471	6	744	319	299	27
	N/A	2	409	1	318	0	0	3	379	0
	Total	474	300	84	478	13	747	571	336	34
1993	1	0	0	0	0	0	0	0	0	1
	2	117	257	17	424	5	631	139	291	20
	3	194	245	13	374	5	114	212	250	21
	N/A	0	0	0	0	0	0	0	0	1
	Total	311	250	30	403	10	372	351	266	43
1994	1	0	0	0	0	0	0	0	0	0
	2	75	137	11	49	0	0	86	126	23
	3	190	177	11	233	4	75	205	178	52
	N/A	4	166	0	0	0	0	4	166	2
	Total	269	165	22	141	4	75	295	162	77
1995	1	0	0	0	0	0	0	0	0	0
	2	20	56	1	49	0	0	21	56	41
	3	58	88	4	81	1	39	63	87	83
	N/A	0	0	0	0	0	0	0	0	2
	Total	78	80	5	74	1	39	84	79	126
Total		2822	211	420	404	89	305	3331	238	309

GAO/PEMD-96-2 FDA Medical Device Review Time

Fiscal year	Medical specialty		proved Days		ndrawn Days)ther Days		otal Days	Ope N
1989	Cardiovascular	135	137	14	403	6	62	155	158	0
	Ophthalmic	392	214	106	343	12	50	510	237	0
	Other	112	165	17	460	8	423	137	216	1
	N/A	1	569	0	0	0	0	1	569	0
	Total	640	190	137	363	26	167	803	219	1
1990	Cardiovascular	180	149	14	573	7	1	201	173	0
	Ophthalmic	273	173	37	310	6	0	316	185	4
	Other	103	170	19	601	10	327	132	244	6
	N/A	1	131	0	0	0	0	1	131	C
	Total	557	164	70	442	23	142	650	193	10
1991	Cardiovascular	177	168	7	714	1	197	185	189	7
	Ophthalmic	211	258	46	356	7	662	264	286	4
	Other	104	256	19	626	3	58	126	307	7
	N/A	1	777	0	0	1	746	2	762	0
	Total	493	226	72	462	12	479	577	261	18
1992	Cardiovascular	171	255	29	528	1	197	201	294	19
	Ophthalmic	180	352	37	478	7	749	224	385	e
	Other	122	284	18	396	5	854	145	318	g
	N/A	1	468	0	0	0	0	1	468	C
	Total	474	300	84	478	13	747	571	336	34
1993	Cardiovascular	139	235	7	451	4	140	150	242	13
	Ophthalmic	95	262	14	318	4	570	113	279	16
	Other	77	263	9	496	2	442	88	291	13
	N/A	0	0	0	0	0	0	0	0	1
	Total	311	250	30	403	10	372	351	266	43
1994	Cardiovascular	140	186	9	235	2	3	151	186	27
	Ophthalmic	68	117	10	53	0	0	78	109	13
	Other	59	173	3	153	2	148	64	171	36
	N/A	2	141	0	0	0	0	2	141	
	Total	269	165	22	141	4	75	295	162	77
1995	Cardiovascular	43	77	3	89	1	39	47	77	57
	Ophthalmic	20	74	1	49	0	0	21	73	34
	Other	15	95	1	57	0	0	16	93	33
	N/A	0	0	0	0	0	0	0	0	2
	Total	78	80	5	74	1	39	84	79	126
Total		2822	211	420	404	89	305	3331	238	309

Table III.11: Average Days to Decision on PMA Supplements by Medical Specialty of Device and Number of Open Cases (October 1, 1988 - May 18, 1995)

1989 DCLD 29 112 1 106 0 30 112 0 DGRD 57 189 6 421 6 540 69 240 0 DOD 394 214 106 343 12 50 512 237 0 DRAER 18 192 9 549 2 71 29 295 1 Total 640 190 137 363 26 167 803 219 1 1990 DCLD 21 110 4 370 0 0 25 152 1 DGRD 48 168 8 798 8 187 64 249 1 DGRD 48 166 6 577 2 887 33 3 Total 557 164 70 442 23 142 650 193 10 1991	Fiscal year	Division		oroved Days		ndrawn Days)ther Days		otal Days	Oper N
DCRND 142 137 15 392 6 52 163 157 0 DGRD 57 189 6 421 6 540 69 240 0 DRAER 18 192 9 549 2 71 29 295 1 Total 640 190 137 363 26 167 803 219 1 1990 DCLD 21 110 4 370 0 0 25 152 1 DGRD 48 168 8 788 8 187 64 249 1 DGRD 48 168 6 577 2 887 36 313 3 Total 557 164 70 442 23 142 650 193 10 1991 DCLD 30 247 3 740 1 11 34 283 1	1989		29	112	1	106	0	0	30	112	0
DGRD 57 189 6 421 6 540 69 240 0 DOD 394 214 106 343 12 50 512 237 0 DRAER 18 192 9 549 2 71 29 295 1 1990 DCLD 21 110 4 370 0 0 25 152 1 DGRD 186 149 14 573 7 1 207 172 1 DGRD 48 168 8 78 8 187 64 249 1 DOD 274 173 38 304 6 0 318 185 Total 557 164 70 442 23 142 650 183 10 1991 DCLD 30 247 3 740 1 11 343 3 3 3	1000										
DOD DRAER 394 18 214 195 106 549 549 2 2 71 25 237 803 0 29 295 11 1990 DCLD DCRND 21 110 4 370 0 0 25 157 803 219 1 1990 DCLD DCRND 21 110 4 370 0 0 25 152 1 DGRD 48 168 8 798 8 137 64 249 1 DGRD 48 166 6 577 2 887 36 313 3 Total 557 164 70 442 23 142 650 193 10 1991 DCLD DGRD 30 247 3 740 1 11 34 283 1 DCRD 185 178 7 714 1 197 193 198 8 DOD 211 258 46 356 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
DRAER 18 192 9 549 26 17 29 295 1 1990 DCLD 21 110 4 370 0 0 25 167 803 219 1 1990 DCLD 21 110 4 370 0 0 25 152 1 DCRND 186 149 573 7 1 207 172 1 DGRD 274 173 38 304 6 0 318 185 4 DOD 274 173 38 304 6 0 318 185 4 Total 557 164 70 442 23 142 650 193 100 1991 DCLD 30 247 3 740 1 11 34 283 1 DCRND 185 178 7 742 264 38 289 <td></td>											
Total 640 190 137 363 26 167 803 219 1 1990 DCLD 21 110 4 370 0 0 25 152 1 DCRND 186 149 14 573 7 1 207 172 1 DGRD 48 168 8 798 8 187 64 249 1 DGRD 48 168 70 442 23 142 650 193 10 1991 DCLD 30 247 7 74 1 117 34 283 1 DCRND 185 178 7 714 1 197 193 198 8 DGRD 34 257 12 583 2 373 48 343 5 DGRD 33 246 72 482 472 380 224 285 30											
DCRND 186 149 14 573 7 1 207 172 1 DCRD 48 168 8 798 8 187 64 249 1 DCD 274 173 38 304 6 0 318 185 4 DRAER 28 216 6 577 2 887 36 313 3 Total 557 164 70 442 23 142 650 193 10 1991 DCLD 30 247 3 740 1 11 34 283 1 DCRD 34 257 12 656 7 662 264 286 4 DRAER 33 247 4 668 1 162 38 289 0 Total 493 226 72 462 12 479 37 30 22					-						-
DCRND 186 149 14 573 7 1 207 172 1 DCRD 48 168 8 798 8 187 64 249 1 DCD 274 173 38 304 6 0 318 185 4 DRAER 28 216 6 577 2 887 36 313 3 Total 557 164 70 442 23 142 650 193 10 1991 DCLD 30 247 3 740 1 11 34 283 1 DCRD 34 257 12 656 7 662 264 286 4 DRAER 33 247 4 668 1 162 38 289 0 Total 493 226 72 462 12 479 37 30 22	1990	DCLD	21	110	4	370	0	0	25	152	1
DGRD 48 168 8 798 8 187 64 249 1 DCD 274 173 38 304 6 0 318 185 4 DRAER 28 216 6 577 2 887 36 313 3 1991 DCLD 30 247 3 740 1 11 34 283 1 DGRD 34 257 12 563 2 373 48 343 5 DOD 211 258 46 356 7 662 248 46 DRAER 33 247 4 668 1 162 38 289 0 Total 493 226 72 462 12 479 377 261 18 1992 DCLD 22 290 8 219 1 223 31 270 2					14			1			
DOD DRAER 274 28 173 216 38 6 304 6 6 577 0 2 887 887 36 36 313 31 33 30 1991 DCLD 30 247 3 740 1 11 34 283 1 DCRND 185 178 7 714 197 193 198 8 DGRD 34 257 12 583 2 373 48 343 5 DOD 211 258 46 356 7 662 264 286 4 DRAER 33 247 4 668 1 162 38 289 0 Total 493 226 72 462 12 479 577 261 18 1992 DCLD 22 290 8 219 1 223 31 270 2 DGRD 43 334 5 338 1 979 49											
DRAER Total 28 557 216 164 6 70 6 442 23 23 142 142 36 650 313 10 3 10 1991 DCLD DCRND 30 247 3 3 740 1 11 34 197 283 193 1 193 198 8 193 1 193 198 8 193 1 193 198 8 193 1 193 1 197 1 193 1 197 1 193 1 193 1 193 2 12 5 6 33 2 373 4 8 343 5 6 34 3 43 5 6 34 3 43 5 6 34 3 47 4 6 6 6 4 1 162 3 8 289 0 1 22 2 6 26 4 1 18 1 197 2 8 30 2 2 3 3 1 2 2 3 3 1 2 3 3 3 3 3 3 3 3 3											
Total 557 164 70 442 23 142 650 193 10 1991 DCLD 30 247 3 740 1 11 34 283 1 DCRND 185 178 7 714 1 197 193 198 8 DGRD 34 257 12 563 2 373 48 343 5 DOD 211 258 46 356 7 662 264 286 4 DRAER 33 247 4 666 1 162 38 299 0 Total 493 226 72 462 12 479 577 261 18 1992 DCLD 22 290 8 219 1 223 31 270 2 DGRD 43 334 5 338 1 979 49 347 3											3
DCRND 185 178 7 714 1 197 193 198 8 DGRD 34 257 12 583 2 373 48 343 5 DOD 211 258 46 356 7 662 264 286 4 DRAER 33 247 4 668 1 162 38 289 0 Total 493 226 72 462 12 479 577 261 18 1992 DCLD 22 290 8 219 1 223 31 270 2 DCRND 177 259 30 550 1 197 49 347 3 DCD 180 352 37 478 7 749 224 385 30 1 Total 474 300 84 478 13 747 571 336 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>											
DGRD 34 257 12 583 2 373 48 343 5 DOD 211 258 46 356 7 662 264 286 4 DRAER 33 247 4 668 1 162 38 289 0 Total 493 226 72 462 12 479 577 261 18 1992 DCLD 22 290 8 219 1 223 31 270 2 DGRD 43 334 5 338 1 979 49 347 3 DOD 180 352 37 478 7 749 224 385 6 DRAER 52 236 4 629 3 1023 59 303 1 Total 474 300 84 478 13 747 571 336 24 13	1991	DCLD	30	247	3	740	1	11	34	283	1
DOD 211 258 46 356 7 662 264 286 4 DRAER 33 247 4 668 1 162 38 289 0 Total 493 226 72 462 12 479 577 261 18 1992 DCLD 22 290 8 219 1 223 31 270 2 DGRD 43 334 5 338 1 979 49 347 3 DOD 180 352 37 478 7 749 224 385 6 DRAER 52 236 4 629 3 1023 59 303 1 Total 474 300 84 478 13 747 571 336 34 1993 DCLD 15 284 5 693 0 0 23 375 7<		DCRND	185	178	7	714	1	197	193	198	8
DRAER 33 247 4 668 1 162 38 289 0 1992 DCLD 22 290 8 219 1 223 31 270 2 DGRD 177 259 30 550 1 197 208 300 22 DGRD 43 334 5 338 1 979 49 347 3 DOD 180 352 37 478 7 749 224 336 66 DRAER 52 236 4 629 3 1023 59 303 1 Total 474 300 84 478 13 747 571 336 34 1993 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15		DGRD	34	257	12	583	2	373	48	343	5
Total 493 226 72 462 12 479 577 261 18 1992 DCLD 177 259 30 550 1 197 208 300 22 DGRD 43 334 5 338 1 979 49 347 3 DOD 180 352 37 478 7 749 224 385 6 DRAER 52 236 4 629 3 1023 59 303 1 Total 474 300 84 478 13 747 571 336 34 1993 DCLD 15 284 5 693 0 0 20 387 2 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279		DOD	211	258	46	356	7	662	264	286	4
1992 DCLD 22 290 8 219 1 223 31 270 2 DGRND 177 259 30 550 1 197 208 300 22 DGRD 43 334 5 338 1 979 49 347 3 DOD 180 352 37 478 7 749 224 385 6 DRAER 52 236 4 629 3 1023 59 303 1 1933 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 0 23 <t< td=""><td></td><td>DRAER</td><td>33</td><td>247</td><td>4</td><td>668</td><td>1</td><td>162</td><td>38</td><td>289</td><td>0</td></t<>		DRAER	33	247	4	668	1	162	38	289	0
DCRND 177 259 30 550 1 197 208 300 22 DGRD 43 334 5 338 1 979 49 347 3 DOD 180 352 37 478 7 749 224 385 6 DRAER 52 236 4 629 3 1023 59 303 1 Total 474 300 84 478 13 747 571 336 34 1993 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 <					72						18
DGRD 43 334 5 338 1 979 49 347 3 DOD 180 352 37 478 7 749 224 385 6 DRAER 52 236 4 629 3 1023 59 303 1 Total 474 300 84 478 13 747 571 336 34 1993 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 100 372 351 266 43 1994<	1992	DCLD	22	290	8	219	1	223	31	270	2
DOD 180 352 37 478 7 749 224 385 6 DRAER 52 236 4 629 3 1023 59 303 1 Total 474 300 84 478 13 747 571 336 34 1993 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 23 275 7 Total 311 250 30 403 10 372 351 266 43 199		DCRND	177	259	30	550	1	197	208	300	22
DRAER Total 52 474 236 300 4 84 629 478 3 13 1023 747 59 571 336 336 1 34 1993 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DDD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 0 23 275 7 Total 311 250 30 403 10 372 351 266 43 1994 DCLD 10 223 0 0 1 295 11 229 7 DGRD 29 169 2 131 1 0 32		DGRD	43	334	5	338	1	979	49	347	3
Total 474 300 84 478 13 747 571 336 34 1993 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 0 23 275 7 Total 311 250 30 403 10 372 351 266 43 1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 </td <td></td> <td>DOD</td> <td>180</td> <td>352</td> <td>37</td> <td>478</td> <td>7</td> <td>749</td> <td>224</td> <td>385</td> <td>6</td>		DOD	180	352	37	478	7	749	224	385	6
1993 DCLD 15 284 5 693 0 0 20 387 2 DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 0 23 275 7 Total 311 250 30 403 10 372 351 266 43 1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 48 77 </td <td></td> <td>DRAER</td> <td>52</td> <td>236</td> <td>4</td> <td>629</td> <td>3</td> <td>1023</td> <td>59</td> <td>303</td> <td>1</td>		DRAER	52	236	4	629	3	1023	59	303	1
DCRND 145 233 7 451 4 140 156 241 15 DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 0 23 275 7 Total 311 250 30 403 10 372 351 266 43 1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 14 137 111		Total	474	300	84	478	13	747	571	336	34
DGRD 35 247 2 395 2 442 39 264 3 DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 0 23 275 7 Total 311 250 30 403 10 372 351 266 43 1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 10 13 DRAER 14 137 0 0 0 0 4 124 7 DCAD 4	1993							-			
DOD 95 262 14 318 4 570 113 279 16 DRAER 21 291 2 108 0 0 23 275 7 Total 311 250 30 403 10 372 351 266 43 1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 80 110 13 DRAER 14 137 0 0 0 0 144 137 11 DDD 70 118 10 53 0 0 44 137 11 D		DCRND	145			451				241	
DRAER Total 21 291 2 108 0 0 23 275 7 1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 14 137 11 DRAER 14 137 0 0 0 0 14 137 11 Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 48 77 60 DGRD 7 92 1 57 0 8 88 12 DOD <td></td> <td>DGRD</td> <td>35</td> <td>247</td> <td>2</td> <td>395</td> <td>2</td> <td>442</td> <td>39</td> <td>264</td> <td>3</td>		DGRD	35	247	2	395	2	442	39	264	3
Total 311 250 30 403 10 372 351 266 43 1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 80 110 13 DRAER 14 137 0 0 0 14 137 11 Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 48 77 60 DGRD 7 92 1 57 0 8 88 12 DOD 20<		DOD	95	262	14	318	4	570	113	279	16
1994 DCLD 10 223 0 0 1 295 11 229 7 DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 80 110 13 DRAER 14 137 0 0 0 0 144 137 11 Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 4 124 7 DCRND 44 77 3 89 1 39 48 77 60 DGRD 7 92 1 57 0 8 88 12 DOD		DRAER	21	291	2	108	0	0	23	275	7
DCRND 146 186 10 231 2 3 158 187 31 DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 80 110 13 DRAER 14 137 0 0 0 0 144 137 11 Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 4 124 7 DCRND 44 77 3 89 1 39 48 77 60 DGRD 7 92 1 57 0 8 88 12 DDD 20 74 1 49 0 21 73 35 DRAER 3 66		Total	311	250	30	403	10	372	351	266	43
DGRD 29 169 2 131 1 0 32 161 15 DOD 70 118 10 53 0 0 80 110 13 DRAER 14 137 0 0 0 0 14 137 11 Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 4 124 7 DCRND 44 77 3 89 1 39 48 77 60 DGRD 7 92 1 57 0 8 88 12 DOD 20 74 1 49 0 0 21 73 35 DRAER 3 66 0 0 0 21 73 35 DRAER 3 80 5 <td>1994</td> <td></td>	1994										
DOD 70 118 10 53 0 0 80 110 13 DRAER 14 137 0 0 0 0 14 137 11 Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 4 124 7 DGRD 4 124 0 0 0 0 4 124 7 DGRD 7 92 1 57 0 8 88 12 DOD 20 74 1 49 0 21 73 35 DRAER 3 66 0 0 0 21 73 35 DRAER 3 66 0 0 0 3 68 12 Total 78 80 5 74 1											
DRAER 14 137 0 0 0 0 14 137 11 Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 4 124 7 DGRND 44 77 3 89 1 39 48 77 60 DGRD 7 92 1 57 0 0 8 88 12 DOD 20 74 1 49 0 21 73 35 DRAER 3 66 0 0 0 21 73 35 DRAER 3 66 0 0 0 3 68 12 Total 78 80 5 74 1 39 84 79 126											
Total 269 165 22 141 4 75 295 162 77 1995 DCLD 4 124 0 0 0 0 4 124 7 DCRND 44 77 3 89 1 39 48 77 60 DGRD 7 92 1 57 0 0 8 88 12 DOD 20 74 1 49 0 21 73 35 DRAER 3 66 0 0 0 3 68 12 Total 78 80 5 74 1 39 84 79 126											
1995 DCLD 4 124 0 0 0 0 4 124 7 DCRND 44 77 3 89 1 39 48 77 60 DGRD 7 92 1 57 0 0 8 88 12 DOD 20 74 1 49 0 0 21 73 35 DRAER 3 66 0 0 0 3 68 12 Total 78 80 5 74 1 39 84 79 126											
DCRND 44 77 3 89 1 39 48 77 60 DGRD 7 92 1 57 0 0 8 88 12 DOD 20 74 1 49 0 0 21 73 35 DRAER 3 66 0 0 0 3 68 12 Total 78 80 5 74 1 39 84 79 126											
DGRD7921570088812DOD207414900217335DRAER366000036812Total78805741398479126	1995								-		
DOD207414900217335DRAER366000036812Total78805741398479126											
DRAER 3 66 0 0 0 0 3 68 12 Total 78 80 5 74 1 39 84 79 126											
Total 78 80 5 74 1 39 84 79 126											
Total 2822 211 420 404 89 305 3331 238 309	Total		2822	211	420	404	89	305	3331	238	309

Table III.12: Average Days to Decision on PMA Supplements by Reviewing Division

				Original P	MAs					
Fiscal year	N	FDA review time	Total FDA time	Non-FDA time	Time Iapse		centile: ne laps 50		Number of amendments	Requests for informatic
1989	45	230	320	92	412	71	351	954	8	3
1990	36	327	547	211	758	168	530	1702	12	4
1991	21	264	441	115	556	60	585	1023	8	3
1992	21	346	591	165	756	495	780	1060	12	4
1993	7	264	495	80	575	327	557	815	9	3
1994	3	138	155	34	189	147	196	225	1	2
1995	0	0	0	0	0	0	0	0	0	0
Total	133	280	449	137	586	72	501	1421	10	3
				PMA supp	lements					
		FDA	Total			Perce	ntiles f	for		Requests
		FDA							Maria Iana - 4	
Fiscal		review	FDA	Non-FDA	Time	time	lapse		Number of	for
	N			Non-FDA time	Time lapse	time 5	lapse 50	95	amendments	
year	N 640	review	FDA					95 484		
year 1989		review time	FDA time	time	lapse	5	50		amendments	informatio
year 1989 1990	640	review time 113	FDA time 126	time 64	lapse 190	5 24	50 160	484 448 965	amendments	informatic 1 1 1
year 1989 1990 1991	640 557	review time 113 85	FDA time 126 105	time 64 59	lapse 190 164	5 24 20	50 160 115	484 448	amendments 1 1	informatio
Fiscal year 1989 1990 1991 1992 1993	640 557 493	review time 113 85 117	FDA time 126 105 147	time 64 59 79	lapse 190 164 226	5 24 20 18	50 160 115 139	484 448 965	amendments 1 1 1	informatic 1 1 1
year 1989 1990 1991 1992	640 557 493 474	review time 113 85 117 164	FDA time 126 105 147 202	time 64 59 79 98	lapse 190 164 226 300	5 24 20 18 23	50 160 115 139 204	484 448 965 878	amendments 1 1 1 1	informatic 1 1 1 2
year 1989 1990 1991 1992 1993	640 557 493 474 311	review time 113 85 117 164 135	FDA time 126 105 147 202 157	time 64 59 79 98 93	lapse 190 164 226 300 250	5 24 20 18 23 22	50 160 115 139 204 204	484 448 965 878 618	amendments 1 1 1 1 1 1	informatio 1 1 2 1

		(Original	PMAs			I	PMA sup	plements	
Class	N	FDA review time	Total FDA time	Non-FDA time	Time Iapse	N	FDA review time	Total FDA time	Non-FDA time	Time lapse
1	3	267	353	283	636	2	57	57	41	98
11	25	210	303	61	364	588	92	105	54	159
	99	299	478	152	630	2223	121	146	79	225
N/A	6	255	625	141	766	9	120	188	88	276
Tier										
1	0	0	0	0	0	2	57	57	41	98
2	62	269	365	89	454	1317	139	158	71	229
3	62	294	531	176	707	1487	94	118	77	195
Exempt	1	301	380	826	1206	0	0	0	0	0
N/A	8	246	464	125	589	16	145	180	61	241
Medical										
specialty										
Cardiovascular	34	233	542	170	712	985	85	111	72	183
Ophthalmic	55	280	359	97	456	1239	138	158	71	229
Other	39	323	482	168	650	592		137	81	218
N/A	5	262	560	109	669	6	156	244	127	371
Division										
DCLD	15	353	433	82	515	131	136	147	54	201
DCRND	36	229	540		713	1025		113	73	186
DGRD	12	312	496	225	721	253		125	97	222
DOD	58	282	366	95	461	1244		157	71	228
DRAER	12	297	548	215	763	169	102	148	78	226
Total	133	280	449	137	586	2822	115	137	74	211

			c	Driginal	PMAs			I	PMA sup	plements	
Fiscal year	Class	N	FDA review time	Total FDA time	Non-FDA time	Time lapse	N	FDA review time	Total FDA time	Non-FDA time	Time Iapse
1989	1	0	0	0	0	0	0	0	0	0	0
	11	14	161	208	61	269	154	100	112	58	170
	Ш	31	262	370	106	476	485	116	129	66	195
	N/A	0	0	0	0	0	1	335	335	234	569
	Total	45	230	320	92	412	640	113	126	64	190
1990	1	1	74	254	23	277	1	114	114	0	114
	11	4	211	450	82	532	116	70	78	49	127
	HI	30	354	556	231	787	439	89	112	62	174
	N/A	1	224	953	299	1252	1	0	0	131	131
	Total	36	327	547	211	758	557	85	105	59	164
1991	Ŧ	0	0	0	0	0	1	0	0	81	81
	11	2	143	267	90	357	112	90	110	44	154
	111	19	277	460	117	577	379	125	158	89	247
	N/A	0	0	0	0	0	1	230	500	277	777
	Total	21	264	441	115	556	493	117	147	79	226
1992	I	1	301	380	826	1206	0	0	0	0	0
	П	4	458	558	31	589	85	132	157	49	206
	111	15	328	601	164	765	388	171	211	109	320
	N/A	1	214	778	59	837	1	118	379	89	468
	Total	21	346	591	165	756	474	164	202	98	300
1993	I	1	426	426	0	426	0	0	0	0	0
	П	0	0	0	0	0	71	87	92	70	162
	111	2	164	506	39	545	240	149	175	100	276
	N/A	4	274	505	122	627	0	0	0	0	0
	Total	7	264	495	80	575	311	135	157	93	250
1994	I	0	0	0	0	0	0	0	0		0
	II	1	49	101	46	147	44	63	64	69	133
	III	2	182	182	29	211	222	102	119	53	172
	N/A	0	0	0	0	0	3	98	124	14	138
	Total	3	138	155	34	189	269	96	109	56	165
1995	I	0	0	0	0	0	0	0	0		0
		0	0	0	0	0	6	52	52		58
	III	0	0	0	0	0	70	26	25	57	82
	N/A	0	0	0	0	0	2	53	53	11	64
	Total	0	0	0	0	0	78	29	29	51	80

				Original	1 10.45				FINA SU	pplements	•
Fiscal year	Tier		FDA review time	Total FDA time	Non-FDA time	Time lapse	N	FDA review time	Total FDA time	Non-FDA time	Time lapse
1989	1	0	0	0	0	0	0	0	0	0	0
1909	2	27	196	265	60	325	399	138	149	65	214
		17	279								
	3 Evenant			404	130	534	238	70	87	62	149
	Exempt	0	0	0	0	0	0	0	0	0	0
	N/A	1	335	376	288	664	3	127	134	109	243
	Total	45	230	320	92	412	640	113	126	64	190
1990	1	0	0	0	0	0	1	114	114	0	114
	2	15	317	461	125	586	283	101	116	50	166
	3	19	351	644	292	936	268	68	94	69	163
	Exempt	0	0	0	0	0	0	0	0	0	0
	N/A	2	163	268	85	353	5	113	113	50	163
	Total	36	327	547	211	758	557	85	105	59	164
1991	1	0	0	0	0	0	1	0	0	81	81
	2	9	273	318	83	401	227	142	182	82	264
	3	12	257	535	138	673	263	95	117	77	194
	Exempt	Ö	0	000	0	Ő	200	õ	0	0	0
	N/A	ŏ	ŏ	ŏ	ŏ	õ	2	139	273	139	412
	Total	21	264	441 441	115	556	493	117	147	79	226
1992	1	0	0	0	0	0	0	0	0	0	0
	2	9	413	577	135	712	196	226	260	85	345
	3	10	304	605	137	742	276	119	159	108	267
	Exempt	1	301	380	826	1206	2,0	0	0	0	0
	N/A	1	214	778	59	837	2	234	364	45	409
	Total	21	346	591	165	756	474	164	202	98	300
1993	1	0	0	0	0	0	0	0	0	0	0
	2	1	426	426	õ	426	117	138	145	112	257
	3	2	164	506	39	545	194	134	163	82	245
	Exempt	4	274	505	122	627	0	0	0		0
	N/A	ò	0	0	0	0	ŏ	ŏ	Ő		õ
	Total	7	264	495	80 80	575	311	135	157	93	250
1994	1	0	0	0	0	0	0	0	0	0	0
	2	1	49	101	46	147	75	83	83	54	137
	3	2	182	182	29	211	190	100	120	57	177
	Exempt	Ő	0	0	29	0	190	0	0		0
	N/A	ŏ	0	0	0	0	4	158	158	8	166
	Total	3	138	155	34	189	269	96	109	56	165
1995	1	0	0	0	0	0	0	0	0	0	0
	2	ŏ	0 0	ŏ	Ő	ŏ	20	36	37		57
	3	ŏ	Ő	ŏ	0	õ	58	26	26		88
	Exempt	ő	0	ő	0	0	0	20	20		0
	N/A	ŏ	ŏ	ŏ	Ö	ŏ	ő	Ő	0		ő
	Total	ŏ	Ő	ŏ	õ	ŏ	78	29	29	51	80

Fiscal vear Medical vertice ve				(Original	PMAs			P	'MA su	oplements	
1989 Cardiovascular Ophalmic 9 226 409 137 546 135 54 74 64 138 Other 11 270 371 172 543 112 95 106 59 165 54 74 64 138 NA 0 0 0 0 1 335 335 234 669 Total 45 230 320 92 412 640 113 126 64 190 1990 Cardiovascular 7 238 632 310 942 180 65 90 59 149 Opthalmic 11 374 468 139 607 273 105 122 51 173 Other 18 33 563 216 779 103 68 90 80 170 N/A 0 0 0 11 137 176 82 258 Opthalmic 9 373 397 102 499 104 <				review	FDA	-			review	FDA	Non-FDA	
Opthalmic 25 214 266 40 306 392 137 149 65 214 Other 11 270 371 172 543 112 95 106 59 166 N/A 0 0 0 0 1 335 234 569 Total 45 230 320 92 412 640 113 126 64 190 1990 Cardiovascular 7 238 632 310 942 180 65 90 59 149 Other 18 333 563 216 779 103 68 90 80 170 N/A 0 0 0 0 11 131 161 65 225 Other 4 337 397 102 499 104 131 161 95 256 Other 4 337 397	year	speciality	N	time	time	time	lapse	N	time	time	time	lapse
Opther 15 214 266 40 306 392 137 149 65 214 Other 11 270 371 172 543 112 95 106 59 165 Total 45 230 320 92 412 640 113 126 64 190 1990 Cardiovascular 7 238 632 310 942 180 65 90 59 149 Opthalminic 11 374 488 139 607 273 105 122 51 173 Other 18 333 653 216 779 103 88 90 80 170 N/A 0 0 0 0 131 131 161 52 258 Other 4 337 397 102 499 104 131 161 95 256 N/A 0 </td <td>1989</td> <td>Cardiovascular</td> <td>9</td> <td>226</td> <td>409</td> <td>137</td> <td>546</td> <td>135</td> <td>54</td> <td>74</td> <td>64</td> <td>138</td>	1989	Cardiovascular	9	226	409	137	546	135	54	74	64	138
Other 11 270 371 172 543 112 95 106 59 165 N/A 0 0 0 0 0 0 0 1 335 335 234 569 Total 45 230 320 92 412 640 113 126 64 190 1990 Cardiovascular 7 238 632 310 942 180 65 90 59 149 Other 18 333 563 216 779 103 88 90 80 170 N/A 0 0 0 0 0 0 0 11 137 164 1991 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 273 318 83 401 211 137 176 82 <		Opthalmic	25	214	266	40	306	392	137	149	65	
N/A 0 0 0 0 1 335 335 234 569 Total 45 230 320 92 412 640 113 126 64 190 1990 Cardiovascular 7 238 632 310 942 180 65 90 59 149 Optnalmic 11 374 468 139 607 273 105 122 51 173 Other 18 333 563 216 779 103 68 90 80 170 N/A 0 0 0 0 1 758 577 85 105 59 164 1991 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 378 150 227 777 130 250 59 255 Optha		Other	11	270	371	172	543	112	95	106	59	165
1990 Cardiovascular 7 238 632 310 942 180 65 90 59 149 Opthalmic 11 374 468 139 607 273 105 122 51 173 Other 18 333 563 216 779 103 68 90 80 170 N/A 0 0 0 0 0 1 0 131 131 Total 36 327 547 211 758 557 85 105 59 164 1991 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 273 318 83 401 211 137 176 82 256 N/A 0 0 0 0 0 123 500 277 777 777 171 110 156 99 255 97 352 97 352 97 352		N/A	0	0	0	0	0	1	335	335	234	569
Opthalmic 11 374 468 139 607 273 105 122 51 173 Other 18 333 563 216 779 103 68 90 60 170 N/A 0 0 0 0 0 0 0 0 131 131 Total 36 327 547 211 758 557 85 105 59 164 1991 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 273 318 83 401 211 137 166 92 256 Other 4 337 397 102 499 104 131 161 95 256 M/A 0 0 0 0 122 153 89 245 M/A 1 214 <t< td=""><td></td><td>Total</td><td>45</td><td>230</td><td>320</td><td></td><td>412</td><td></td><td></td><td></td><td></td><td></td></t<>		Total	45	230	320		412					
Other 18 333 563 216 779 103 68 90 80 170 N/A 0 0 0 0 0 0 1 0 0 131 131 Total 36 327 547 211 758 557 85 105 59 164 1891 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 273 318 83 401 211 137 176 82 258 Other 4 337 397 102 499 104 131 161 95 256 Other 21 264 441 115 556 493 117 147 79 226 1992 Cardiovascular 7 283 614 143 757 171 110 156 99 284	1990	Cardiovascular	7	238	632	310	942	180	65	90	59	149
N/A 0 0 0 0 0 1 0 0 131 131 Total 36 327 547 211 758 557 85 105 59 164 1391 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 273 318 83 401 211 137 176 82 256 Other 4 337 397 102 499 104 131 161 95 256 N/A 0 0 0 0 0 1413 757 171 110 156 99 255 Opthalmic 9 378 550 227 777 180 222 255 97 352 Opthalmic 9 378 591 165 756 474 164 202 98 300		Opthalmic	11	374	468	139	607	273	105	122	51	173
Total 36 327 547 211 758 557 85 105 59 164 1991 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 273 318 83 401 211 137 176 82 258 Other 4 337 397 102 499 104 131 161 95 256 N/A 0 0 0 0 0 1230 500 277 777 Total 21 264 441 115 556 493 117 147 79 226 1992 Cardiovascular 7 283 614 143 757 171 110 156 99 284 N/A 1 214 778 59 837 1 118 379 89 468 106 <t< td=""><td></td><td></td><td>18</td><td>333</td><td>563</td><td>216</td><td></td><td>103</td><td>68</td><td></td><td></td><td></td></t<>			18	333	563	216		103	68			
Total 36 327 547 211 758 557 85 105 59 164 1991 Cardiovascular 8 218 603 156 759 177 84 101 67 168 Opthalmic 9 273 318 83 401 211 137 176 82 258 Other 4 337 397 102 499 104 131 161 95 256 N/A 0 0 0 0 1 230 500 277 777 Total 21 264 441 115 556 493 117 147 79 226 1992 Cardiovascular 7 283 614 143 757 171 110 156 99 284 N/A 1 214 778 59 837 1 118 379 89 468 77		N/A	0	0	0	0	0	1	0	0	131	131
Opthalmic 9 273 318 83 401 211 137 176 82 258 Other 4 337 397 102 499 104 131 161 95 256 N/A 0 0 0 0 1 230 500 277 777 Total 21 264 441 115 556 493 117 147 79 226 1992 Cardiovascular 7 263 614 143 757 171 110 156 99 255 Opthalmic 9 378 550 227 777 180 222 255 97 352 Other 4 418 592 837 1 118 379 89 468 Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular		Total	36	327	547	211	758	557	85	105		164
Other 4 337 397 102 499 104 131 161 95 256 N/A 0 0 0 0 0 0 1 230 500 277 777 Total 21 264 441 115 556 493 117 147 79 226 1992 Cardiovascular 7 283 614 143 757 171 110 156 99 255 Opthalmic 9 378 550 227 777 180 222 255 97 352 Other 4 418 592 92 684 122 152 185 99 284 N/A 1 214 778 59 837 1 118 379 89 468 Total 21 346 591 165 756 139 122 153 82 235	1991	Cardiovascular	8	218	603	156	759	177	84	101	67	168
N/A 0 0 0 0 0 1 230 500 277 777 Total 21 264 441 115 556 493 117 147 79 226 1992 Cardiovascular 7 283 614 143 757 171 110 156 99 255 Opthalmic 9 378 550 227 777 180 222 255 97 352 Other 4 418 592 92 684 122 152 185 99 284 N/A 1 214 778 59 837 1 118 379 89 468 Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular 2 164 506 39 545 139 122 153 82 235 1993 Cardiovascular 1 426 426 0 426 7		Opthalmic	9	273	318	83	401	211	137	176	82	258
Total 21 264 441 115 556 493 117 147 79 226 1992 Cardiovascular 7 283 614 143 757 171 110 156 99 255 Opthalmic 9 378 550 227 777 180 222 255 97 352 Other 4 418 592 92 684 122 152 185 99 284 N/A 1 214 778 59 837 1 118 379 89 468 Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular 2 164 506 39 545 139 122 153 82 235 Opthalmic 0 0 0 0 0 0 0 0 0 0 0<		Other	4	337	397	102	499	104	131	161	95	256
1992 Cardiovascular Opthalmic 7 283 614 143 757 171 110 156 99 255 Opthalmic 9 378 550 227 777 180 222 255 97 352 Other 4 418 592 92 684 122 125 185 99 284 N/A 1 214 778 59 837 1 118 379 89 468 Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular 2 164 506 39 545 139 122 153 82 235 Opthalmic 0		N/A	0	0	0	0	0	1	230	500	277	777
Opthalmic 9 378 550 227 777 180 222 255 97 352 Other 4 418 592 92 684 122 152 185 99 284 N/A 1 214 778 59 837 1 118 379 89 468 Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular 2 164 506 39 545 139 122 153 82 235 Opthalmic 0 0 0 0 0 95 147 156 106 262 Other 1 426 426 0 426 77 143 166 97 263 N/A 4 274 505 122 627 0 0 0 0 0 0 0 0		Total	21	264	441	115	556	493	117	147	79	226
Other 4 418 592 92 684 122 152 185 99 284 N/A 1 214 778 59 837 1 118 379 89 468 Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular 2 164 506 39 545 139 122 153 82 235 Opthalmic 0 0 0 0 95 147 156 106 262 Other 1 426 426 0 426 77 143 166 97 263 N/A 4 274 505 122 627 0 0 0 0 0 0 93 250 1994 Cardiovascular 1 168 168 57 225 140 96 120 66	1992	Cardiovascular	7	283	614	143	757	1 71		156	99	255
N/A 1 214 778 59 837 1 118 379 89 468 Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular 2 164 506 39 545 139 122 153 82 235 Opthalmic 0 0 0 0 0 95 147 156 106 262 Other 1 426 426 0 426 77 143 166 97 263 N/A 4 274 505 122 627 0 </td <td></td> <td>Opthalmic</td> <td>9</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>352</td>		Opthalmic	9									352
Total 21 346 591 165 756 474 164 202 98 300 1993 Cardiovascular 2 164 506 39 545 139 122 153 82 235 Opthalmic 0 0 0 0 95 147 156 106 262 Other 1 426 426 0 426 77 143 166 97 263 N/A 4 274 505 122 627 0 0 0 0 0 Total 7 264 495 80 575 311 135 157 93 250 1994 Cardiovascular 1 168 168 57 225 140 96 120 66 186 Opthalmic 1 49 101 46 147 68 80 79 38 117 Other		Other	4	418				122				284
1993Cardiovascular Opthalmic21645063954513912215382235Opthalmic0000095147156106262Other142642604267714316697263N/A427450512262700000Total726449580575311135157932501994Cardiovascular1168168572251409612066186Opthalmic1491014614768807938117Other119619601965911412053173N/A00000212612615141Total31381553418926996109561651995Cardiovascular000002038383674Opthalmic000000000001995Cardiovascular0000000000N/A0000000000001995Cardiovascular0<												
Opthalmic 0 0 0 0 95 147 156 106 262 Other 1 426 426 0 426 77 143 166 97 263 N/A 4 274 505 122 627 0<		Total	21	346	591	165	756	474	164	202	98	300
Other 1 426 426 0 426 77 143 166 97 263 N/A 4 274 505 122 627 0	1993	Cardiovascular										
N/A 4 274 505 122 627 0 0 0 0 0 0 Total 7 264 495 80 575 311 135 157 93 250 1994 Cardiovascular 1 168 168 57 225 140 96 120 66 186 Opthalmic 1 49 101 46 147 68 80 79 38 117 Other 1 196 196 0 196 59 114 120 53 173 N/A 0 0 0 0 0 2 126 126 15 141 Total 3 138 155 34 189 269 96 109 56 165 1995 Cardiovascular 0 0 0 0 0 20 38 38 36 74 Opthalmic 0 0 0 0 0 20 38 38 36 </td <td></td> <td>Opthalmic</td> <td>0</td> <td></td> <td>0</td> <td></td> <td></td> <td></td> <td></td> <td>156</td> <td></td> <td></td>		Opthalmic	0		0					156		
Total 7 264 495 80 575 311 135 157 93 250 1994 Cardiovascular 1 168 168 57 225 140 96 120 66 186 Opthalmic 1 49 101 46 147 68 80 79 38 117 Other 1 196 196 0 196 59 114 120 53 173 N/A 0 0 0 0 269 96 109 56 165 1995 Cardiovascular 0 0 0 0 0 20 38 38 36 74 Opthalmic 0 0 0 0 15 51 51 44 95 N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0												
1994 Cardiovascular 1 168 168 57 225 140 96 120 66 186 Opthalmic 1 49 101 46 147 68 80 79 38 117 Other 1 196 0 196 59 114 120 53 173 N/A 0 0 0 0 269 96 109 56 165 1995 Cardiovascular 0 0 0 0 0 43 16 17 61 78 1995 Cardiovascular 0 0 0 0 203 38 36 74 Opthalmic 0 0 0 0 15 51 51 44 95 N/A 0 <												
Opthalmic 1 49 101 46 147 68 80 79 38 117 Other 1 196 0 196 59 114 120 53 173 N/A 0 0 0 0 2 126 126 15 141 Total 3 138 155 34 189 269 96 109 56 165 1995 Cardiovascular 0 0 0 0 43 16 17 61 78 Opthalmic 0 0 0 0 20 38 38 36 74 Other 0 0 0 0 15 51 51 44 95 N/A 0		Total	7	264	495	80	575	311	135	157	93	250
Other 1 196 196 0 196 59 114 120 53 173 N/A 0 0 0 0 0 2 126 126 15 141 Total 3 138 155 34 189 269 96 109 56 165 1995 Cardiovascular 0 0 0 0 43 16 17 61 78 Opthalmic 0 0 0 0 20 38 38 36 74 Other 0 0 0 0 15 51 51 44 95 N/A 0	1994											
N/A 0 0 0 0 0 2 126 126 15 141 Total 3 138 155 34 189 269 96 109 56 165 1995 Cardiovascular 0 0 0 0 43 16 17 61 78 Opthalmic 0 0 0 0 20 38 38 36 74 Other 0 0 0 0 15 51 51 44 95 N/A 0												
Total 3 138 155 34 189 269 96 109 56 165 1995 Cardiovascular 0 0 0 0 43 16 17 61 78 Opthalmic 0 0 0 0 20 38 38 36 74 Other 0 0 0 0 15 51 51 44 95 N/A 0 0 0 0 0 0 0 0 0 0 0 0 0 0												
1995 Cardiovascular 0 0 0 0 43 16 17 61 78 Opthalmic 0 0 0 0 20 38 36 74 Other 0 0 0 0 15 51 51 44 95 N/A 0 0 0 0 0 0 0 0 0												
Opthalmic 0 0 0 0 20 38 36 74 Other 0 0 0 0 0 15 51 51 44 95 N/A 0 <td></td> <td>Total</td> <td>3</td> <td>138</td> <td>155</td> <td>34</td> <td>189</td> <td>269</td> <td>96</td> <td>109</td> <td>56</td> <td>165</td>		Total	3	138	155	34	189	269	96	109	56	165
Other 0 0 0 0 0 15 51 51 44 95 N/A 0 0 0 0 0 0 0 0 0 0	1995											
N/A 0 0 0 0 0 0 0 0 0 0												
Total 0 0 0 0 0 78 29 29 51 80												
		Total	0	0	0	0	0	78	29	29	51	80

			(Driginal	PMAs				PMA sup	plements	
			FDA	Total				FDA	Total		
Fiscal			review		Non-FDA	Time		review		Non-FDA	Time
year	Division	Ν	time	time	time	lapse	N	time	time	time	lapse
1989	DCLD	3	275	334	77	411	29	77	81	31	112
1303	DCRND	10	220	427	156	583	142	55	74		138
	DGRD	3	247			551	57				
		25		312 266				108	119		189
	DOD		214			306	394	138	148		214
	DRAER	4	311	396	145	541	18	94	118		192
	Total	45	230	320	92	412	640	113	126	64	190
1990	DCLD	5	325	380	115	495	21	59	72	38	110
	DCRND	8	229	608	284	892	186	65	90	59	149
	DGRD	7	336	544	253	797	48	66	73	95	168
	DOD	11	374	468	139	607	274	104	121	52	173
	DRAER	5	368	794	290	1084	28	80	127		216
	Total	36	327	547	211	758	557	85	105	59	164
1991	DCLD	3	306	385	85	470	30	129	150	97	247
	DCRND	8	218	603		759	185	86	106		178
	DGRD	1	432	432		585	34	152	154		257
	DOD	9	273	318	83	401	211	137	176		258
	DRAER	ŏ	0	0		0	33	118	178		247
	Total	21	264	441	115	556	493	117	147		226
1992	DCLD	3	503	686	41	727	22	236	245	45	290
1332	DCRND	7	283	614		757	177	113	162		259
	DGRD	1	203	778	59	837	43	178	202		334
	DOD	9	378					222			
		9		550	227	777	180		255		352
	DRAER		162	311	245	556	52	88	136		236
	Total	21	346	591	165	756	474	164	202	98	300
1993	DCLD	1	426	426		426	15	196	207		284
	DCRND	2	164	506		545	145	120	150		233
	DGRD	0	0	0		0	35	129	129		247
	DOD	3	324	506		564	95	147	156		262
	DRAER	1	122	504		815	21	152	218		291
	Total	7	264	495	80	575	311	135	157	93	250
1994	DCLD	0	0	0	0	0	10	185	185	38	223
	DCRND	1	168	168	57	225	146	96	121	65	186
	DGRD	0	0	0	0	0	29	96	96	73	169
	DOD	1	49	101	46	147	70	81	81	37	118
	DRAER	1	196	196	0	196	14	105	111	26	137
	Total	3	138	155	34	189	269	96	109	56	165
1995	DCLD	0	0	0	0	0	4	124	124	0	124
	DCRND	ō	ō	ō		õ	44	17	18		78
	DGRD	ō	ō	ō		ō	7	4	4		92
	DOD	Ō	Ō	ō		ō	20	38	38		74
	DRAER	ō	õ	õ		õ	3	61	61		68
	Total	ŏ	ŏ	ő		ŏ	78	29	29		80
Total		133	280	449	137	586	2822	115	137	74	211

Investigational Device Exemption Tables IV.1 - IV.6

Tables	Page
Table IV.1:Average Days to Decision on Investigational DeviceExemptions by Fiscal Year	67
Table IV.2:Summary of Average Days to Decision onInvestigational Device Exemptions	68
Table IV.3:Average Days to Decision on Investigational DeviceExemptions by Class of Medical Device	69
Table IV.4:Average Days to Decision on Investigational DeviceExemptions by Tier of Medical Device	70
Table IV.5:Average Days to Decision on Investigational DeviceExemptions by Medical Specialty of Device	71
Table IV.6:Average Days to Decision on Investigational DeviceExemptions by Reviewing Division	72

	(0	ctober 1	, 1988 -	May 18	, 1995)								
Fiscal	Арр	roved	Den	ied	Witi	ndrawn	Other		Total	Percentile			Mean
year	NI	Days	NI	Days	NI	Days	N	Days	Ν	5	50	95	
1989	89	31	142	30	6	25	7	45	244	21	29	47	31
1990	95	29	150	29	2	29	17	49	264	24	30	30	30
1991	71	28	133	29	0	0	17	64	221	23	30	30	32
1992	74	29	136	29	4	29	14	26	228	21	29	30	29
1993	58	29	161	27	4	50	18	22	241	9	29	30	27
1994	42	28	120	29	5	27	4	13	171	21	29	30	28
1995	59	30	44	30	2	26	4	18	109	22	30	40	30
Total	488	29	886	29	23	31	81	38	1478	21	30	31	30

		Approve	d		Denied			Withdra	awn		Other		Total	P	ercer	ntilo	
Class	N	Percent		Ν	Percent		Ν	Percent		Ν	Percent	Days	N	5		95	Mean
1	7	41.2	28	7	41.2	30	1	5.9	28	2	11.8	75	17	21	29	120	34
II	89	33.5	29	158	59.4	30	4	1.5	27	15	5.6	49	266	25	30	40	31
M	339	35.6	29	569	59 .7	29	8	0.8	30	37	3.9	31	953	20	30	30	29
N/A	53	21.9	29	152	62. 8	29	10	4.1	33	27	11.2	40	242	20	29	40	30
Tier																	
1	4	30.8	29	7	53.8	29	1	7.7	28	1	7.7	120	13	27	29	120	36
2	208	44.3	29	230	49.0	29	5	1.1	27	26	5.5	38	469	20	30	32	29
3	231	29.0	30	531	66.6	29	7	0.9	36	28	3.5	33	797	23	30	30	29
Exempt	0	0	0	1	50.0	30	0	0	0	1	50.0	29	2	29	30	30	30
N/A	45	22.8	29	117	59.4	29	10	5.1	29	25	12.7	41	197	14	29	41	30
Medical specialty																	
Cardiovascular	107	27.6	29	270	69.6	30	2	0.5	22	9	2.3	34	388	25	30	30	29
Ophthalmic	136	50.7	28	114	42.5	26	3	1.1	29	15	5.6	23	268	9	29	30	27
Other	209	32.2	30	400	61.5	29	9	1.4	35	32	4.9	45	650	24	30	33	30
N/A	36	20.9	29	102	59.3	29	9	5.2	29	25	14.5	41	172	14	29	44	31
Division																	
DCLD	3	25.0	29	2	16.7	28	1	8.3	29	6	50.0	48	12	9	29	98	38
DCRND	169	29.5	29	373	65.1	29	5	0.9	31	26	4.5	44	573	24	30	31	30
DGRD	79	24.5	31	219	67.8	29	10	3.1	27	15	4.6	35	323	22	30	32	30
DOD	141	50.4	28	121	43.2	26	2	0.7	29	16	5.7	23	280	10	29	30	27
RAER	96	33.1	29	171	59.0	29	5	1.7	38	18	6.2	44	290	24	30	33	30
Fotal	488	33.0	29	886	59.9	29	23	1.6	31	81	5.5	38	1478	21	30	31	30

Fiscal ∕ear	Class		roved)ays	Dei NE	nied Days		ndrawn Days		her Days	Tot N [al Days
1989	I	0	0	1	30	0	0	0	0	1	30
1303	ii ii	14	29	24	31	4	27	2	105	44	33
	ш	67	31	99	30	1	15	3	22	170	30
	N/A	8	29	18	29	1	30	2	21	29	28
	Total	89	31	142	30	6	25	7	45	244	31
990	1	3	29	0	0	1	28	0	0	4	29
	II	17	30	35	29	0	0	4	68	56	32
	111	66	28	100	29	1	30	9	32	176	29
	N/A	9	28	15	28	0	0	4	70	28	34
	Total	95	29	150	29	2	29	17	49	264	30
1991	1	0	0	1	30	0	0	1	120	2	75
	II	18	28	32	29	0	0	4	30	54	29
	III	43	27	81	29	0	0	5	69	129	30
	N/A	10	29	19	30	0	0	7	71	36	37
	Total	71	28	133	29	0	0	17	64	221	32
1992	I	2	25	3	30	0	0	1	29	6	28
	11	8	30	18	29	0	0	0	0	26	29
	111	53	29	76	29	1	15	7	23	137	29
	N/A	11	28	39	29	3	33	6	29	59	29
	Total	74	29	136	29	4	29	14	26	228	29
1993	I	0	0	1	29	0	0	0	0	1	29
	II	5	30	20	30	0	0	4	28	29	30
	HI	45	29	109	26	2	43	10	20	166	27
	N/A	8	29	31	29	2	56	4	20	45	29
	Total	58	29	161	27	4	50	18	22	241	27
1994	I	1	30	1	29	0	0	0	0	2	30
	II	8	28	22	31	0	0	1	28	31	30
	III	31	28	79	29	2	34	1	11	113	29
	N/A	2	30	18	28	3	22	2	6	25	25
	Total	42	28	120	29	5	27	4	13	171	28
1995	I.	1	28	0	0	0	0	0	0	1	28
	11	19	30	7	31	0	0	0	0	26	30
	111	34	29	25	30	1	29	2	30	62	30
	N/A	5	34	12	29	1	22	2	6	20	28
	Total	59	30	44	30	2	26	4	18	109	30
Total		488	29	866	29	23	31	81	38	1478	30

Table IV.3: Average Days to Decision on Investigational Device Exemptions by Class of Medical Device (October 1, 1988 - May 18, 1995)

Fiscal /ear	Tier		oroved Days		nied Days		idrawn Days		ther Days	Tota N I	al Days
1989	1	0	0	1	29	0	0	0	0	1	29
	2	32	28	40	30	4	27	2	105	78	31
	3	51	33	93	30	1	15	3	22	148	31
	Exempt	0	0	0	0	0	0	0	0	0	0
	N/A	6	29	8	29	1	30	2	21	17	28
	Total	89	31	142	30	6	25	7	45	244	31
990	1	3	29	3	28	1	28	0	0	7	28
	2	42	29	48	29	0	0	6	55	96	31
	3	46	28	91	29	1	30	8	33	146	29
	Exempt	0	0	0	0	0	0	0	0	0	0
	N/A	4	28	8	29	0	0	3	83	15	39
	Total	95	29	150	29	2	29	17	49	264	30
1991	1	32	27	1	30	0	0	1	120	34	30
	2	33	29	41	29	õ	ŏ	5	31	79	29
	2	0	29	74	29	0	0	5	68	79	32
	Exempt	6	29	1	30	0	0	0	0	7	29
	N/A	0	0	16	30	0	0	6	78	22	43
	Total	71	28	133	29	0	0	17	64	221	32
992	1	1	28	2	30	0	0	1	27	4	29
	2	34	30	29	29	2	43	6	22	71	29
	3	29	28	72	29	0	0	1	29	102	29
	Exempt	ō	ō	0	0	2	15	6	29	8	25
	N/A	10	28	33	29	ō	0	ŏ	0	43	28
	Total	74	29	136	29	4	29	14	26	228	29
002	4	20	20	37	27	4	20	11	22	97	27
993	1	38	29	37	27	1	30	11	23	87	27
	2	12	29	100	26	1	56	3	21	116	27
	3	0	0	0	0	0	0	0	0	0	0
	Exempt	8	29	24	28	2	56	4	20	38	29
	N/A	0	0	0	0	0	0	0	0	0	0
	Total	58	29	161	27	4	50	18	22	241	27
994	1	11	28	27	29	0	0	1	28	39	29
	2	27	28	77	29	1	38	1	11	106	29
	3	0	0	Ó	õ	ò	Õ	ò	0	0	ō
	Exempt	4	29	16	27	4	24	2	6	26	26
	N/A	ō	29	0	0	ō	24	õ	0	20	20
	Total	42	28	120	29	5	27	4	13	171	28
1005		40	24	~	20	~	~	0	~	07	
1995	1	19	31	8	29	0	0		0	27	30
	2	33	30	24	31	0	0	2	30	60	30
	3	0	0	0	0	1	29	0	0	0	0
	Exempt	7	30	12	30	0	0	2	6	22	26
	N/A	0	0	0	0	1	22	0	0	2	11
	Total	59	30	44	30	2	26	4	18	109	30
Fotal		488	29	886	29	23	31	81	38	1478	30

Other 37 34 67 30 4 24 4 65 112 32 NA 6 29 6 28 1 30 2 21 15 28 Total 89 31 142 30 6 25 7 45 244 31 Cardiovascular 21 28 38 29 0 0 4 35 63 26 Ophthalmic 27 29 25 29 1 30 2 29 55 29 Other 43 29 81 29 1 28 8 50 133 30 Cardiovascular 13 29 35 29 0 0 2 48 50 30 Cardiovascular 13 29 35 29 0 0 1 36 34 26 41 Total 71 28	iscal ear	Medical specialty		roved Days	De N [nied Days		ndrawn Days		her Days	Tota N [l Days
Ophthalmic 17 27 14 31 1 27 1 18 33 28 Other 37 34 67 30 4 24 4 65 112 32 N/A 6 29 6 28 1 30 2 21 15 28 Total 89 31 142 30 6 25 7 45 244 31 Cardiovascular 21 28 38 29 0 0 4 35 63 29 Ophthalmic 27 29 25 29 1 28 8 50 133 30 N/A 4 28 6 29 0 0 3 83 13 44 Total 95 29 150 29 2 29 17 49 264 30 Ophthalmic 17 25 150 <t< th=""><th>989</th><th>Cardiovascular</th><th>29</th><th>29</th><th>55</th><th>30</th><th>0</th><th>0</th><th>0</th><th>0</th><th>84</th><th>- 30</th></t<>	989	Cardiovascular	29	29	55	30	0	0	0	0	84	- 30
Other 37 34 67 30 4 24 4 65 112 32 N/A 6 29 6 28 1 30 2 21 15 28 Total 89 31 142 30 6 25 7 45 244 31 Cardiovascular 21 28 38 29 0 0 4 35 63 29 Other 43 29 81 29 1 28 8 50 133 30 Other 43 29 35 29 0 0 3 83 13 44 Total 95 29 150 29 2 29 17 49 264 30 Cardiovascular 13 29 35 29 0 0 8 60 112 31 N/A 5 29 14 30 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td></td>							-	-	-	-		
N/A 6 29 6 28 1 30 2 21 15 28 Total 89 31 142 30 6 25 7 45 244 31 Cardiovascular 21 28 38 29 0 0 4 35 63 29 Ophthalmic 27 29 25 29 1 30 2 29 55 29 Other 43 29 81 29 1 28 8 50 133 30 N/A 4 28 6 29 0 0 2 48 50 30 Ophthalmic 17 25 16 29 0 0 1 36 34 28 Ophthalmic 17 28 133 29 0 0 1 36 34 28 Ophthalmic 17 28 133 29 0 0 17 64 221 33 Ophthalmic 32 </td <td></td> <td>-</td>												-
Total 89 31 142 30 6 25 7 45 244 31 Cardiovascular 21 28 38 29 0 0 4 35 63 29 Ophthalmic 27 29 25 29 1 30 2 29 55 29 Other 43 29 81 29 1 28 8 50 133 30 N/A 4 28 6 29 0 0 3 83 13 41 Total 95 29 150 29 2 29 17 49 264 30 Cardiovascular 13 29 35 29 0 0 1 36 34 28 Ophthalmic 17 25 16 29 0 0 17 64 221 32 Cardiovascular 8 28 34 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>1</td> <td></td> <td></td> <td></td> <td></td> <td></td>							1					
Ophthalmic 27 29 25 29 1 30 2 29 55 29 Other 43 29 81 29 1 28 8 50 133 30 N/A 4 28 6 29 0 0 3 83 13 41 Total 95 29 150 29 2 29 17 49 264 30 Cardiovascular 13 29 35 29 0 0 2 48 50 30 Ophthalmic 17 25 16 29 0 0 1 36 34 28 Other 36 29 68 29 0 0 67 78 25 41 Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 15 2 22 45 29 Ophthalmic 3			89		142		6					
Other 43 29 81 29 1 28 8 50 133 30 N/A 4 28 6 29 0 0 3 83 13 41 Total 95 29 150 29 2 29 17 49 264 30 Cardiovascular 13 29 35 29 0 0 2 48 50 30 Ophthalmic 17 25 16 29 0 0 1 36 34 28 Other 36 29 68 29 0 0 1 78 25 41 Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 15 2 22 45 43 30 Ophthalmic 32 30 14 30 0 17 64 23 85 29 N/A)	Cardiovascular	21	28	38	29	0	0		35	63	29
N/A 4 28 6 29 0 0 3 83 13 44 Total 95 29 150 29 2 29 17 49 264 30 Cardiovascular 13 29 35 29 0 0 2 48 50 30 Ophthalmic 17 25 16 29 0 0 2 48 50 30 Ophthalmic 17 25 16 29 0 0 1 36 34 28 Other 36 29 68 29 0 0 67 78 25 41 Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 15 2 22 45 29 20 17 44 23 85 29 20 28 33 29 21 35 29 36 29		Ophthalmic	27	29	25	29	1	30	2	29	55	29
Total 95 29 150 29 2 29 17 49 264 30 Cardiovascular 13 29 35 29 0 0 2 48 50 30 Ophthalmic 17 25 16 29 0 0 1 36 34 28 Other 36 29 68 29 0 0 8 60 112 31 N/A 5 29 14 30 0 0 6 78 25 41 Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 70 4 23 85 29 Ophthalmic 32 30 14 30 0 0 22 48 30 Other 25 28 55 29			-		81						133	
Cardiovascular 13 29 35 29 0 0 2 48 50 30 Ophthalmic 17 25 16 29 0 0 1 36 34 28 Other 36 29 68 29 0 0 8 60 112 31 N/A 5 29 14 30 0 0 6 78 25 41 Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 15 2 22 45 29 Ophthalmic 32 30 14 30 0 0 2 28 48 30 Other 25 28 55 29 1 70 4 23 85 29 N/A 9 28 33 29 2 15 6 29 50 28 Ophthalmic 36			•		-		-	-	-		13	
Ophthalmic 17 25 16 29 0 0 1 36 34 28 Other 36 29 68 29 0 0 8 60 112 31 N/A 5 29 14 30 0 0 6 78 25 41 Total 71 28 133 29 0 0 17 64 221 33 Cardiovascular 8 28 34 29 1 15 2 22 45 29 Ophthalmic 32 30 14 30 0 0 2 28 48 30 Other 25 28 55 29 1 70 4 23 85 25 N/A 9 28 33 29 2 15 6 29 50 26 Ophthalmic 36 29 33 18 </td <td></td> <td>Total</td> <td>95</td> <td>29</td> <td>150</td> <td>29</td> <td>2</td> <td>29</td> <td>17</td> <td>49</td> <td>264</td> <td>30</td>		Total	95	29	150	29	2	29	17	49	264	30
Other 36 29 68 29 0 0 8 60 112 31 N/A 5 29 14 30 0 0 6 78 25 41 Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 15 2 22 45 25 Ophthalmic 32 30 14 30 0 0 2 28 48 30 Other 25 28 55 29 1 70 4 23 85 25 N/A 9 28 33 29 2 15 6 29 50 28 Total 74 29 136 29 0 0 1 29 50 28 Cardiovascular 4 30 45 29 0 0 1 29 50 28 Ophthalmic 36	1											
N/A 5 29 14 30 0 0 6 78 25 41 Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 15 2 22 45 29 Ophthalmic 32 30 14 30 0 0 2 28 48 30 Other 25 28 55 29 1 70 4 23 85 29 N/A 9 28 33 29 2 15 6 29 50 28 Total 74 29 136 29 0 0 1 29 50 28 Cardiovascular 4 30 45 29 0 0 1 29 50 29 Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10							-	-				
Total 71 28 133 29 0 0 17 64 221 32 Cardiovascular 8 28 34 29 1 15 2 22 45 29 Ophthalmic 32 30 14 30 0 0 0 2 28 48 30 Other 25 28 55 29 1 70 4 23 85 29 N/A 9 28 33 29 2 15 6 29 50 28 Total 74 29 136 29 4 29 14 26 228 29 Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10 29 61 29 1 56 4 20 36 29 N/A 8 29 22 <td></td> <td>Other</td> <td>36</td> <td></td> <td>68</td> <td>29</td> <td>-</td> <td>-</td> <td>8</td> <td></td> <td>112</td> <td>31</td>		Other	36		68	29	-	-	8		112	31
Cardiovascular 8 28 34 29 1 15 2 22 45 29 Ophthalmic 32 30 14 30 0 0 2 28 48 30 Other 25 28 55 29 1 70 4 23 85 29 N/A 9 28 33 29 2 15 6 29 50 28 Total 74 29 136 29 4 29 14 26 228 29 Cardiovascular 4 30 45 29 0 0 1 29 50 28 Ophthalmic 36 29 22 29 14 26 228 29 Other 10 29 61 29 0 0 1 29 50 29 Other 10 29 61 29 1 56 4 20 36 29 Total 58 29 161 <td></td>												
Ophthalmic 32 30 14 30 0 0 2 28 48 30 Other 25 28 55 29 1 70 4 23 85 29 N/A 9 28 33 29 2 15 6 29 50 28 Total 74 29 136 29 4 29 14 26 228 29 Cardiovascular 4 30 45 29 0 0 1 29 50 29 Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10 29 61 29 1 56 4 28 76 29 N/A 8 29 121 27 4 50 18 22 241 27 Cardiovascular 17 28 45		Total	71	28	133	29	0	0	17	64	221	32
Other 25 28 55 29 1 70 4 23 85 29 N/A 9 28 33 29 2 15 6 29 50 28 Total 74 29 136 29 4 29 14 26 228 29 Cardiovascular 4 30 45 29 0 0 1 29 50 29 Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10 29 61 29 1 56 4 28 76 29 N/A 8 29 122 29 2 56 4 20 36 29 Total 58 29 161 27 4 50 18 22 241 27 Cardiovascular 17 28 45 <t< td=""><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>			-									
N/A 9 28 33 29 2 15 6 29 50 28 Total 74 29 136 29 4 29 14 26 228 29 Cardiovascular 4 30 45 29 0 0 1 29 50 29 Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10 29 61 29 1 56 4 28 76 29 N/A 8 29 22 29 2 56 4 20 36 29 N/A 8 29 22 29 2 56 4 20 36 29 N/A 8 29 121 27 4 50 18 22 241 27 Cardiovascular 17 28 45 30 0 0 0 0 15 28 Ophthalmic 4 <								-				
Total 74 29 136 29 4 29 14 26 228 29 Cardiovascular 4 30 45 29 0 0 1 29 50 29 Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10 29 61 29 1 56 4 28 76 29 N/A 8 29 22 29 2 56 4 20 36 29 Total 58 29 161 27 4 50 18 22 241 27 Cardiovascular 17 28 45 30 0 0 0 0 15 28 Ophthalmic 4 30 11 27 3 22 2 6 19 24 Total 42 28 120												
Cardiovascular 4 30 45 29 0 0 1 29 50 29 Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10 29 61 29 1 56 4 28 76 29 N/A 8 29 22 29 2 56 4 20 36 29 Total 58 29 161 27 4 50 18 22 241 27 Cardiovascular 17 28 45 30 0 0 0 0 62 29 Ophthalmic 4 30 11 27 0 0 0 15 28 Ophthalmic 4 30 11 27 0 0 0 15 28 Other 19 28 52 29 5 27 4 13 171 28 Cardiovascular 15 29 <			-						-			
Ophthalmic 36 29 33 18 1 30 9 19 79 23 Other 10 29 61 29 1 56 4 28 76 29 N/A 8 29 22 29 2 56 4 20 36 29 Total 58 29 161 27 4 50 18 22 241 27 Cardiovascular 17 28 45 30 0 0 0 0 62 29 Ophthalmic 4 30 11 27 0 0 0 15 28 Other 19 28 52 29 2 34 2 20 75 29 N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5		Total	74	29	136	29	4	29	14	26	228	29
Other 10 29 61 29 1 56 4 28 76 29 N/A 8 29 22 29 2 56 4 20 36 29 Total 58 29 161 27 4 50 18 22 241 27 Cardiovascular 17 28 45 30 0 0 0 62 29 Ophthalmic 4 30 11 27 0 0 0 62 29 N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0			•				-	-				
N/A 8 29 22 29 2 56 4 20 36 29 Total 58 29 161 27 4 50 18 22 241 27 Cardiovascular 17 28 45 30 0 0 0 0 62 29 Ophthalmic 4 30 11 27 0 0 0 62 29 Ophthalmic 4 30 11 27 0 0 0 62 29 Other 19 28 52 29 2 34 2 20 75 28 N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1		•							-			
Total 58 29 161 27 4 50 18 22 241 27 Cardiovascular 17 28 45 30 0 0 0 0 62 29 Ophthalmic 4 30 11 27 0 0 0 05 15 28 Other 19 28 52 29 2 34 2 20 75 29 N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0 0 0 4 25 Other 39 30 16 3			-									
Cardiovascular 17 28 45 30 0 0 0 0 62 29 Ophthalmic 4 30 11 27 0 0 0 0 15 28 Other 19 28 52 29 2 34 2 20 75 29 N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0 0 4 25 Other 39 30 16 31 0 2 30 57 33 N/A 2 29 9 30 1 22 2 6 14 26												
Ophthalmic 4 30 11 27 0 0 0 0 15 28 Other 19 28 52 29 2 34 2 20 75 29 N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0 0 4 25 Other 39 30 16 31 0 2 30 57 30 N/A 2 29 9 30 1 22 2 6 14 26		Total	58	29	161	27	4	50	18	22	241	27
Other 19 28 52 29 2 34 2 20 75 29 N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0 0 0 4 25 Other 39 30 16 31 0 0 2 30 57 30 N/A 2 29 9 30 1 22 2 6 14 26	4											
N/A 2 30 12 27 3 22 2 6 19 24 Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0 0 0 4 25 Other 39 30 16 31 0 0 2 30 57 30 N/A 2 29 9 30 1 22 2 6 14 26							-	-	-	-		
Total 42 28 120 29 5 27 4 13 171 28 Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0 0 0 4 25 Other 39 30 16 31 0 0 2 30 57 30 N/A 2 29 9 30 1 22 2 6 14 26							_	•			• •	
Cardiovascular 15 29 18 31 1 29 0 0 34 30 Ophthalmic 3 29 1 14 0 0 0 4 25 Other 39 30 16 31 0 0 2 30 57 30 N/A 2 29 9 30 1 22 2 6 14 26												
Ophthalmic 3 29 1 14 0 0 0 4 25 Other 39 30 16 31 0 0 2 30 57 30 N/A 2 29 9 30 1 22 2 6 14 26		iotal	42	28	120	29	5	27	4	13	171	28
Other 39 30 16 31 0 0 2 30 57 30 N/A 2 29 9 30 1 22 2 6 14 26	5								-	-		
N/A 2 29 9 30 1 22 2 6 14 26			-		-							
iotai 59 30 44 30 2 26 4 18 109 30					-							
		IOTAI	59	30	44	30	2	26	4	18	109	30

	(Ocu	ober 1,	1988 -	May 18,	1995)							
Fiscal year	Division	Appro N [oved Days	Den N [ied Days	With NC	drawn)ays		her Days	Tota N E	l Days	
1989	DCLD	0	0	0	0	0	0	0	0	0	0	
	DCRND	41	30	65	29	0	0	2	64	108	30	
	DGRD	14	41	41	30	4	24	1	21	60	32	
	DOD	18	27	14	31	1	27	1	18	34	28	
	DRAER	16	29	22	30	1	30	3	50	42	31	
	Total	89	31	142	30	6	25	7	45	244	31	
1990	DCLD	0	0	0	0	0	0	2	95	2	95	
	DCRND	31	28	55	29	0	0	5	36	91	29	
	DGRD	17	29	36	29	2	29	2	19	57	29	
	DOD	29	29	25	29	0	0	2	29	56	29	
	DRAER	18	30	34	29	0	0	6	63	58	33	
	Total	95	29	150	29	2	29	17	49	264	30	
1991	DCLD	1	29	0	0	0	0	1	29	2	29	
	DCRND	24	28	51	29	0	0	8	71	83	33	
	DGRD	16	29	41	29	0	0	5	61	62	32	
	DOD	16	25	17	29	0	0	1	36	34	28	
	DRAER	14	29	24	29	0	0	2	74	40	31	
	Total	71	28	133	29	0	0	17	64	221	32	
1992	DCLD	0	0	0	0	0	0	1	30	1	30	
	DCRND	17	28	64	29	1	15	5	26	87	29	
	DGRD	13	28	30	29	3	33	3	25	49	29	
	DOD	32	30	15	28	0	0	3	29	50	29	
	DRAER	12	28	27	29	0	0	2	19	41	28	
	Total	74	29	136	29	4	29	14	26	228	29	
1993	DCLD	0	0	1	27	0	0	0	0	1	27	
	DCRND	10	29	60	29	1	56	3	22	74	29	
	DGRD	2	30	36	29	0	0	3	27	41	29	
	DOD	37	29	36	19	1	30	9	19	83	23	
	DRAER	9	29	28	29	2	56	3	24	42	30	
	Total	58	29	161	27	4	50	18	22	241	27	
1994	DCLD	0	0	1	29	1	29	1	28	3	29	
	DCRND	25	28	55	30	2	28	1	8	83	29	
	DGRD	2	27	25	29	0	0	1	11	28	28	
	DOD	6	30	11	27	0	0	0	0	17	28	
	DRAER	9	29	28	29	2	25	1	3	40	28	
	Total	42	28	120	29	5	27	4	13	171	28	
1995	DCLD	2	29	0	0	0	0	1	9	3	22	
	DCRND	21	29	23	31	1	29	2	30	47	30	
	DGRD	15	30	10	30	1	22	0	0	26	30	
	DOD	3	29	3	24	0	0	0	0	6	26	
	DRAER	18	31	8	30	0	0	1	3	27	30	
	Total	59	30	44	30	2	26	4	18	109	30	
Total		488	29	886	29	23	31	81	38	1478	30	

Table IV.6: Average Days to Decision on Investigational Device Exemptions by Reviewing Division (October 1, 1988 - May 18, 1995) Fiscal Approved Denied Withdrawn Other Total

Comparision in Table V of Alternative Methods for Determining Average Days to Decision by Fiscal Year

Alternative Calculation of Review Time by Year of Decision

We reported our findings according to the fiscal year in which the applications were submitted to FDA (date-of-submission cohort). By contrast, FDA commonly reports review time according to the fiscal year in which the review was completed (date-of-decision cohort). This led to discrepancies between our results and those reported by FDA. The following table illustrates the differences in calculating total elapsed time by the year that the application was submitted and the year that a decision was rendered. Comparisons are provided for 510(k)s, PMA supplements, original PMAs, and IDES.

Our dataset did not include applications submitted before October 1, 1988. Consequently, the results presented in the following table understated the number of cases, as well as the elapsed time, when calculated by the year of decision. That is, an application submitted in fiscal year 1988 and completed in 1989 would not have been in our dataset.

Table V: Comparison of Alternative Methods for Determining Average Days to Decision by Fiscal Year (October 1, 1988 - May 18, 1995)

		5	10(k)			Origina	I PMA			PMA s	upplem	ent		IC)E	
Fiscal year		cision Days		nission Days		ision Days		mission Day s		ision Days		nission Day s		cision Days		missior Days
1989	4819	82	7021	124	25	138	81	513	359	107	803	219	228	31	244	31
1990	6148	`120	5835	121	46	324	67	744	780	176	650	193	259	30	264	30
1991	5374	122	5763	153	38	492	60	580	553	189	577	261	226	30	221	32
1992	4938	150	6479	245	37	479	37	674	465	198	572	336	223	31	228	29
1993	5120	225	6102	269	48	804	21	462	420	305	350	264	248	27	241	27
1994	7167	247	5635	166	58	846	8	222	466	394	295	162	174	29	171	28
1995	4973	256	1705	67	23	876	1	23	288	369	84	79	120	30	109	30
Total	38539	175	38540	175	275	591	275	591	3331	237	3331	237	1478	30	1478	30
Open	2410	0	2410	0	126	0	126	0	309	0	309	0	0	0	0	0

Comments From the Food and Drug Administration

Note: GAO comments			
supplementing those in the report text appear at the			
end of this appendix.	South STRUCES LE	DEPARTMENT OF HEALTH & HUMAN SERVICES	Public Health Service Food and Drug Administration
	"HITHIANGIC	AUG 0 2 1995	Memorandum
	Date	Associate Commissioner for Legislative Affa: Through: Margaret Porter, Chief Counsel, Of Counsel, GCF-1	irs, HFW-1 ffice of General
	Subject	Comments on GAO Draft Report Entitled "Me Review Time."	edical Devices: FDA
	То	Kwai-Cheung Chan, Director Program Evaluator in Physical Systems Area	
		We have reviewed the subject draft report a comments.	and have the attached
		Serve T. Att	Telland for
		Diane E. Thom	
		Attachment	

 Food and Drug Administration Comments on the General Accounting office Draft Report Entitled, <u>MEDICAL DEVICES FDA Review Time</u> The Food and Drug Administration (FDA) appreciates the opportunity to review and comment on the subject draft report. We recognize that both GAO and FDA are interested in presenting an accurate and fair analysis of FDA's performance with respect to reviewing medical devices during the past few years. As written, however, we believe the report seriously misrepresents the current state of the review program by omitting the significant progress made since the start of FY1994. Therefore, in addition to the following comments, we would appreciate the opportunity to meet with the study team to further discuss the report and changes we believe to be necessary to correct some inaccuracies and misperceptions. For your information, we are also enclosing a copy of a letter that was sent to device manufacturers on May 18, 1995 further explaining review process improvements. DA is particularly concerned that the report does not reflect recent improvements in device review times, nor does it interest of this decade, the review process became very sing the first part of this decade, the review process became very times. It also does not correctly describe key aspects of the device who and enumber of reasons. However, recent management initiatives and reemphasis on doing thorough reviews in a timely more target comments, comments on the Premarket Approal (PMA) review process, and comments on the Premarket Approal (PMA) review process, and comments on the review process better if it included a discussion of the changes that the report. M noted above, FDA has made a number of changes to the review process better if it included a discussion of the changes that the PMA; pMA; e refuse to accept/file policies for IDEs, 510(k)s, and PMA; e appediter review of 510(k); e appediter review of 510(k)s; 	Office Draft Report Entitled, <u>MEDICAL DEVICES FDA Review Time</u> The Food and Drug Administration (FDA) appreciates the opportunity to review and comment on the subject draft report. We recognize that both GAO and FDA are interested in presenting a accurate and fair analysis of FDA's performance with respect to reviewing medical devices during the past few years. As witten, however, we believe the report seriously misrepresents the current state of the review program by omitting the past few years. As grant and year interested in presenting the current state of the review core accurate state of the review program by omitting the past few years. As witten, however, we believe the report seriously misrepresents the current state of the texture to be necessary to correct some inaccuracies and misperceptions. For your information, we are anufacturers on May 18, 1995 further explaining review process inprovements. DA is particularly concerned that the report does not reflect freent improvements in device review times, nor does it acknowledge recent initiatives designed to further improve review the inst. It also does not correctly describe key aspects of the device evaluation program. The Agency acknowledges that during the first part of this decade, the review process became very slow for a number of reasons. However, recent management initiatives and reemphasis on doing thorough reviews in a timely to review process, and comments on the Premarket Notification (510(k)) review process, comments on the Premarket Notification (510(k)) review process, and comments on the Premarket Notification (510(k)) review process, comments on the Premarket Notification (510(k)) review process, and comments on the Premarket Notification (510(k)) review process, and comments on the Premarket Notification (510(k)) review process, and comments on the Premarket Notification (510(k)) review process, and comments on the premarket prove the report would be enhanced and serve the report. We believe the report would be enhanc		
Office Draft Report Entitled, <u>MEDICAL DEVICES FDA Review Time</u> The Food and Drug Administration (FDA) appreciates the opportunity to review and comment on the subject draft report. We recognize that both GAO and FDA are interested in presenting an accurate and fair analysis of FDA's performance with respect to reviewing medical devices during the past few years. As written, however, we believe the report seriously misrepresents the current state of the review program by omitting the significant progress made since the start of FY1994. Therefore, in addition to the following comments, we would appreciate the opportunity to meet with the study team to further discuss the report and changes we believe to be necessary to correct some anufacturers on May 18, 1995 further explaining review process improvements. DA is particularly concerned that the report does not reflect recent improvements in device review times, nor does it acknowledge recent initiatives designed to further improve review times. It also does not correctly describe key aspects of the device evaluation program. The Agency acknowledges that during the first part of this decade, the review process became very slow for a number of reasons. However, recent management initiatives and reemphasis on doing thorough reviews in a timely anner have brought about significant performance improvements in the further discusses, and comments on the Premarket Notification (510(k)) review process, comments on the review proport. We believe the report would be enhanced and serve there of the review therefort, source the sense the changes the review the set beneformed and serve the set been to backlog and current at a not eview times. Among the changes are: In the interest, S10(k)s and JDB that and the sense the review for S10(k)s, and prove times. Among t	Office Draft Report Entitled, MEDICAL DEVICES FDA Review Time The Food and Drug Administration (FDA) appreciates the opportunity to review and comment on the subject draft report. We recognize that both GAO and FDA are interested in presenting accurate and fair analysis of FDA's performance with respect to reviewing medical devices during the past few years. As written, however, we believe the report seriously misrepresents the current state of the review program by omitting the subject draft report, add changes we believe to be necessary to correct some anadycate and haisperceptions. For your information, we are inaccuracies and misperceptions. For your information, we are inaccuracies and misperceptions. For your information, we are inaccuracies and misperceptions. For your information, we are inforcements in device review times, nor does it acturers on May 18, 1995 further explaining review process improvements. DA is particularly concerned that the report does not reflect facthowledge recent initiatives designed to further improve review times. It also does not correctly describe key aspects of the device evaluation program. The Agency acknowledges that during the tare not evident in this report. In the interest of clarity, we have grouped our comments into four categories: general comments, comments on the Premarket Notification (510(k)) review process, comments on the Premarket Notification (510(k)) review process, comments on the Premarket Notification (510(k)) review process, and comments on the serview for the set betwee the report would be enhanced and serve the proot soute been instituted to address the problems of backlog and serve the set be report would be enhanced and serve the correct soute the set of the changes are: In the interest of clarity, we have groupes of the change to the review for the set of the report. We believe the report would be enhanced and serve the proot would be enhanced and serve the proot would be enhanced and serve the correct wee been intit		
 opportunity to review and comment on the subject draft report. We recognize that both GAO and FDA are interested in presenting an accurate and fair analysis of FDA's performance with respect to reviewing medical devices during the past few years. As written, however, we believe the report seriously misrepresents the current state of the review program by omitting the significant progress made since the start of FY1994. Therefore, in addition to the following comments, we would appreciate the opportunity to meet with the study team to further discuss the report and changes we believe to be necessary to correct some inaccuracies and misperceptions. For your information, we are also enclosing a copy of a letter that was sent to device manufacturers on May 18, 1995 further explaining review process improvements. FDA is particularly concerned that the report does not reflect recent improvements in device review times, nor does it acknowledge recent initiatives designed to further improve review times. It also does not correctly describe key aspects of the device evaluation program. The Agency acknowledges that during the first part of this decade, the review process became very slow for a number of reasons. However, recent management initiatives and reemphasis on doing thorough reviews in a timely manner have brought about significant performance improvements that are not evident in this report. In the interest of clarity, we have grouped our comments into four categories; general comments, comments on the Premarket Approval (PMA) review process, and comments on the Investigational Devices Exemption (IDE) review process. GENERAL COMMENTS As noted above, FDA has made a number of changes to the review process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the opproval (PMA) review process the problems of backlog and extended review times. Among the changes that have been instituted to ad	 opportunity to review and comment on the subject draft report. We recognize that both GAO and FDA are interested in presenting an accurate and fair analysis of FDA's performance with respect to reviewing medical devices during the past few years. As written, however, we believe the report seriously misrepresents the current state of the review program by omitting the significant progress made since the start of FY1994. Therefore, in addition to the following comments, we would appreciate the opportunity to meet with the study team to further discuss the report and changes we believe to be necessary to correct some inaccuracies and misperceptions. For your information, we are also enclosing a copy of a letter that was sent to device manufacturers on May 18, 1995 further explaining review process improvements. FDA is particularly concerned that the report does not reflect recent improvements in device review times, nor does it acknowledge recent initiatives designed to further improve review times. It also does not correctly describe key aspects of the device evaluation program. The Agency acknowledges that during the first part of this decade, the review process became very slow for a number of reasons. However, recent management initiatives and reemphasis on doing thorough reviews in a timely maner have brought about significant performance improvements that are not evident in this report. In the interest of clarity, we have grouped our comments into four categories: general comments, comments on the Premarket Approval (PMA) review process, comments on the Thremarket Approval (PMA) review process, comments on the Premarket Approval (PMA) review process that are not discussed in the report. We believe the report would be enhanced and serve the congress better if included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes that have been instituted to address the problems of backlog and extende	Fo Of	od and Drug Administration Comments on the General Accounting fice Draft Report Entitled, <u>MEDICAL DEVICES FDA Review Time</u>
 recent improvements in device review times, nor does it acknowledge recent initiatives designed to further improve review times. It also does not correctly describe key aspects of the device evaluation program. The Agency acknowledges that during the first part of this decade, the review process became very slow for a number of reasons. However, recent management initiatives and reemphasis on doing thorough reviews in a timely manner have brought about significant performance improvements that are not evident in this report. In the interest of clarity, we have grouped our comments into four categories: general comments, comments on the Premarket Notification {510(k)} review process, comments on the Premarket Approval (PMA) review process, and comments on the Investigational Devices Exemption (IDE) review process. GENERAL COMMENTS As noted above, FDA has made a number of changes to the review process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are: triage/tier review of 510(k)s; refuse to accept/file policies for IDEs, 510(k)s, and PMAs; expedited review for breakthrough products; 	 recent improvements in device review times, nor does it acknowledge recent initiatives designed to further improve review times. It also does not correctly describe key aspects of the device evaluation program. The Agency acknowledges that during the first part of this decade, the review process became very slow for a number of reasons. However, recent management initiatives and reemphasis on doing thorough reviews in a timely manner have brought about significant performance improvements that are not evident in this report. In the interest of clarity, we have grouped our comments into four categories: general comments, comments on the Premarket Notification {510(k)} review process, and comments on the Premarket Approval (PMA) review process, and comments on the Investigational Devices Exemption (IDE) review process. GENERAL COMMENTS As noted above, FDA has made a number of changes to the review process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are: triage/tier review of 510(k)s; refuse to accept/file policies for IDEs, 510(k)s, and PMAs; expedited review for breakthrough products; 	op We an to wr th si in op re in al ma	portunity to review and comment on the subject draft report. a recognize that both GAO and FDA are interested in presenting a accurate and fair analysis of FDA's performance with respect b reviewing medical devices during the past few years. As ritten, however, we believe the report seriously misrepresents the current state of the review program by omitting the gnificant progress made since the start of FY1994. Therefore, a addition to the following comments, we would appreciate the portunity to meet with the study team to further discuss the export and changes we believe to be necessary to correct some accuracies and misperceptions. For your information, we are aso enclosing a copy of a letter that was sent to device anufacturers on May 18, 1995 further explaining review process
<pre>four categories: general comments, comments on the Premarket Notification {510(k)} review process, comments on the Premarket Approval (PMA) review process, and comments on the Investigational Devices Exemption (IDE) review process. GENERAL COMMENTS As noted above, FDA has made a number of changes to the review process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are:</pre>	<pre>four categories: general comments, comments on the Premarket Notification {510(k)} review process, comments on the Premarket Approval (PMA) review process, and comments on the Investigational Devices Exemption (IDE) review process. GENERAL COMMENTS As noted above, FDA has made a number of changes to the review process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are:</pre>	re ac ti de th sl in ma	ecent improvements in device review times, nor does it Exhowledge recent initiatives designed to further improve review mes. It also does not correctly describe key aspects of the evice evaluation program. The Agency acknowledges that during the first part of this decade, the review process became very ow for a number of reasons. However, recent management hitiatives and reemphasis on doing thorough reviews in a timely noner have brought about significant performance improvements
<pre>As noted above, FDA has made a number of changes to the review process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are: - triage/tier review of 510(k)s; - refuse to accept/file policies for IDEs, 510(k)s, and PMAs; - expedited review for breakthrough products;</pre>	<pre>As noted above, FDA has made a number of changes to the review process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are: - triage/tier review of 510(k)s; - refuse to accept/file policies for IDEs, 510(k)s, and PMAs; - expedited review for breakthrough products;</pre>	fo No Ap	our categories: general comments, comments on the Premarket otification {510(k)} review process, comments on the Premarket oproval (PMA) review process, and comments on the
<pre>process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are:</pre>	<pre>process for PMAs, 510(k)s and IDEs that are not discussed in the report. We believe the report would be enhanced and serve the Congress better if it included a discussion of the changes that have been instituted to address the problems of backlog and extended review times. Among the changes are:</pre>	GE	NERAL COMMENTS
 refuse to accept/file policies for IDEs, 510(k)s, and PMAs; expedited review for breakthrough products; 	 refuse to accept/file policies for IDEs, 510(k)s, and PMAs; expedited review for breakthrough products; 	pr re Co ha	rocess for PMAs, 510(k)s and IDEs that are not discussed in the port. We believe the report would be enhanced and serve the ongress better if it included a discussion of the changes that ave been instituted to address the problems of backlog and
<pre>PMAs; expedited review for breakthrough products;</pre>	<pre>PMAs; expedited review for breakthrough products;</pre>		 triage/tier review of 510(k)s;
			 expedited review for breakthrough products;

See comment 1.

	 delegation of decision-making authority to lower levels; and
	hiring and training new reviewers. We also suggest that a section of the report be devoted to the increasing complexity of applications and the mix of simple versus complex applications received. FDA has recently taken steps to exempt certain low-risk devices from premarket notification or approval. This has resulted in a greater proportion of the submissions being complex rather than simple. Other factors that have impacted on the complexity of applications are advancements and innovations in medical technology. Together, the result has been applications that require significantly more time to review than was the case in past years. Simultaneously, however, the industry has benefitted by being able to market low-risk devices without prior FDA review.
See comment 2.	The report would be more useful if it provided a more comprehensive overview of the methodology used for analysis. For example, the report measures performance based on date-of- submission cohorts, whereas FDA's usual method for measuring device review performance is based on date-of-decision cohorts. While the report acknowledges that these approaches can vary substantially, it does not explain the variances or the implications of each for understanding and explaining FDA performance. We should note at this point that because the report uses date-of-submission cohorts, FDA's statistical analyses over the past several years may not agree with GAO's, although the trends should be in the same direction. This may become a source of confusion for the readers of the report.
See comment 3.	We also note that the report deals only with calculations of averages and percentiles. We believe it would be useful to include additional performance measures as well. For example, median review times can provide a better measure of "typical" performance by reducing the effects of outliers (unusually "quick" and unusually "slow" reviews).
	Also, while some of the tables in the report include data for the 5th, 50th, and 95th percentiles, the text discusses only average (mean) review times. Indeed, on page 9 the report says GAO cannot determine whether review times continued to increase after 1992 for PMAs and after 1993 for 510(k)s because of the increasing number of open cases. Average time is not a helpful statistic while open cases remain in the date-of-receipt cohort. Others have used percentiles as a more meaningful statistic to interpret receipt cohort data. A comparison of percentiles can help determine whether this trend continued. For example, by May 18, 1995, GAO's cutoff date, 87.5% of 510(k)s submitted in FY1994 had received a final action. A comparison of median times (i.e.,
	2


 e comment 4. b the 50th percentile, or the time to complete 50% of f applications) or the 75th or 85th percentiles from FY FY1994 can help answer this question. 510(K) REVIEW As briefly introduced above, the value of the report enhanced if recent improvements in review performance achnowledged. We are particularly concerned that the concludes that, while 510(K) review time increased fi increasing number of open cases". While it is true if the increased in the early 1990s, the data for FY199 significant improvement. For example, using GAO's di submission cohort methodology, including withdrawls deletions, we calculate that; the median review time has dropped (from 10 FY1993, 2461 in FY1994, and 2045 in the fir months of FY1993, 2461 in FY1994, and 2045 in the fir months of FY1995). backlogs of 510(K)s under review over 90 di substantially reduced (1978 in December, 19 204 in June, 1995). By focusing exclusively on the one measure of perform excluding the data from 1994-1995, the report presend distorted view of the current situation, and leaves di impression of a static review process that remains pi ridden. e comment 5. 	
 deletions, we calculate that; the median review time has dropped (from 16 FY1993, to 100 days in FY 1994 and 108 days more 510(k)s are being reviewed within 90 of FY1993, 2461 in FY1994, and 2045 in the find months of FY1995), backlogs of 510(k)s under review over 90 days substantially reduced (1978 in December, 15 204 in June, 1995). By focusing exclusively on the one measure of perform excluding the data from 1994-1995, the report present distorted view of the current situation, and leaves 1 impression of a static review process that remains puriden. The report would be more useful for analytical purpor also included information about FDA review times ratio total elapsed time. The Agency has kept statistics imanner for some time and believes this to be an impor analysis for understanding how the review process won improvements are needed and can be made. By focusing on the total elapsed times, the report essentially for time not under its control and for attempting to worth sponsors to improve the quality of their submissions become approvable. For example, in most cases when I identifies substantial problems that would justify of their submissions become approvable. For example, in most cases when I identifies substantial problems that would justify of the substantial problems that woul	FY1989 through t would be ce were ne report from 1989 to the that review 994 shows a date-of-
ridden. The report would be more useful for analytical purpose also included information about FDA review times rath total elapsed time. The Agency has kept statistics : manner for some time and believes this to be an impor analysis for understanding how the review process wor improvements are needed and can be made. By focusing on the total elapsed times, the report essentially fa time not under its control and for attempting to work sponsors to improve the quality of their submissions become approvable. For example, in most cases when I identifies substantial problems that would justify c	169 days in ys in FY1995), days (1536 in irst seven days have been 1993, versus rmance and its a the
applicant the file is kept open for up to a full year the applicant to submit additional information rather submitting an entirely new application. The report h acknowledged this FDA practice, and therefore, all th allowed for the applicant to strengthen its applicat counted as FDA review time, skewing the results in a	oses if it ther than just in this ortant orks and where ng exclusively faults FDA for ck with the s so they may FDA closing out y to the ar to allow er than has not the time tion is

	way. Although the report includes rough estimates of non-FDA time, the information is too general to be useful. By distinguishing between FDA review time and total elapsed time, the report will enable readers to more accurately assess FDA's performance.
ee comment 6.	The report also has a built-in bias for the purposes of workload analysis because of the selection of FY1989 as the benchmark year. FDA received an unusually high number of 510(k) applications during that particular year because of the need to review applications for all existing and new patient examination gloves. Prior to FY1989, these gloves were exempt from FDA premarket notification requirements. In 1989, because of the increasing concerns relating to AIDS/HIV transmission, FDA revoked the exemption and required 510(k) submissions for all existing and new patient examination gloves. As a result, the Agency received more than 1500 applications for gloves in FY1989. This one-time surge should be taken into account in examining review performance and application receipts over time. FDA's data show that, taking patient examination gloves into account, 510(k) receipts have increased over the last few years.
ee comment 7.	The report should not apply the tier-based analysis to the data for years prior to FY1994. The tier review approach was developed in FY1993 and phased into use beginning on June 30, 1993 (end of the 3rd quarter, FY1993) and extending into FY1994. In fact, the first full year of operating using the tier approach is FY1995. Statistics showing tiers should not have been used prior to that time. We acknowledge that FDA contributed to the confusion by extrapolating tier data for the prior years in the database we provided to GAO. We apologize for the confusion this caused, and suggest that we work with the study team to correct this error. It should be noted, however, that the tier approach applies <u>only</u> to 510(k)s, and not to PMAs or IDEs.
	The report states that "FDA does not make a determination on the safety or effectiveness of the new {510(k)} device." This is not accurate. When evaluating 510(k) applications, FDA does not make a determination of the absolute safety or effectiveness of the new device, but makes a determination based on comparative safety and effectiveness to determine substantial equivalencethe device under review must be shown to be at least as safe and effective as other legally-marketed predicate devices.
	<u>PMA REVIEW</u>
ee comment 8.	The draft report inappropriately mixes data for PMAs with data for PMA supplements without recognizing the two distinctly different workloads. PMAs are entirely new; PMA supplements represent changes to existing devices. The complexity of the two are quite different. PMAs frequently involve novel technologies and issues of safety and effectiveness that FDA has not
	4

	theretofore confronted. PMA supplements always follow an approved PMA and benefit from the baseline knowledge gained during the PMA review. Original PMAs generally take considerably more time to review than do PMA supplements.
ee comment 1.	As noted above, the report omits any reference to the recent management initiatives that promise to have a significant favorable impact on the time required to review the typical PMA application. Chief among these initiatives is the institution of a project management approach to reviews to help process PMAs in a more efficient and timely manner.
	The report points out that there has been a reduction in the number of PMAs received by FDA, yet, it fails to explain this phenomenon. Part of the downward trend in receipts is attributable to FDA actions to reduce the regulatory burden on the industry by reclassifying devices from class III into class I or II, thereby allowing submission of 510(k)s instead of PMAs or PMA supplements. This is a significant reduction in data requirements for the affected devices. For example, magnetic resonance imaging (MRI) systems, sutures, and daily wear contact lenses have been reclassified and no longer require PMA review. The number of approved PMAs for these three devices total 147, and the number of FMA supplements for the three is 1475. Since reclassification, 513 510(k)s have been received for the three devices, representing a mixture of what would have been new PMAs and PMA supplements.
	Another factor in the reduction of PMAs is market saturation, particularly in the ophthalmic area, which has reduced the incentive for manufacturers to seek to enter this market. A consequence of these two factors is that the PMAs received by FDA are proportionately more first-of-a-kind, innovative products that require more time to review as well as more expertise.
	The report apparently includes some invalid data in the PMA statistics. The data tables include an "exempt" category, which is erroneous. We will be happy to work with GAO to correct this error.
See comment 9.	The report fails to use data that would allow a more accurate assessment of changes in the device review performance. The report notes that the average elapsed time for review is declining, but observes that the decline may be misleading because of the number of applications remaining open. We have analyzed the data provided to GAO and constructed the figure below, which shows the elapsed time since receipt of an original PMA application. The figure demonstrates that since the beginning of 1994, for pending PMAs the elapsed time has remained stable at approximately 700 days. This means that FDA is not accumulating an additional backlog of old PMAs, as was the case from 1991 through 1993. We recognize that the total elapsed time
	5


See comment 10.	for original PMAs must be reduced to a level comparable to that for PMA supplements, which has substantially decreased since October of 1994 and is now running around 200 days. See Figures 1 and 2 (inserts). <u>IDE REVIEW</u> The report should describe recent management improvements in the IDE review process which have reduced the number of review cycles through which IDEs typically go. There have been substantial improvements in the IDE program which are not reflected by either the data presented in the report or in the discussion of this data in the text. For example, FDA has been encouraging sponsors to engage in pre-submission meetings with the review staff and has also been using a more interactive review process than was used in the past. Implementation of these initiatives in January, 1995, has resulted in an increase in the approval rate for initial submissions from a level of approximately 30% to over 60% as of now. In addition, the total time to approval for all original IDEs has decreased by about 50%, from approximately 200 days in recent years to just over 100 days.
FDA also provided technical comments, which have been incorporated into the text where appropriate but have not been reprinted here.	





	The following are GAO's comments on the August 2, 1995, letter from FDA.
GAO Comments	1. The purpose of our review was to provide to FDA's congressional oversight committee descriptive statistics on review time for medical device submissions between 1989 and May 1995. It was not to perform an audit of whether FDA was in compliance with statutory review time, nor to examine how changes in FDA management practices may have resulted in shortening (or lengthening) review times. FDA officials suggested that a number of process changes and other factors may have contributed to the trends we reported—for example, the increased complexity of the typical submission that resulted from the agency's exemption from review of certain low-risk devices. We are not able to verify the effect changes have actually had on review time, and it may be that it is still too early for their impact to be definitively assessed.
	2. In discussing our methodology in the draft report, we noted the differences between FDA's typical method of reporting review time according to the year in which action on applications is finalized, as opposed to our method of assigning applications to the year in which they were submitted. We also included an appendix that compares the results of the two different approaches. (See appendix V.) We agree with FDA that it is important for the reader to understand these differences and have further expanded our discussion of methodology to emphasize this point. (See p. 14.)
	3. We agree with FDA that our report "deals only with calculations of averages and percentiles"—that is, with means, medians (or 50th percentile), as well as the 5th and 95th percentiles. However, FDA's suggested additions do not extend beyond such descriptive statistics.
	We also agree that mean review times in the presence of numerous open cases may not be meaningful. For this reason, we have included open cases in our tables that report review time, but we have excluded them from the calculation of means. FDA suggests that we include open cases in our calculation of medians. We have adopted this suggestion and presented our discussion of trends in terms of the median review time for all cases. It should be noted, however, that including open cases increases our estimate of review time. (For example, including open cases raises the calculation of 510(k) median review time from the 126 days we reported for 1994 to 152 days.)

Figure VI.1 depicts the relationship among the three measures of elapsed time for 510(k) submissions: the mean of closed cases, the median of closed cases, and the median of all cases. The two measures of closed cases reveal roughly parallel trends, with median review time averaging some 45 days fewer than mean review time. The two estimates of median review time are nearly identical from 1989 through 1990 since there are very few cases from that period that remain open. The divergence between the two medians increases as the number of open cases increases in recent years until 1995, when the median, including open cases, is larger than the mean of closed cases.



^aFiscal year 1995 includes actions only through May 18, 1995.

Figure VI.1: Total Elapsed Time for 510(k) Reviews, 1989-95: Mean, Median for Closed Cases, and Median for All Cases^a 4. While we are unable to reproduce the calculations performed by FDA, we agree in general with the trends indicated by FDA. Specifically,

- Our calculations, as presented in our draft report tables II.7 and following, showed a decrease from 1993 to 1994 in FDA review time for finding a 510(k) submission substantially equivalent. By our calculation, this declined from a mean of 173 days in 1993 to 100 days in 1994.
- The proportion of 510(k) applications reaching initial determination within 90 days of submission increased from 15.8 percent in 1993 to 32 percent in 1994 and 57.9 percent between October 1, 1994, and May 18, 1995.

Clearly, since 1993, more 510(k) cases have been determined within 90 days, and the backlog of undetermined cases has been reduced. Because a review of the nature and complexity of the cases still open was beyond the scope of this study, we cannot predict with certainty whether, when these cases are ultimately determined, average review time for 1995 cases will be shorter than for cases submitted in 1993.

5. FDA time was reported in our draft report tables II.7 through II.12, and findings contrasting the differences between FDA time and non-FDA time were also included. Additional language addressing this distinction has been included in the text of the report.

6. FDA's contends that 1989 was an atypical year for 510(k) submissions and therefore a poor benchmark. However, we do not believe that starting our reporting in 1989 introduced any significant bias into our report of the 510(k) workload. Indeed, our draft report concluded that the number of 510(k) submissions had "remained relatively stable" over the 1989-94 period. If we had extrapolated the data from the first 7-1/2 months of 1995 to a full year, we would have concluded that the current fiscal year would have a substantially lower number of 510(k) submissions (16 percent to 31 percent) than any of the previous 6 years.

7. The tier classification was created by FDA to manage its review workload; however, it was not our intention to evaluate or in any way assess the use of tiers for such purposes. The tier classification was based on "the potential risk and complexity of the device." Accordingly, both class and tier provide a rough indication of a device's complexity.

8. We agree that our draft report aggregated original PMA submissions and PMA supplements in summarizing its findings. We have now disaggregated PMA statistics throughout.

9. We interpret the figures presented by FDA to represent the mean number of days elapsed between receipt (or filing) of a PMA submission and a given month for cases that have not been decided. We agree with FDA that the average review time for open original PMAs does not appear to have increased substantially since the beginning of calendar 1994 and that the average review time has decreased for PMA supplements since late 1994. Decreasing these averages is the product of either an increasing number of new cases entering the system or of closing out older cases in the backlog or both. Since the number of PMAs (originals and supplements) submitted in recent years has declined, the evidence suggests that the drop in average time for pending PMA supplements resulted from eliminating lengthy backlogged cases.

10. As noted earlier, assessing the impact of specific management initiatives is beyond the scope of this report. However, we do agree with FDA that the approval rate for initial IDE submissions doubled between 1994 and 1995; by our calculations, it increased from 25 percent to 54 percent. We have not independently examined the total time to approval for all IDEs.

Appendix VII Major Contributors to This Report

Program Evaulation and Methodology Division	Robert E. White, Assistant Director Bertha Dong, Project Manager Venkareddy Chennareddy, Referencer Elizabeth Scullin, Communications Analyst
---	--

Ordering Information

The first copy of each GAO report and testimony is free. Additional copies are \$2 each. Orders should be sent to the following address, accompanied by a check or money order made out to the Superintendent of Documents, when necessary. Orders for 100 or more copies to be mailed to a single address are discounted 25 percent.

Orders by mail:

U.S. General Accounting Office P.O. Box 6015 Gaithersburg, MD 20884-6015

or visit:

Room 1100 700 4th St. NW (corner of 4th and G Sts. NW) U.S. General Accounting Office Washington, DC

Orders may also be placed by calling (202) 512-6000 or by using fax number (301) 258-4066, or TDD (301) 413-0006.

Each day, GAO issues a list of newly available reports and testimony. To receive facsimile copies of the daily list or any list from the past 30 days, please call (202) 512-6000 using a touchtone phone. A recorded menu will provide information on how to obtain these lists.

For information on how to access GAO reports on the INTERNET, send an e-mail message with "info" in the body to:

info@www.gao.gov



United States General Accounting Office Washington, D.C. 20548-0001

Official Business Penalty for Private Use \$300

Address Correction Requested

Bulk Rate Postage & Fees Paid GAO Permit No. G100